

? e au=wentworth, paul?

Ref	Items	Index-term
E1	66	AU=WENTWORTH, PAUL, JR.
E2	17	AU=WENTWORTH, PAUL, JR
E3	0	AU=WENTWORTH, PAUL?
E4	11	AU=WENTWORTH, PEGGY
E5	1	AU=WENTWORTH, PEGGY A
E6	19	AU=WENTWORTH, PEGGY A.
E7	2	AU=WENTWORTH, PEGGY ANN
E8	1	AU=WENTWORTH, PETER
E9	1	AU=WENTWORTH, PETER DOW
E10	1	AU=WENTWORTH, PHYLLIS ANN
E11	1	AU=WENTWORTH, PRESTON R.
E12	3	AU=WENTWORTH, R
E13	17	AU=WENTWORTH, R.
E14	1	AU=WENTWORTH, R. (HARVARD UNIV., CAMBRIDGE, MA (U
E15	48	AU=WENTWORTH, R. A.
E16	4	AU=WENTWORTH, R. A. D.
E17	51	AU=WENTWORTH, R. A. D.
E18	5	AU=WENTWORTH, R. C.
E19	1	AU=WENTWORTH, R. H.
E20	28	AU=WENTWORTH, R. L.
E21	7	AU=WENTWORTH, R.A.
E22	1	AU=WENTWORTH, R.A. (CORNELL UNIV., ITHACA, N.Y. (
E23	2	AU=WENTWORTH, R.A.D.
E24	17	AU=WENTWORTH, R.C.
E25	4	AU=WENTWORTH, R.H.

Enter PAGE for more

? s e1-e2

66	AU=WENTWORTH, PAUL, JR.
17	AU=WENTWORTH, PAUL, JR
S1	83 S E1-E2

? s s1 and (antibod? and sensitizer)

Processing

83	S1
5618120	ANTIBOD?
52092	SENSITIZER
S2	1 S S1 AND (ANTIBOD? AND SENSITIZER)

? e au=lerner, richard

Ref	Items	Index-term
E1	2	AU=LERNER, RG
E2	38	AU=LERNER, RICHARD
E3	114	AU=LERNER, RICHARD A.
E4	1356	AU=LERNER, RICHARD A.
E5	1	AU=LERNER, RICHARD A,
E6	3	AU=LERNER, RICHARD ALAN
E7	103	AU=LERNER, RICHARD ALAN (ED)
E8	3	AU=LERNER, RICHARD ALLEN
E9	8	AU=LERNER, RICHARD M.
E10	8	AU=LERNER, RICHARD M.
E11	1	AU=LERNER, RICHARD MARTIN
E12	1	AU=LERNER, RICHARD NEIL
E13	2	AU=LERNER, RICHARD P.
E14	4	AU=LERNER, RICHARD W.
E15	1	AU=LERNER, RICKARD
E16	1	AU=LERNER, RITA G
E17	6	AU=LERNER, RITA G.
E18	7	AU=LERNER, RM
E19	7	AU=LERNER, ROB D.
E20	8	AU=LERNER, ROBERT

ozone3.txt

E21 5 AU=LERNER, ROBERT A.
E22 1 AU=LERNER, ROBERT EARL
E23 14 AU=LERNER, ROBERT G.
E24 2 AU=LERNER, ROBERT M.
E25 14 AU=LERNER, ROBERT M.
Enter PAGE for more

? s e1-e13
2 AU=LERNER, RG
38 AU=LERNER, RICHARD
114 AU=LERNER, RICHARD A.
1356 AU=LERNER, RICHARD A.
1 AU=LERNER, RICHARD A,
3 AU=LERNER, RICHARD ALAN
103 AU=LERNER, RICHARD ALAN (ED)
3 AU=LERNER, RICHARD ALLEN
8 AU=LERNER, RICHARD M.
8 AU=LERNER, RICHARD M.
1 AU=LERNER, RICHARD MARTIN
1 AU=LERNER, RICHARD NEIL
2 AU=LERNER, RICHARD P.
S3 1633 S E1-E13

? s s3 and (antibody and sensitizer0
>>>W: Unmatched parentheses
>>>E: There is no result

? s s3 and (antibody and sensitizer)
1633 S3
3747881 ANTIBODY
52092 SENSITIZER
S4 3 S S3 AND (ANTIBODY AND SENSITIZER)

? s ((antibody or immunoglobulin or Fab or Fv or sFv) and (sensitizer or photosensitizer))
Processing

3747881 ANTIBODY
1443662 IMMUNOGLOBULIN
138385 FAB
49031 FV
0 SFVZ
52092 SENSITIZER
44716 PHOTOSENSITIZER
S5 2172 S ((ANTIBODY OR IMMUNOGLOBULIN OR FAB OR FV OR SFVZ) AND (SENSITIZER OR PHOTOSENSITIZER))

?
? s ((antibody or immunoglobulin or Fab or Fv or s
>>>W: Unmatched parentheses
>>>E: There is no result

? s ((antibody or immunoglobulin or Fab or Fv or sFv) and (sensitizer or photosensitizer))
3747881 ANTIBODY
1443662 IMMUNOGLOBULIN
138385 FAB
49031 FV
11579 SFV
52092 SENSITIZER
44716 PHOTOSENSITIZER
S6 2182 S ((ANTIBODY OR IMMUNOGLOBULIN OR FAB OR FV OR SFV) AND (SENSITIZER OR PHOTOSENSITIZER))

ozone3.txt

?
? s s6 and (adminis\$ or inject\$ or inocul\$ or intra\$)
2182 S6
0 ADMINIS\$
0 INJECT\$
0 INOCUL\$
0 INTRA\$
S7 0 S S6 AND (ADMINIS\$ OR INJECT\$ OR INOCUL\$ OR INTRA\$)

?
? s s6_and (ADMINIS? OR INJECT? OR INOCUL? OR INTRA?)
Processing
Processing
Processing
Processing
Processing
Processing
Processing
2182 S6
10734921 ADMINIS?
4523036 INJECT?
991495 INOCUL?
11634513 INTRA?
S8 863 S S6 AND (ADMINIS? OR INJECT? OR INOCUL? OR INTRA?)

?
? s s8_and (infection or disease or disorder)
Processing
Processing
863 S8
7663610 INFECTION
21475289 DISEASE
3462439 DISORDER
S9 281 S S8 AND (INFECTION OR DISEASE OR DISORDER)

?
rd
">>>W: Duplicate detection is not supported for File 393.
Duplicate detection is not supported for File 391.
Records from unsupported files will be retained in the RD set.
S10 174 RD (UNIQUE ITEMS)

?
s s10_and photosensitizer
174 S10
44716 PHOTOSENSITIZER
S11 98 S S10 AND PHOTOSENSITIZER

?
t s11/3,k1-98
>>W: KWIC option is not available in file(s): 399
11/3,k1 (Item 1 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rights reserved.

Author: Korbelik Mladen (Reprint); Cecic Ivana
Author Address: British Columbia Canc Agcy, 675 W 10th Ave, Vancouver, BC V5Z 1L3,
Canada** Canada

Author E-mail Address: mkorbelik@bccrc.ca
Journal: Journal of Photochemistry and Photobiology B Biology 93 (1): p 53-59
OCT 16 2008 2008

Item Identifier: doi:10.1016/j.jphotobiol.2008.04.005

ISSN: 1011-1344

Document Type: Article

Record Type: Abstract

Language: English

Abstract: ...was examined following treatment of murine squamous cell carcinomas SCVII by PDT mediated by the photosensitizer Photofrin. A marked decrease was detected in the expression of all three mCRPs on cancer... ...more vulnerable to complement attack. In order to amplify this effect, following PDT mice were injected with antibodies neutralizing either Crry, protectin, or DAR with anti-Crry and anti-protectin this... ...cell signaling). Further examination including other complement regulatory proteins showed that combining antitumor PDT with antibody-mediated neutralization of factor H (soluble negative complement regulator) or injection of properdin (positive complement regulator) increased the cure rates of PDT-treated tumors. The use...

DESCRIPTORS:

Diseases: ...neoplastic disease, therapy

Mesh Terms:

Miscellaneous Terms: Concept Codes: antibody-mediated neutralization

11/3,K/2 (Item 2 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

0020171613 Biosis No.: 200800218552

Anti-chronic graft versus host disease activity though a regulatory T cell dependent mechanism after photodynamic therapy

Author: Bastien Kan-Philippe (Reprint); Krosl Gorazd; Dube Pascale; Therien Cynthia ; Scotto Christian; Roy Denis-Claude

Author Address: Hop Maison Neuve Rosemont, Res Ctr, Montreal, PQ, Canada**Canada

Journal: Blood 110 (11, Part 1): p 963A-964A NOV 16 2007 2007

Conference/Meeting: 49th Annual Meeting of the American-Society-of-Hematology

Atlanta, GA, USA December 08 -11, 2007; 20071208

Sponsor: Amer Soc Hematol

ISSN: 0006-4971

Document Type: Meeting; Meeting Poster

Record Type: Abstract

Language: English

Anti-chronic graft versus host disease activity though a regulatory T cell dependent mechanism after photodynamic therapy

Abstract: Graft-versus-host disease (GVHD) is the principal cause of morbidity and mortality after hematopoietic stem cell transplantation. Even....in its chronic form. Photodynamic therapy (PDT) using TH9402 (4,5-dibromorhodamine methyl ester), a photosensitizer, which upon activation with visible light, exhibits specific toxicity against activated T lymphocytes, while preserving... ...pts). This inhibitory effect disappeared following inhibition of Pgp-171 by verapamil, which promoted TH9402 intracellular retention and effector cell elimination upon light exposure, indicating that Tregs must not only be... ...with CD4+CD25+ depleted PDT cells ($p<0.001$). Addition of anti-IL- 10 monoclonal antibody (mAb) to the co-culture (PDT-treated cells with cGVHD cells) resulted in a 3...

DESCRIPTORS:

Diseases: graft-versus-host disease--... ...immune system disease, drug therapy, therapy

Mesh Terms: Graft vs Host Disease (MeSH)

Chemicals & Biochemicals: ...antineoplastic-drug, efficacy, photosensitizer, safety

11/3,K/3 (Item 3 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

0020059061 Biosis No.: 200800106000

Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins

Author: Bhuvaneswari Ramaswamy; Yuen Gan Yik; Chee Soo Khee; Olivo Malini (Reprint)

Author Address: Natl Canc Ctr Singapore, 11 Hosp Dr, Singapore 169610, Singapore**Singapore

Author E-mail Address: dmsmcd@nccs.com.sg

Journal: Photochemical & Photobiological Sciences 6 (12): p 1275-1283 2007 2007

Item Identifier: doi:10.1039/b705763f

ISSN: 1474-905X

Document Type: Article

Record Type: Abstract

Language: English

Abstract: Photodynamic therapy (PDT) is a therapeutic modality in which a photosensitizer is locally or systemically administered followed by light irradiation of suitable wavelength to achieve selective tissue damage. In addition, PDT... .inhibitors into the treatment regimen. Avastin (bevacizumab), a vascular endothelial growth factor (VEGF) specific monoclonal antibody in combination with chemotherapy is offering hope to patients with metastatic colorectal cancer. In this... .response. Experiments were conducted on bladder carcinoma xenografts established subcutaneously in Balb/c nude mice. Antibody array, enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC) were performed to assess VEGF concentrations...

DESCRIPTORS:

Diseases: ...urologic disease, neoplastic disease;digestive system disease, neoplastic disease, drug therapy , diagnosis

Mesh Terms:

Chemicals & Biochemicals: ...monoclonal antibody;

11/3,K/4 (Item 4 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

0019912080 Biosis No.: 200700571821

Fluorescence characterisation of multiply-loaded anti-HER2 single chain

Fv-photosensitizer conjugates suitable for photodynamic therapy

Author: Kuimova Marina K; Bhatti Manpreet; Deonarain Mahendra (Reprint); Yahiooglu Gokhan; Levitt James A; Stamati Ioanna; Suhlingd Klaus; Phillips David

Author Address: Univ London Imperial Coll Sci Technol and Med, Dept Chem, Fac Nat Sci, Div Cell and Mol Biol, Exhibit Ed, London SW7 2AZ, UK**UK

Author E-mail Address: m.deonarain@imperial.ac.uk; g.yahiooglu@imperial.ac.uk; d.phillips@imperial.ac.uk

Journal: Photochemical & Photobiological Sciences 6 (9): p 933-939 2007 2007

Item Identifier: doi:10.1039/b708320c

ISSN: 1474-905X

Document Type: Article

Record Type: Abstract

Language: English

Fluorescence characterisation of multiply-loaded anti-HER2 single chain

Fv-photosensitizer conjugates suitable for photodynamic therapy

Abstract: We report the synthesis, spectroscopic properties and intracellular imaging of recombinant antibody single chain fragment (scFv) conjugates with photosensitizers used for photodynamic therapy of cancer (PDT). Two... .a and verteporfin have been conjugated to an anti-HER2 scFv containing on average ten

ozone3.txt

photosensitizer molecules per scFv with a small contribution (<= 20%) from non-covalently bound molecules. Confocal fluorescence... ...of cellular uptake and prolonged retention in SKOV-3 cells is observed compared to free photosensitizer. In clinical applications this could provide increased potency and desired selectivity towards malignant tissue, leaving surrounding healthy tissue unharmed and reducing skin photosensitivity. The present study highlights the usefulness of photosensitizer immunoconjugates with scFvs for targeted PDT.

DESCRIPTORS:

Diseases: ...neoplastic disease, therapy... ...eye disease

Mesh Terms:

Chemicals & Biochemicals: antibody single chain fragment {scFv...}

11/3,K/5 (Item 5 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

18973359 Biosis No.: 200600318754

Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate

Author: Fabbrini Monica; Trachsel Eveline; Soldani Patrizia; Bindi Stefano; Alessi Patrizia; Bracci Luisa; Kosmehl Hartwig; Zardi Luciano; Neri Dario (Reprint); Neri Paolo

Author Address: Swiss Fed Inst Technol, ETH Honggerberg, Dept Chem and Appl Biosci, Wolfgang Pauli Str 10, HCl G396, CH-8093 Zurich, Switzerland**Switzerland

Author E-mail Address: neri@pharma.ethz.ch

Journal: International Journal of Cancer 118 (7): p 1805-1813 APR 1 2006 2006

ISSN: 0020-7136

Document Type: Article

Record Type: Abstract

Language: English

Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate

Abstract: ...tumors of nutrients and oxygen and causing an avalanche of tumor cell deaths. The human antibody L19, specific to the ED8 domain of fibronectin, a marker of angiogenesis, is capable of... ...payloads to the tumor neovasculature. Here we show that a chemical conjugate of the L19 antibody with the photosensitizer bis(triethanolamine)Sn(IV) chlorin e6, after intravenous injection and irradiation with red light, caused an arrest of tumor growth in mice with subcutaneous tumors. By contrast, a photosensitizer conjugate obtained with an antibody of identical pharmacokinetic properties but irrelevant specificity did not exhibit a significant therapeutic effect. These... ...blood vessels, have a significant anticancer therapeutic potential and encourage the use of anti-body-photosensitizer conjugates for the therapy of superficial tumors and possibly other angiogenesis-related pathologies. (c) 2005...

DESCRIPTORS:

Diseases: ...neoplastic disease, drug therapy

Mesh Terms:

Chemicals & Biochemicals: ...L19 antibody; ...radiosensitizer-drug, pharmaceutical adjunct-drug, intravenous administration, pharmacokinetics, toxicity

11/3,K/6 (Item 6 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

18558086 Biosis No.: 200510252586

Photodynamic therapy of rabbit corneal neovascularization with photosensitizer conjugated to antibody against the extradomain-B of fibronectin

ozone3.txt

Author: Biro A (Reprint); Fabbrini M; Giovannoni L; Nicolo M; Balza E; Gaggero B;
Berta A; Cilli M; Neri D; Zardi L
Author Address: Univ Siena, Mol Biol Lab, I-53100 Siena, Italy**Italy
Journal: IOVS 45 (Suppl. 2): p U524 APR 2004 2004
Conference/Meeting: Annual Meeting of the
Association-for-Research-in-Vision-and-Ophthalmology Ft Lauderdale, FL, USA
April 24 -29, 2004; 20040424
Sponsor: Assoc Res Vis & Ophthalmol
ISSN: 0146-0404
Document Type: Meeting; Meeting Poster
Record Type: Abstract
Language: English
Photodynamic therapy of rabbit corneal neovascularization with photosensitizer conjugated to antibody against the extradomain-B of fibronectin

Abstract: ...the neovasculation. our objective was to evaluate the efficacy of an immunoconjugate composed of the photosensitizer (PS) Sn(IV)chlorin e6 and the high affinity human antibody against B-FN named SIPL19 in the photodynamic therapy of experimental corneal neovascularization in theprepared by incubating PS in the monoester form with SIPL19 and purified from non conjugated photosensitizer by size exclusion chromatography. The conjugate was characterized by its antibody/photosensitizer stochiometric ratio, migration profile in acrylamide gel and fast protein liquid chromatography (FPLC), immunoreactivity and... ...immunoconjugate migrated as a single band of 80kd, had an immunoreactivity of > 75% and an antibody/PS ratio of 1/3.1 and selectively accumulated around newly developed corneal vessels as early as 4 hours post-administration. Occlusion of corneal neovascularization was obtained after 635nm diode laser irradiation with energies $\geq 150J/cm^2$ at a fluence rate of 600mW/cm 2 . No antibodies were detected against immunoconjugates composed of photosensitizer and rabbit IgG. Conclusions: PDT of newly developed vessels was effective with the Sn(IV)chlorin e6/SIPL19 immunoconjugate in the rabbit corneal micropocket assay. We conclude that SIPL19-mediated photosensitizer delivery maybe beneficial in the treatment of ocular neovascular diseases.

DESCRIPTORS:

Diseases: ...eye disease

Mesh Terms:

Chemicals & Biochemicals: ...anti-immunoconjugate antibody

11/3,K/7 (Item 7 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

17752499 Biosis No.: 200400123256

Photodynamic treatment and H2O2-induced oxidative stress result in different patterns of cellular protein oxidation.

Author: Sakharov Dmitri V (Reprint); Bunschoten Anton; Van Weelden Huib; Wirtz Karel W A
Author Address: CBLE, Utrecht University, 3508 TB, PO Box 80.054, utrecht,
Netherlands** Netherlands
Author E-mail Address: d.sakharov@chem.uu.nl
Journal: European Journal of Biochemistry 270 (24): p 4859-4865 December 2003
2003
Medium: print
ISSN: 0014-2956 _ (ISSN print)
Document Type: Article
Record Type: Abstract
Language: English

Abstract: ...The ROS generated may oxidize a variety of biomolecules within the cell, loaded with a photosensitizer. The high reactivity of these ROS restricts

ozone3.txt

their radius of action to 5-20 nm from the site of their generation, we studied oxidation of intracellular proteins during PDT using the ROS-sensitive probe acetyl-tyramine-fluorescein (acetylTyr-Fluo). This probe... ...fluorescein-labeled proteins can be visualized after gel electrophoresis and subsequent Western blotting using the antibody against fluorescein. We found that PDT of rat or human fibroblasts, loaded with the photosensitizer Hypocrellin A, resulted in labeling of a set of intracellular proteins that was different from that observed on treatment of the cells with H₂O₂. This... ...treatment. We hypothesize that the pattern of protein oxidation observed with Hypocrellin A reflects the intracellular localization of the photosensitizer. The application of acetylTyr-Fluo may be useful for characterizing protein targets of oxidation by...

DESCRIPTORS:

Diseases: ...neoplastic disease

Mesh Terms:

Chemicals & Biochemicals: ...intracellular localization, reactive oxygen species-sensitive probe... ...photosensitizer;intracellular proteins

Miscellaneous Terms: Concept Codes: ...disease management

11/3,K/8 (Item 8 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

16325689 Biosis No.: 200100497528

Apoptosis repressor gene Bcl-w is overexpressed in the region-at-risk following photothrombotic ring stroke in rats

Author: Hu X L (Reprint); Olsson T (Reprint); Brannstrom T; Johansson I M; Wester P (Reprint)

Author Address: Medicine, Public Health and Clinical Medicine, Umea University, Umea, Sweden**Sweden

Journal: Society for Neuroscience Abstracts 27 (1): p 544 2001 2001

Medium: print

Conference/Meeting: 31st Annual Meeting of the Society for Neuroscience San Diego, California, USA November 10-15, 2001; 20011110

ISSN: 0190-5295

Document Type: Meeting; Meeting Abstract

Record Type: Abstract

Language: English

Abstract: ...intensity (no reperfusion) laser ring-beam through the translucent skull bone in conjunction with the photosensitizer erythrosin B i.v. Frozen coronal sections from the center of the lesion were processed... ...4, 10, 24, 48, 72h and 7d after stroke induction. The specificity of Bcl-w antibody (21 kDa) was verified by Western blots. Following ring-stroke with reperfusion there was a...

DESCRIPTORS:

Diseases: ...nervous system disease, vascular disease, photothrombotic ring

Mesh Terms:

Chemicals & Biochemicals: ...intravenous administration, photosensitizer

11/3,K/9 (Item 9 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

16180503 Biosis No.: 200100352342

Photodynamic therapy with motexafin lutetium (Lu-Tex) reduces experimental graft coronary artery disease

Author: Yamaguchi Atsushi; Woodburn Kathryn W; Hayase Motoya; Hoyt Grant; Robbins Robert C (Reprint)

Author Address: Department of Cardiothoracic Surgery, Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA, 94305, USA**USA

Journal: Transplantation (Baltimore) 71 (11): p 1526-1532 June 15, 2001 2001

Medium: print

ISSN: 0041-1337

Document Type: Article

Record Type: Abstract

Language: English

Photodynamic therapy with motexafin lutetium (Lu-Tex) reduces experimental graft coronary artery disease

Abstract: ...can be activated by farred light. Lu-Tex biolocalization was examined in graft coronary artery disease (GCAD) with a rodent allograft model. After photoactivation, the effect on intimal proliferation was assessed... ...to ACI rat heterotopic heart transplantation model was used. Lu-Tex (10 mg/kg) was intravenously administered 90 days after transplantation. Photoactivation was performed 24 hr after Lu-Tex administration. A light-emitting diode, central wavelength of 742 nm, was used to illuminate the intraperitoneally placed allografts via a laparotomy (light fluence of 75 J/cm² at a power density... ...cm²). Animals were divided into four groups according to postoperative treatments: PDT with Lu-Tex injection and light illumination (n=21), Lu-Tex injection and laparotomy (n=14), laparotomy with light only (n=14), and laparotomy only (n=16... ...to all other control study groups. alpha-Smooth muscle cell actin and anti-rat macrophage antibody-positive areas were significantly reduced within the neointima in allografts treated with PDT compared to...

DESCRIPTORS:

Diseases: experimental graft coronary artery disease--... ...heart disease, vascular disease, treatment

Mesh Terms:

Chemicals & Biochemicals: ...cardiovascular-drug, photosensitizer

Methods & Equipment: ...posttransplantation coronary artery disease, transplantation method...

Geographical Name:

11/3_K/10 (Item 10 from file: 5) Links

Fulltext available through: STICs Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

16127639 Biosis No.: 200100299478

Photodynamic therapy (PDT) of B-lineage non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL)

Author: Roy D C (Reprint); Dallaire N (Reprint); Moreau B (Reprint); Paquette Y (Reprint); Balassy A (Reprint); Giorgi O (Reprint); Gladu I (Reprint); Hamel R
Author Address: Hematology-Immunology, Maisonneuve-Rosemont Hosp., Montreal, QC, Canada** Canada

Journal: Blood 96 (11 Part 1): p 185a November 16, 2000 2000

Medium: print

Conference/Meeting: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000; 20001201

Sponsor: American Society of Hematology

ISSN: 0006-4971

Document Type: Meeting; Meeting Abstract

Record Type: Abstract

Language: English

Abstract: ...NHL, particularly follicular lymphomas, and CLL, may contribute to relapse after autologous transplantation. While monoclonal antibody approaches can be used to target cell surface antigens, few strategies use alternative pathways to... ...TH9402 is a dibromorhodamine derivative with potent photosensitizing capacity that targets malignant cells through specific intracellular handling and mitochondrial localization, leading to the demise of targeted cells via oxydative damage. The... ...flow-cytometry, was observed after 20-40 minutes of incubation.

ozone3.txt

Decreasing the extracellular concentration of photosensitizer induced its rapid efflux (30 min), and was followed by a plateau effect. Cytotoxicity towards...

DESCRIPTORS:

Diseases: ...blood and lymphatic disease, neoplastic disease;blood and lymphatic disease, immune system disease, neoplastic disease;blood and lymphatic disease, immune system disease, neoplastic disease, B-lineage

Mesh Terms:

Chemicals & Biochemicals: ...monoclonal antibody--

11/3,K/11 (Item 11 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

15897228 Biosis No.: 200100069067

Biodistribution of charged 17.1A photoimmunoconjugates in a murine model of hepatic metastasis of colorectal cancer

Author: Hamblin M R; Del Gubernatore M; Rizvi I; Hasan T (Reprint)

Author Address: Weilman Laboratories of Photomedicine, Massachusetts General Hospital, and Department of Dermatology, Harvard Medical School, Boston, MA, 02114, USA** USA

Journal: British Journal of Cancer 83 (11): p 1544-1551 December, 2000 2000

Medium: print

ISSN: 0007-0920

Document Type: Article

Record Type: Abstract

Language: English

Abstract: Optimizing photodynamic therapy involves attempting to increase both the absolute tumour content of photosensitizer and the selectivity between tumour and surrounding normal tissue. One reason why photodynamic therapy has... ...liver. This report details an alternative approach to increasing this selectivity by the use of antibody-targeted photosensitizers (or photoimmunoconjugates) to target intrahepatic tumours caused by human colorectal cancer cells in the nude mouse, and explores the role of molecular charge on the tumour-targeting efficiency of macromolecules. The murine monoclonal antibody 17.1A (which recognizes an antigen expressed on HT 29 cells) was used to prepare site-specific photoimmunoconjugates with the photosensitizer chlorine6. The conjugates had either a predominant cationic or anionic charge and were injected i.v. into tumour-bearing mice. Biodistribution 3 or 24 h later was measured by... ...polylysine conjugates in an attempt to define the effect of molecular charge as well as antibody targeting. The anionic 17.1A conjugate delivered more than twice as much photosensitizer to the tumour at 3 h than other species (5 times more than the cationic...).

DESCRIPTORS:

Diseases: ...digestive system disease, neoplastic disease, hepatic metastases... ...intrahepatic tumor... ...digestive system disease, neoplastic disease

Mesh Terms:

Chemicals & Biochemicals: ...immunoconjugates, murine monoclonal antibody;

11/3,K/12 (Item 12 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

15839343 Biosis No.: 200100011182

Early mammary tumor reaction due to photodynamic therapy (PDT) on transgenic mice

Author: Walt H (Reprint); Nap M; Ladner D (Reprint); Leers M P G; Tennent B J; Bjorklund V; Beamer W G

Author Address: Department of Obstetrics and Gynecology, University Hospital, Zurich, Switzerland**Switzerland

Journal: Tumor Biology 21 (Supplement 1): p 137 September, 2000 2000

ozone3.txt

Medium: print

Conference/Meeting: 28th Meeting of the International Society for Oncodevelopmental Biology and Medicine Munich, Germany September 08-13, 2000; 20000908
Sponsor: International Society for Oncodevelopmental Biology and Medicine
ISSN: 1010-4283

Document Type: Meeting; Meeting Abstract; Meeting Poster

Record Type: Citation

Language: English

DESCRIPTORS:

Diseases: ...neoplastic disease, early tumor reaction

Mesh Terms:

Chemicals & Biochemicals: M30-CytoDEATH antibody----...activity, monoclonal mouse IgG2b antibody

Methods & Equipment: ...photosensitizer SC 102... ...intraperitoneal injection, laboratory equipment

Geographical Name:

11/3,K/13 (Item 13 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

15731493 Biosis No.: 200000449806

Photodynamic therapy induces apoptosis in intimal hyperplastic arteries

Author: LaMuraglia Glenn M (Reprint); Schiereck Jan; Heckenkamp Joerg; Nigri Giuseppe; Waterman Peter; Leszczynski Dariusz; Kossodo Sylvie

Author Address: Massachusetts General Hospital, ACC 464, Boston, MA, 02114, USA**USA

Journal: American Journal of Pathology 157 (3): p 867-875 September, 2000 2000

Medium: print

ISSN: 0002-9440

Document Type: Article

Record Type: Abstract

Language: English

Abstract: ...vessel wall. This study investigates the mechanisms of PDT-induced cell death. PDT, using the photosensitizer chloroaluminum-sulfonated phthalocyanine (1 mg/kg) and laser light (λ = 675 nm) 100 J/cm² was administered to rat carotid arteries after balloon injury-induced intimal hyperplasia. Apoptosis was determined by cell... ...were present in the neointima and media. Immunofluorescence using an alpha-smooth muscle cell actin antibody confirmed the disappearance of all neointimal and medial cells within 24 hours. No inflammatory cell...

DESCRIPTORS:

Diseases: ...vascular disease;vascular disease

Mesh Terms:

11/3,K/14 (Item 14 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

15467025 Biosis No.: 200000185338

Neutrophil elastase inhibition reduces cerebral ischemic damage in the middle cerebral artery occlusion

Author: Shimakura Akira; Kamanaka Yoshihisa; Ikeda Yasuhiko; Kondo Kazunao; Suzuki Yasuhiro; Umemura Kazuo (Reprint)

Author Address: Department of Pharmacology, Hamamatsu University School of Medicine, 3600 Handa-cho, Hamamatsu, 431-3192, Japan**Japan

Journal: Brain Research 858 (1): p 55-60 March 6, 2000 2000

Medium: print

ISSN: 0006-8993

Document Type: Article
Record Type: Abstract
Language: English

Abstract: ...MCA) was occluded by a thrombus induced by photochemical reaction between green light and the photosensitizer dye, Rose Bengal. Photochemical reaction causes endothelial injury followed by formation of a platelet and... .measured and neuronal deficits were examined 24 h after the MCA occlusion. ONO-5046 was administered at various doses as continuous infusion for 24 h, starting just after the MCA occlusion... .30 mg/kg'/h significantly ($p = 0.01$) improved neuronal deficits. ONO-5046 which was administered starting from 3 h after the MCA occlusion, also reduced the size of cerebral damage. Neutropenia by anti-neutrophil antibody injection significantly ($p < 0.01$) reduced the size of cerebral damage. Elastase released from activated neutrophils... .

DESCRIPTORS:

Diseases: ...nervous system disease, vascular disease

Mesh Terms:

11/3/K/15 (Item 15 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

15458508 Biosis No.: 200000176821

Intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates

Author: Molpus Kelly L; Hamblin Michael R; Rizvi Imran; Hasan Tayyaba (Reprint)
Author Address: Wellman Laboratories of Photomedicine, Department of Dermatology,
Division of Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical
School, 55 Fruit Street, Boston, MA, 02114, USA**USA
Journal: Gynecologic Oncology 76 (3): p 397-404 March, 2000 2000

Medium: print

ISSN: 0090-8258

Document Type: Article

Record Type: Abstract

Language: English

Intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates

Abstract: ...study was to compare the efficacy of photoimmunoconjugates with cationic and anionic molecular charges on intraperitoneal photoimmunotherapy of ovarian cancer xenografts in nude mice. Methods: The photosensitizer chlorine6 (ce6) was conjugated via a poly-L-lysine linker to the F(ab')2 fragment of the murine anti-ovarian cancer monoclonal antibody OC125, resulting in a photoimmunoconjugate with a pronounced cationic charge. Alternatively, by succinylating the poly... .with a pronounced anionic charge was obtained. A murine model of ovarian cancer derived from intraperitoneal inoculation of NIH:OVCAR-5 cells was employed. The conjugate was injected intraperitoneally followed after 3 h by red light delivered through a fiber into the peritoneal cavity... .were compared with those obtained with free ce6 and control. The extent of residual macroscopic disease and death from disease were the evaluable outcomes for tumorcidal and survival studies, respectively. Results: In contrast to other intraperitoneal photosensitizers, mice showed no systemic toxicity or morbidity from the treatment. In this initial study... .

DESCRIPTORS:

Diseases: ...neoplastic disease, reproductive system disease/female

Mesh Terms:

Methods & Equipment: intraperitoneal photoimmunotherapy...

Geographical Name:

ozone3.txt

11/3,K/16 (Item 16 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

15235350 Biosis No.: 199900495010

Combination photoimmunotherapy and cisplatin: Effects on human ovarian cancer Ex vivo

Author: Duska Linda R; Hamblin Michael R; Miller Jaimie L; Hasan Tayyaba (Reprint)

Author Address: Department of Dermatology, Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA**USA

Journal: Journal of the National Cancer Institute (Bethesda) 91 (18): p 1557-1563 Sept. 15, 1999 1999

Medium: print

ISSN: 0027-8874

Document Type: Article

Record Type: Abstract

Language: English

Abstract: ...is clinically resistant to cisplatin-based chemotherapy have little hope of a cure of their disease. Photoimmunotherapy, which involves the antibody-targeted delivery of a nontoxic photosensitizer that is activated to a cytotoxic state with visible light, may offer a new treatment option. Photoimmunotherapy may be applied intraperitoneally to target disseminated tumor. We tested the hypothesis that this treatment in combination with cisplatin... ...tumor samples obtained from 14 patients with ovarian cancer who were undergoing primary surgery. The photosensitizer chlorin e6 was conjugated to the F(ab')2 fragment of the murine monoclonal antibody OC-125, which is directed against the antigen CA 125. Cytotoxicity was measured by the...

11/3,K/17 (Item 17 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

14481682 Biosis No.: 199800275929

Immunophotodynamic therapy: Current developments and future prospects

Author: Miller Gerald G (Reprint); Low J William

Author Address: Noujaim Inst. Pharmaceutical Oncology Res., Fac. Pharm.

Pharmaceutical Sci., Univ. Alberta, Edmonton, AB T6G 2N8, Canada**Canada

Journal: Drug Development Research 42 (3-4): p 182-197 Nov.-Dec., 1997 1997

Medium: print

ISSN: 0272-4391

Document Type: Article; Literature Review

Record Type: Abstract

Language: English

Abstract: ...offer an enhanced therapeutic index via one or more of the following modalities: a) preferential photosensitizer uptake by the target tissue, b) specific illumination of target tissue to excite the photosensitizer, c) strategic timing of light application to minimize toxicity to normal tissues, d) topical application of the photosensitizer restricted to the target tissue, infusion of the photosensitizer to the vasculature immediately upstream of the target, and intra-target administration. While each photosensitizer has inherent properties of biodistribution, it is generally accepted that few provide a significant therapeutic... ...of the reticuloendothelial system, will usually be surrounded by normal stroma with greater concentrations of photosensitizer than are present in the tumor at a given post-administration interval, presenting a major obstacle to practical therapy. Deep-seated or large solid malignancies are not amenable to topical application of the photosensitizer and single tumor masses are frequently served by multiple arterial sources, rendering major dosimetric obstacles for

ozone3.txt

photosensitizers administered via the upstream vasculature. One approach to specific photosensitizer delivery is via covalently bound immunoconjugates of photosensitizer and antibodies or antibody fragments to unique tumor markers. This approach is the subject of several clinical trials and...

DESCRIPTORS:

Diseases: ...neoplastic disease

Mesh Terms:

Miscellaneous Terms: Concept Codes: ...preferential photosensitizer uptake...

11/3,K/18 (Item 18 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

13871807 Biosis No.: 199799505867

Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumours

Author: Reddi Elena

Author Address: Dep. Biol., Univ. Padova, via Trieste 75, 35121 Padova, Italy**Italy

Journal: Journal of Photochemistry and Photobiology B Biology 37 (3): p 189-195
1997 1997

ISSN: 1011-1344

Document Type: Article; Literature Review

Record Type: Abstract

Language: English

Abstract: ...therapy of tumours. Lipid-based delivery vehicles, such as liposomes and oil emulsions, allow the administration of water-insoluble photosensitizers, widening the choice of photosensitizers potentially useful for treating tumours. In some cases, these delivery vehicles increase the selectivity of tumour targeting by favoring photosensitizer uptake in tumour tissue. However, a higher selectivity of tumour targeting could be obtained through... demonstrated a higher tumour uptake compared with the same photosensitizers delivered with other formulations. Monoclonal antibody-coupled photosensitizers have been tested mainly *in vitro*, and have shown a high selectivity towards...

DESCRIPTORS:

Miscellaneous Terms: Concept Codes: ...NEOPLASTIC DISEASE;

11/3,K/19 (Item 19 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

13687699 Biosis No.: 199799321759

Effect of charge on the interaction of site-specific photoimmunoconjugates with human ovarian cancer cells

Author: Hamblin Michael R; Miller Jaimie L; Hasan Tayyaba (Reprint)

Author Address: Wellman Lab. Photomed., Dep. Dermatol., Massachusetts General Hosp., WEL224, Harvard Med. Sch., Boston, MA 02114, USA**USA

Journal: Cancer Research 56 (22): p 5205-5210 1996 1996

ISSN: 0008-5472

Document Type: Article

Record Type: Abstract

Language: English

Abstract: ...a photoimmunoconjugate (PIC) was demonstrated. A site-specific conjugation strategy was developed to attach the photosensitizer chlorin-e6 (c-e6) to the F(ab')-2 fragment of the murine antiovarian cancer monoclonal antibody OC125. Poly-L-lysine linkers carrying c-e6 with a cationic charge or by polysuccinylation with an anionic charge were used and covalently attached to partially reduced

antibody via a heterobifunctional reagent. PICs were purified by column chromatography and were also radiolabeled with... both cationic and anionic charges preserved antigen binding as shown by competition studies with native antibody, but the cationic PIC had up to 17 times higher cellular uptake of c-e6... increased relative phototoxicity. These data suggest cationic PICs may have advantages for photoimmunotherapy of disseminated intracavity cancer following local administration.

DESCRIPTORS:

Miscellaneous Terms: Concept Codes: ...DISSEMINATED INTRACAVITY CANCER...
...NEOPLASTIC DISEASE; ...PHOTOSENSITIZER;

11/3,K/20 (Item 20 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

13628815 Biosis No.: 199699262875

Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model

Author: Goff B A; Blake J; Bamberg M P; Hasan T (Reprint)

Author Address: Massachusetts General Hosp., Wellman Lab. Photomedicine, 55 Fruit St., Boston, MA 02114, USA**USA

Journal: British Journal of Cancer 74 (8): p 1194-1198 1996 1996

ISSN: 0007-0920

Document Type: Article

Record Type: Abstract

Language: English

Abstract: ...turnout tissue death. In order to target ovarian cancer with increased specificity, a chlorin-based photosensitizer (Chlorin e-6 monoethylendiamine monoamide) was conjugated to OC125, a monoclonal antibody recognizing an antigen expressed in 80% of non-mucinous ovarian cancers. In previous work, this... vs multiple treatments was also made. For in vivo experimentation, Balb C nude mice were injected with 30 times 10-6 NIH:OVCAR 3 cancer cells to create an ascitic tumour model. Animals were then given intraperitoneal injections of the immunoconjugate (0.5 mg kg-1). Twenty-four hours later the intraperitoneal surfaces were exposed to 656 nm light from an argon-ion pumped-dye laser (50... were alive after 50 days. Evaluation with Log-rank test revealed a significant survival with intraperitoneal PDT compared with controls ($P = 0.0006$). These preliminary results suggest that PDT with an... multiple treatments, similar to fractionated radiation therapy and cyclic chemotherapy, in order to control malignant disease with acceptable toxicity to normal tissue.

DESCRIPTORS:

Miscellaneous Terms: Concept Codes: ...NEOPLASTIC DISEASE; ...REPRODUCTIVE SYSTEM DISEASE/FEMALE

11/3,K/21 (Item 21 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

12384283 Biosis No.: 199497405568

Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization

Author: Wagner Stephen J (Reprint); Robinette D; Storry J; Chen X Y; Shumaker J; Benade L

Author Address: Product Dev. Dep., Jerome H. Holland Lab. Biomed. Sci., American Red. Cross Blood Serv., 15601 Crabb's Branch Way, Rockville, MD 20855, USA**USA

Journal: Transfusion (Bethesda) 34 (6): p 521-526 1994 1994

ISSN: 0041-1132

Document Type: Article

Record Type: Abstract
 Language: English

Abstract: Background: Previous studies explored the feasibility of using the photosensitizer methylene blue (MB) as a virucidal agent in red cell suspensions. Under treatment conditions (5... ...a dose-dependent fashion. Study Design and Methods: Inactivation of three additional extracellular viruses and intracellular human immunodeficiency virus type 1 (HIV-1) was assessed after MS phototreatment of red cell... ...4.1 times 10⁻⁴ J per m⁻² fluences resulted in any inactivation of intracellular HIV as represented by changes in the amount of p24 antigen produced during co-culture... ...6 log₁₀) white cell-reduction filters or additional inactivation steps to deplete or inactivate intracellular virus.

DESCRIPTORS:

Major Concepts: ...Infection;

Biosystematic Names:

Miscellaneous Terms: Concept Codes: IMMUNOGLOBULIN G...

11/3,K/22 (Item 22 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

11785431 Biosis No.: 199395087697

Epithelial ovarian carcinoma

Author: Sbriglio V S

Author Address: Divisione A, Ospedale Ostetrico-Ginecologico, Sant'Anna 10100 Torino,

Journal: Gazzetta Medica Italiana Archivio per le Scienze Mediche 151 (10): p 405-409 1992

ISSN: 0393-3660

Document Type: Article

Record Type: Abstract

Language: Italian

Abstract: ...obtained over the past decades due to diagnostic difficulties since in 70% of cases the disease is discovered at the 3rd and 4th stage. The first and second treatment followed by:... ...positive response in only 20% of cases. The paper briefly discusses the possibility of using intraperitoneal chemotherapy (with CIS-platino), photodynamic therapy (with photofrin), the use of intraperitoneal interferon and monoclonal antibodies for diagnostic and therapeutic purposes: all these techniques may be useful... ...The author hopes that the quality of life for patients in advanced stages of the disease can be improved since survival may only be a matter of months and certainly not...

DESCRIPTORS:

Miscellaneous Terms: Concept Codes: ...INTRAPERITONEAL CHEMOTHERAPY...

...MONOCLONAL ANTIBODY;PHOTOSENSITIZER;

11/3,K/23 (Item 23 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

11752138 Biosis No.: 199395054404

Tin-chlorin e6 antibacterial immunoconjugates: An in vitro and in vivo analysis

Author: Lu Xiao-Ming; Fischman Alan J; Stevens Emily; Lee Thomas T; Strong Louis; Tompkins Ronald G; Yarmush Martin L (Reprint)

Author Address: Dep. Chem. Biochem. Eng., Rutgers Univ., Piscataway, N.J. 08854, USA**USA

Journal: Journal of Immunological Methods 156 (1): p 85-99 1992

ISSN: 0022-1759

Document Type: Article

Record Type: Abstract
Language: English

Abstract: Monoclonal antibody-Sn-chlorin e6 immunoconjugates were prepared by the site-selective covalent modification of the monoclonal antibody... were prepared. By varying the reaction conditions, conjugates were reproducibly prepared with a range of photosensitizer to mAb molar ratios from 1.6 to 10. Based on a competitive inhibition radioimmunoassay, conjugates prepared by this method showed selectivity and binding affinity comparable to the unmodified antibody. The immunoconjugates had only slightly lower singlet oxygen yields than that observed with the Sn... mice showed that conjugates prepared with axial ligands had significant serum retention 24 h after injection while conjugates prepared without the triethanolamine ligand were much more rapidly cleared. In vivo specificity... left posterior thigh muscle. Target to background ratios exceeded 60 at 120 h after conjugate injection of the specific immunoconjugate, compared to a ratio of only 6 for a non-specific mouse IgG conjugate. Biodistribution patterns at 120 h post injection indicate that the conjugates were both biologically active and structurally intact.

DESCRIPTORS:

Major Concepts: ...Infection;

Biosystematic Names:

Miscellaneous Terms: Concept Codes: ...IMMUNOGLOBULIN G

11/3, K/24 (Item 1 from file: 24) Links

Fulltext available through: STIC Full Text Retrieval Options

CSA Life Sciences Abstracts

(c) 2009 CSA. All rights reserved.

0001380402 IP Accession No: 3595491

Antibody-targeted photolysis of bacteria in vivo

Berthiaume, F; Reiken, SR; Toner, M; Tompkins, RG; Yarmush, ML* Surg. Serv., Massachusetts Gen. Hosp., Shriners Burns Inst., Boston, MA 02114, USA

BIO/TECHNOLOGY , v 12 , n 7 , p 703-706 , 1994

Addl. Source Info: BIO/TECHNOLOGY, vol. 12, no. 7, pp. 703-706, 1994

Publication Date: 1994

Document Type: Journal Article

Record Type: Abstract

Language: English

Summary Language: English

ISSN: 0833-222X

File Segment: Medical & Pharmaceutical Biotechnology Abstracts; Immunology Abstracts

Antibody-targeted photolysis of bacteria in vivo

Abstract:

We have evaluated the efficacy of antibody-targeted photolysis to kill bacteria *in vivo* using specific antibacterial photosensitizer (PS) immunoconjugates. After infecting the dorsal skin in mice with *Pseudomonas aeruginosa*, both specific and nonspecific tin (IV) chlorin e sub(6)-monoclonal antibody conjugates were injected at the infection site. After a 15 min incubation period, the site was exposed to 630 nm light....bacterial growth was observed in animals that were untreated or treated with a nonspecific conjugate. Antibody-targeted photolysis may be a selective and versatile tool for treating a variety of infections.

Subj Catg: , , Antibody based: 06806

Material Class:

11/3.K/25 (Item 1 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options

SciSearch(R) Cited Ref Sci

ozone3.txt

(c) 2009 The Thomson Corp. All rights reserved.

12896971 Genuine Article#: 828YA No. References: 169

Photodynamic therapy: a new antimicrobial approach to infectious disease?

Author: Hamblin MR (REPRINT) ; Hasan T

Corporate Source: Massachusetts Gen Hosp,Wellman Labs Photomed,Boston//MA/02114 (REPRINT); Massachusetts Gen Hosp,Wellman Labs Photomed,Boston//MA/02114; Harvard Univ,Sch Med, Dept Dermatol,Boston//MA/02115 (hamblin@helix.mgh.harvard.edu)
Journal: PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES , 2004 , V 3 , N5 (MAY) , P 436-450

ISSN: 1474-905X Publication date: 20040500

Publisher: ROYAL SOC CHEMISTRY , THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND

Language: English Document Type: REVIEW (ABSTRACT AVAILABLE)

Photodynamic therapy: a new antimicrobial approach to infectious disease?

Abstract: Photodynamic therapy (PDT) employs a non-toxic dye, termed a photosensitizer (PS), and low intensity visible light which, in the presence of oxygen, combine to produce... animal models and some clinical trials: mainly for viral lesions, but also for acne, gastric infection by Helicobacter pylori and brain abscesses. Possible future clinical applications include infections in wounds and burns, rapidly spreading and intractable soft-tissue infections and abscesses, infections in body cavities such as the mouth, ear, nasal...

Identifiers--SIMPLEX VIRUS; RESISTANT STAPHYLOCOCCUS-AUREUS; YEAST SACCHAROMYCES-CEREVISIAE; LIPID-SOLUBLE PHTHALOCYANINES; TOPICAL 5-AMINOEVULINIC ACID; ANTIBODY-TARGETED PHOTOLYSIS; HUMAN-IMMUNODEFICIENCY-VIRUS; 500-NM MONOCHROMATIC LIGHT

11/3/K/26 (Item 1 from file: 45) Links

EMCare

(c) 2009 Elsevier B.V. All rights reserved.

0004984995 EMCARE No: 44740537

Exploiting tumour biology to develop novel drug delivery strategies for PDT

Wojtyk J.T.C.; Goyan R.; Gudgin-Dickson E.; Pottier R.

Department of Chemistry and Chemical Engineering, The Royal Military College of Canada, P.O. Box 17000, Kingston, Ont., K7K 7B4, Canada

AUTHOR EMAIL: James.Wojtyk@rmc.ca

CORRESP. AUTHOR/AFFIL: Wojtyk J.T.C.: Department of Chemistry and Chemical Engineering, The Royal Military College of Canada, P.O. Box 17000, Kingston, Ont., K7K 7B4, Canada

CORRESP. AUTHOR EMAIL: James.Wojtyk@rmc.ca

Medical Laser Application (Med. Laser Appl.) (Germany) November 15, 2006 , 21/4 (225-238)

PUBLISHER: Urban und Fischer Verlag Jena

CODEN: MLAEC ISSN: 1615-1615

PUBLISHER ITEM IDENTIFIER: S1615161506000780

DOI: 10.1016/j.mla.2006.07.005

Item Identifier (DOI): 10.1016/j.mla.2006.07.005

DOCUMENT TYPE: Journal ; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English; German; French

NUMBER OF REFERENCES: 139

...PDT) is a novel modality for cancer treatment that exploits the selective retention of a photosensitizer (PS) in tumour tissues to generate a localized cytotoxic species via light irradiation. While PDT....of PSs have received regulatory approval for the clinical treatment of a limited number of disease states. Even though much progress has been made in the understanding of the therapeutic mechanisms....has synthesized novel PS (and chemotherapeutic) conjugates that utilize the over expression of specific extra/intracellular enzymes, membrane receptors and antigens to selectively target and deliver these therapies.

ozone3.txt

(c) 2006 Elsevier...

DESCRIPTORS:

*
...human; immune system; isothiocyanic acid; low density lipoprotein receptor; macrogol; matrix metalloproteinase; membrane receptor; monoclonal antibody; paclitaxel; photosensitizing agent; phthalocyanine; polylysine; polymer; prodrug; protein expression; protein targeting; target cell; trastuzumab; tumor...
TERMS (UNCONTROLLED):

11/3,K/27 (Item 2 from file: 45) Links

EMCare

(c) 2009 Elsevier B.V. All rights reserved.

0003383437 EMCARE No: 127542776

Photodynamic laser therapy for rheumatoid arthritis: Cell culture studies and animal experiments

Hendrich C.; Huttmann G.; Lehnert C.; Diddens H.; Siebert W.E.
Department of Orthopaedics, Wurzburg University, Brettreichstrasse 11, D-97074
Wurzburg, Germany
CORRESP. AUTHOR/AFFIL: Hendrich C.: Department of Orthopaedics, Wurzburg
University, Brettreichstrasse 11, D-97074 Wurzburg, Germany

Knee Surgery, Sports Traumatology, Arthroscopy (Knee Surg. Sports Traumatol.
Arthroscopy) (Germany) December 1, 1997 , 5/1 (58-63)

PUBLISHER: Springer Verlag

ISSN: 0942-2056

DOCUMENT TYPE: Journal ; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 13

...human synovial fibroblasts obtained from patients with rheumatoid arthritis have demonstrated a cytotoxic effect after administration of Photosan-3 as a photosensitizer and subsequent laser irradiation at 630 nm. For the in vivo studies, IgG-induced arthritis... ...photodynamic laser therapy can be considered a new method in the surgical treatment of inflammatory disease of the synovial membrane. It has the advantage of being minimally invasive, while offering a...

DESCRIPTORS:

*
aluminum; animal model; arthritis; cartilage; cytotoxicity; fibroblast;
hematoporphyrin derivative; holmium; human; immunoglobulin G; in vivo study;
inflammatory disease; joint capsule; knee meniscus; laser; ligament; patient;
photosensitizing agent; rabbit; surgery; synovium ; yttrium
TERMS (UNCONTROLLED):

11/3,K/28 (Item 3 from file: 45) Links

EMCare

(c) 2009 Elsevier B.V. All rights reserved.

0003048277 EMCARE No: 25185470

Evaluation of a newly developed needle type system for phototherapy of deep cancer incorporating laser light and a photosensitizer, lumin

Mito K.

KMCAHP, Kawasaki, Japan

CORRESP. AUTHOR/AFFIL: Mito K.: KMCAHP, Kawasaki, Japan

Japanese Journal of Medical Electronics and Biological Engineering (JPN. J. MED. ELECTRON. BIOL. ENG.) (Japan) July 7, 1995 , 33/1 (40-45)

CODEN: IYSEA ISSN: 0021-3292

DOCUMENT TYPE: Journal ; Article RECORD TYPE: Abstract

LANGUAGE: Japanese SUMMARY LANGUAGE: English; Japanese

...newly developed needle type system for phototherapy of deep cancer

ozone3.txt
incorporating laser light and a photosensitizer, lumin

Lumin in a potent cell activating agent and a photosensitizer characterized by typical absorption peaks at 670nm and 770nm. In our preliminary results, a transplanted human cancer was dramatically cicatrized by collagen and removed by a photoimmunotherapy of small lumin administration with laser light irradiation. To treat a malignant tumor of the deep organs of the... .we developed new needle type photoimmunotherapeutic system. The system is composed of a needle to inject lumin solution and an optical fiber to guide the laser light to a cancer cell... .i.e. a control group, a group receiving laser irradiation only, a group receiving lumin administration only and a group receiving lumin administration with laser irradiation. Lumin of 5ng was injected and the tumor was irradiated with the laser (1.5mW, 60sec.). The treatment was performed every other day for three weeks. In the group receiving lumin administration with laser irradiation, the whole tumor was strongly cicatrized by collagen fiber from the stroma.....laser groups were 0.25 and 0.23, respectively, and the ratio in the lumin administration group was 0.34. That in the lumin administration with laser irradiation group, on the other hand, was 0.57. Thus, it was suggested...

* DESCRIPTORS:

...blood; cancer cell; cancer immunotherapy; collagen; collagen fiber; color; control group; glass fiber; human; immunofluorescence; intratumoral drug administration; irradiation; lung cancer; malignant neoplastic disease; monoclonal antibody; mouse; nonhuman; nude mouse; photodynamic therapy; sampling; stroma; tumor

TERMS (UNCONTROLLED):

11/3_K/29 (Item 1 from file: 72) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0082327674 EMBASE No: 2008132942

The application of low intensive laser rays in complex therapy of perforated gastroduodenal ulcer associated with Helicobacter pylori

Mahmudov M.G.

I Department of Surgical Diseases, AMU, Baku, Azerbaijan

Corresp. Author/Affil: Mahmudov M.G.: I Department of Surgical Diseases, AMU, Baku, Azerbaijan

Azerbaijan Medical Journal (Azerbaijan Med. J.) (Azerbaijan) December 1, 2007 , -/3 (102-105)

CODEN: ATJZB ISSN: 0005-2523

Document Type: Journal ; Article Record Type: Abstract

Language: Russian Summary language: English

Number of References: 12

...patients with perforated gastroduodenal HP associated ulcers by working out and clinical application of rational intracavitary laser and photodynamic therapy methods after the surgical treatment. According to the set tasks the...
...subgroup). Therapy of 24 patients from the main group(I subgroup) embraced PPI + amoxicilline + claritromycine + intracavitary low intensive laser exposure (wave length 632 nm, action time 4 min, output power 1.5 mW), the others 24 patients underwent PPI + amoxicilline + metronidazole + photodynamic therapy (the same parameters, photosensitizer - methylene blue). The results of the treatment were evaluated visually at endoscopic examination on 14...
Drug Descriptors:

* ...drug combination--cb; amoxicillin--drug therapy--dt; clarithromycin --drug combination--cb; clarithromycin--drug therapy--dt; immunoglobulin A--endogenous compound--ec; methylene blue; metronidazole--drug combination--cb;

ozone3.txt

metronidazole--drug therapy--dt; photosensitizing...

Medical Descriptors:

* ...ulcer--drug therapy--dt; *digestive system ulcer--surgery--su; * digestive system ulcer--therapy--th; *Helicobacter infection--drug therapy--dt; *low level laser therapy; *ulcer perforation--complication--co ; *ulcer perforation--drug therapy...
article; clinical article; controlled study; cytology; disease association; enzyme immunoassay; eradication therapy; gastrointestinal endoscopy; gastrointestinal surgery; Helicobacter pylori; histopathology; human; immunoglobulin blood level; immunostimulation; photodynamic therapy; postoperative care; postoperative complication--complication--co; postoperative complication--prevention--pc...

11/3,K/30 (Item 2 from file: 72) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0081051327 EMBASE No: 2006111366

Photodynamic therapy as an alternative antimicrobial modality for oral infections

Komerik N.; MacRobert A.J.

Department of Oral Surgery, Faculty of Dentistry, Suleyman Demirel University, Isparta, Turkey

Author email: Nkomerik@med.sdu.edu.tr

Corresp. Author/Affil: Komerik N.: Department of Oral Surgery, Faculty of Dentistry, Suleyman Demirel University, Isparta, Turkey

Corresp. Author Email: Nkomerik@med.sdu.edu.tr

Journal of Environmental Pathology, Toxicology and Oncology (J. Environ. Pathol. Toxicol. Oncol.) (United States) March 21, 2006 , 25/1-2 (487-504)

CODEN: JEPOE ISSN: 0731-8898

Document Type: Journal ; Review Record Type: Abstract

Language: English Summary language: English

Number of References: 108

...untreated, may lead to potentially life-threatening conditions. Mouth infections, such as caries, pulpitis, periodontal disease, and oral mucosal infections, such as mouth ulcers, are readily accessible and thus well suited...
...a problem leading to the overgrowth of opportunistic organisms. This may be overcome using a photosensitizer linked to an antibody recognizing the target organisms. At present, treatment of infections with PDT appears best for localized... infections, such as abscesses, may also be possible with improvements in the delivery of the sensitizer and light. PDT has the potential to become established as an alternative antimicrobial approach for...
Drug Descriptors:

*aminolevulinic acid--drug therapy--dt; aminolevulinic acid--topical drug administration--tp; antibiotic agent--drug therapy--dt; antifungal agent--drug therapy--dt; antiinfective agent--drug therapy... ...drug therapy--dt; phthalocyanine zinc--drug therapy--dt; polylysine--drug therapy--dt; porphyrin derivative--drug therapy--dt; proflavine--drug therapy--dt; rose bengal--drug therapy--dt; talaporfin--drug therapy--dt; talaporfin--topical drug administration--tp; thionine--drug therapy--dt; tolonium chloride--drug therapy--dt; tolonium chloride--topical drug administration--tp

Medical Descriptors:

* mouth infection--drug therapy--dt; *mouth infection--therapy --th; *photodynamic therapy
abscess--drug therapy--dt; abscess--therapy--th; antimicrobial activity; bacterial infection--drug therapy--dt; bacterial infection --therapy--th; burning sensation--complication--co; cell infiltration; dental caries--drug therapy--dt; dental caries... ...complication--co; erythema--complication--co; Gram negative bacterium; Gram positive bacterium; human; Human immunodeficiency virus

ozone3.txt

infection--drug therapy--dt; hyperpigmentation--complication--co; muscle necrosis--complication--co; nonhuman; oral mucosal disease --drug therapy--dt; oral mucosal disease--therapy--th; pain --complication--co; periodontitis--drug therapy--dt; photodynamics; photosensitization; priority journal; pruritus--complication--co; review; safety; salivary gland disease--complication--co; skin exfoliation --complication--co; ulcer--complication--co

11/3,K/31 (Item 3 from file: 72) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0080735634 EMBASE No: 2005380037

Uses of photodynamic therapy in premalignant and malignant lesions of the gastrointestinal tract beyond the esophagus

Wolfsen H.C.

Esophageal Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, United States; Esophageal Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, United States

Author email: pdt@mayo.edu

Corresp. Author/Affil: Wolfsen H.C.: Esophageal Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 3224, United States

Corresp. Author Email: pdt@mayo.edu

Journal of Clinical Gastroenterology (J. Clin. Gastroenterol.) (United States) September 1, 2005 , 39/8 (653-664)

CODEN: JCGAD ISSN: 0192-0790

Item Identifier (DOI): 10.1097/01.mcg.0000173930.60115.62

Document Type: Journal ; Review Record Type: Abstract

Language: English Summary language: English

Number of References: 161

...Barrett's esophagus. This review, however, describes the clinical experience using photodynamic therapy with various photosensitizer agents for the treatment of diseases in other areas of the gut, especially the pancreaticobiliary...

Drug Descriptors:

*
aminolevulinic acid--clinical trial--ct; aminolevulinic acid--drug therapy --dt;
aminolevulinic acid--intravenous drug administration --iv; aminolevulinic acid--oral
drug administration--po; carnoembryonic antigen; granulocyte colony stimulating
factor; hematoporphyrin derivative--drug therapy--dt; methylene blue; monoclonal
antibody; photofrin--adverse drug reaction--ae; photofrin--clinical trial--ct;
photofrin--drug therapy--dt; photofrin--intravenous drug administration--iv;
photofrin II--drug therapy--dt; photosensitizing agent--drug therapy--dt;
phthalocyanine aluminum; protoporphyrin; talaporfin...

Medical Descriptors:

...pain--side effect--si; pancreas; paralytic ileus--side effect--si;
phototoxicity--side effect--si; pigment disorder--side effect--si; priority journal;
prognosis; review; treatment indication; treatment outcome; Vater papilla
tumor--drug;..

Orig. Descriptors:

11/3,K/32 (Item 4 from file: 72) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0079879575 EMBASE No: 2004064455

On the selectivity of photodynamic therapy of choroidal neovascularization

ozone3.txt
associated with age-related macular degeneration

Van Den Bergh H.; Ballini J.-P.; Sickenberg M.
Swiss Fed. Inst. of Tech. Lausanne, EPFL/LPAS, CH-1015 Lausanne, Switzerland
Author email: Hubert.vandenBergh@epfl.ch
Corresp. Author/Affil: Van Den Bergh H.: Swiss Fed. Inst. of Tech. Lausanne,
EPFL/LPAS, CH-1015 Lausanne, Switzerland
Corresp. Author Email: Hubert.vandenBergh@epfl.ch

Journal Francais d'Ophtalmologie (J. Fr. Ophtalmol.) (France) January 1, 2004 , 27/1 (75-78)
CODEN: JFOPD ISSN: 0181-5512
Document Type: Journal ; Review Record Type: Abstract
Language: English Summary language: English; French
Number of References: 9

...200000 treatments that have been dispensed so far could have resulted in stabilization of the disease for at least a number of years. Clinical observations also indicate that, in addition to... ...macular degeneration are also discussed. Discussion: Novel approaches to improving selectivity could include attaching a photosensitizer to a targeting moiety such as a monoclonal antibody or a peptide. The undesirable closure of normal choriocapillaries in the treated area is one ...
Drug Descriptors:

* benzoporphyrin derivative; *photosensitizing agent--drug administration--ad;
*photosensitizing agent--drug therapy--dt
monoclonal antibody; peptide; placebo; porphyrin--drug administration--ad;
porphyrin--drug therapy--dt

Medical Descriptors:

11/3,K/33 (Item 5 from file: 72) Links
Fulltext available through: STIC Full Text Retrieval Options
EMBASE
(c) 2009 Elsevier B.V. All rights reserved.
0079832808 EMBASE No: 2004017574

Photosensitizer-antibody conjugates for detection and therapy of cancer

Van Dongen G.A.M.S.; Visser G.W.M.; Vrouenraets M.B.
Dept. Otolaryngol./Hd. Neck Surg., VU University Medical Center, De Boelelaan
1117, 1007 MB Amsterdam, Netherlands
Author email: gams.vandongen@vumc.nl
Corresp. Author/Affil: Van Dongen G.A.M.S.: Dept. Otolaryngol./Hd. Neck Surg., VU
University Medical Center, De Boelelaan 1117, 1007 MB Amsterdam, Netherlands
Corresp. Author Email: gams.vandongen@vumc.nl

Advanced Drug Delivery Reviews (Adv. Drug Deliv. Rev.) (Netherlands) January 13, 2004 , 56/1 (31-52)
CODEN: ADDRE ISSN: 0169-409X
Item Identifier (DOI): 10.1016/j.addr.2003.09.003
Document Type: Journal ; Review Record Type: Abstract
Language: English Summary language: English
Number of References: 110
Photosensitizer-antibody conjugates for detection and therapy of cancer

...discussed. This approach is called photoimmunotherapy (PIT). For PIT to be successful, sufficient amounts of sensitizer should be coupled to the MAb without altering its biological properties. A challenging aspect herein...
Drug Descriptors:

* hematoporphyrin derivative--drug therapy--dt; hematoporphyrin derivative
--pharmaceutics--pr; hematoporphyrin derivative--pharmacology--pd; monoclonal
antibody--intravenous drug administration --iv; monoclonal

ozone3.txt

antibody--pharmaceutics--pr; monoclonal antibody--pharmacology--pd;
photofrin--pharmaceutics--pr; phthalocyanine derivative--pharmaceutics--pr;
phthalocyanine derivative --pharmacology--pd; talaporfin--pharmaceutics...
Medical Descriptors:
disease severity; drug selectivity; evaluation; human; hydrophobicity;
immunotherapy; in vitro study; in vivo study; nonhuman; polyacrylamide...
Orig. Descriptors:

11/3, K/34 (Item 6 from file: 72) Links
Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0079114403 EMBASE No: 2002278141

Targeted sonodynamic therapy of cancer using a photosensitizer conjugated with antibody against carcinoembryonic antigen

Abe H.; Kuroki M.; Tachibana K.; Li T.; Awasthi A.; Ueno A.; Matsumoto H.; Imakire T.; Yamauchi Y.; Yamada H.; Ariyoshi A.; Kuroki M.
Department of Biochemistry, School of Medicine, Fukuoka University, 7-45-1
Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan
Corresp. Author/Affil: Kuroki M.: Department of Biochemistry, School of Medicine,
Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan
Corresp. Author Email: kurokima@fukuoka-u.ac.jp

Anticancer Research (Anticancer Res.) (Greece) August 23, 2002 , 22/3
(1575-1580)

CODEN: ANTRD ISSN: 0250-7005

Document Type: Journal ; Article Record Type: Abstract

Language: English Summary language: English

Number of References: 27

Targeted sonodynamic therapy of cancer using a photosensitizer conjugated with antibody against carcinoembryonic antigen

...for the selective destruction of cancer cells by ultrasonic irradiation in the presence of an antibody-conjugated photosensitizer. To this end, a photoimmunoconjugate (PIC) was prepared between ATX-70, a photosensitizer of a gallium-porphyrin analogue, and F11-39, a high affinity monoclonal antibody (MAB) against carcinoembryonic antigen (CEA), which is often overexpressed in various carcinoma cells. This conjugate... ...ultrasound irradiation. When in vivo anti-tumor effects in a mouse xenograft model were assessed, intravenous administration of F39/ATX-70 followed by ultrasonic irradiation produced a marked growth inhibition of tumor compared with irradiation alone or irradiation after administration of ATX-70. These results suggest that the PIC between anti-CEA MAB and ATX...

Drug Descriptors:

* carcinoembryonic antigen monoclonal antibody--drug combination--cb;
*carcinoembryonic antigen monoclonal antibody--drug development--dv;
*carcinoembryonic antigen monoclonal antibody--intravenous drug administration--iv;
*carcinoembryonic antigen monoclonal antibody--pharmacology--pd; *photosensitizing agent--drug combination--cb; *photosensitizing agent--drug development--dv; *photosensitizing agent--intravenous drug administration--iv; *photosensitizing agent--pharmacology--pd
antibody conjugate--drug combination--cb; antibody conjugate --drug development--dv;
antibody conjugate--intravenous drug administration--iv; antibody conjugate--pharmacology--pd; gallium--drug combination--cb; gallium--drug development--dv; gallium-- intravenous drug administration--iv;
gallium--pharmacology --pd; porphyrin derivative--drug combination--cb; porphyrin derivative --drug development--dv; porphyrin derivative--intravenous drug administration--iv; porphyrin derivative--pharmacology--pd; unclassified drug

Medical Descriptors:

* malignant neoplastic disease; *ultrasound therapy

ozone3.txt

Drug Terms (Uncontrolled): ...7,12 bis(1 decyloxyethyl) 2,18 bispropionylaspartic acid 3,8,13,17 tetramethylporphyrinate gallium--intravenous drug administration--iv; 7,12 bis(1 decyloxyethyl) 2,18 bispropionylaspartic acid 3,8,13,17 tetramethylporphyrinate.

Medical Terms (Uncontrolled):

11/3,K/35 (Item 7 from file: 72) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0078431796 EMBASE No: 2001037631

Photodynamic therapy: Shedding light on the biochemical pathways regulating porphyrin-mediated cell death

Granville D.J.; McManus B.M.; Hunt D.W.C.

QLT Inc., 887 Great Northern Way, Vancouver, BC V5T 4T5, Canada

Corresp. Author/Affil: Granville D.J.: QLT Inc., 887 Great Northern Way, Vancouver, BC V5T 4T5, Canada

Corresp. Author Email: dgranvil@qltinc.com

Histology and Histopathology (Histol. Histopathol.) (Spain) February 7, 2001
16/1 (309-317)

CODEN: HIHIE ISSN: 0213-3911

Document Type: Journal ; Review Record Type: Abstract

Language: English Summary language: English

Number of References: 91

...mediated and cardiovascular indications. PDT is a two step procedure. In the first step, the photosensitizer, usually a porphyrin derivative, is administered and taken up by cells. The second step involves activation of the photosensitizer with a specific wavelength of visible light. Exposure to light of an activating wavelength generates reactive oxygen species within cells containing photosensitizer. PDT with porphyrin photosensitzers induces rapid apoptotic cell death, an event which may be attributed...

Drug Descriptors:

* photosensitizing agent--drug dose--do; *photosensitizing agent--drug therapy--dt;
*photosensitizing agent--intravenous drug administration--iv; *photosensitizing agent--pharmacology--pd
...therapy--dt; calcium ion--endogenous compound--ec; caspase--endogenous compound--ec; hypericin--drug therapy--dt; immunoglobulin enhancer binding protein--endogenous compound--ec; photofrin; porphyrin derivative --drug therapy--dt; porphyrin derivative--intravenous drug administration--iv; porphyrin derivative--pharmacology--pd; protein bcl 2--endogenous compound--ec; reactive oxygen metabolite--endogenous...

Medical Descriptors:

autoimmune disease--drug therapy--dt; autoimmune disease --therapy--th; calcium cell level; cancer--drug therapy--dt; cancer --therapy--th; cardiovascular disease--drug therapy--dt; cardiovascular disease--therapy--th; cell survival; drug, mechanism; drug receptor binding; enzyme activity; genetic transfection; human; immune response; intracellular membrane; light exposure; mitochondrial membrane; nonhuman; protein expression; retina macula age related degeneration--drug therapy--dt; retina macula age related degeneration --therapy--th; review; transcription regulation; tumor suppressor gene; virus infection--drug therapy--dt; virus infection--therapy --th

Orig. Descriptors:

11/3,K/36 (Item 1 from file: 73) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0074518396 EMBASE No: 1991023895

8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease

Eppinger T.; Ehninger G.; Steinert M.; Niethammer D.; Dopfer R.
University Children's Hospital, Ruemelinstrasse 19-23, 7400 Tubingen, Germany
Corresp. Author/Affil: Eppinger T.: University Children's Hospital, Ruemelinstrasse
19-23, 7400 Tubingen, Germany

Transplantation (TRANSPLANTATION) (United States) December 1, 1990 , 50/5
(807-811)

CODEN: TRPLA ISSN: 0041-1337

Document Type: Journal ; Article Record Type: Abstract

Language: English Summary language: English

8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease

...ultraviolet A (PUVA) irradiation for treatment of drug-resistant cutaneous manifestations of graft-versus-host disease led us to investigate the effect of this therapy in a larger series of patients.....on CSA for GVH prophylaxis; 5 with mismatched grafts had additionally received methotrexate or monoclonal antibody campath-1 after bone marrow transplantation. Seven patients were on CSA and prednisolone; 2 patients.... duration of PUVA treatment. The 8-methoxypsoralen (0.6 mg/kg bw) was given as photosensitizer before each ultraviolet A irradiation (0.3-8.5 joules/cm² SUP 2). The only...

Medical Descriptors:

* graft versus host reaction; *puva; *skin disease
article; clinical article; human; oral drug administration; priority journal

Orig. Descriptors:

11/3,K/37 (Item 1 from file: 136) Links

Fulltext available through: STIC Full Text Retrieval Options

BioEngineering Abstracts

(c) 2007 CSA. All rights reserved.

0000094756 IP Accession No: 465464

Photoimmunotherapy of ovarian cancer

Moor, Anne CE; Hamblin, Michael; Molpus, Kelly; Duska, Linda R; Rizvi, Imran; Hasan, Tayyaba Massachusetts General Hospital, Boston, MA, USA
Proceedings of SPIE - The International Society for Optical Engineering , v 3909 , p 30-33 , 2000

Publication date: 2000

Publisher: SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS, BELLINGHAM, WA, (USA)

Conference:

Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy IX, San Jose, CA, USA, 01/22-01/23/00

Document Type: Journal Article; Conference

Record Type: Abstract

Language: English

ISSN: 0277-786X

File Segment: BioEngineering Abstracts

Abstract:

Photoimmunotherapy (PIT), which involves the antibody-targeted delivery of a photosensitizer and subsequent illumination, might offer a new treatment option for ovarian cancer. Studies from our... cells. These data suggest further exploration of PIT as an option for the treatment of intraperitoneal disease.

11/3,K/38 (Item 1 from file: 144) Links
Pascal
(c) 2009 INIST/CNRS. All rights reserved.

18975864 PASCAL No.: 09-0051597

Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration : Two-Year Results of the ANCHOR Study

BROWN David M; MICHELS Mark; KAISER Peter K; HEIER Jeffrey S;
SY Judy P; IANCHULEV Tsontcho
Vitreoretinal Consultants, Methodist Hospital, Houston, Texas, United States; Retina Care Specialists, Palm Beach Gardens, Florida, United States; Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, United States; Ophthalmic Consultants of Boston, Boston, Massachusetts, United States; Genentech, Inc, South San Francisco, California, United States
Journal: Ophthalmology : (Rochester, MN),
2009, 116 (1)
57-65

Language: English

Copyright (c) 2009 INIST-CNRS. All rights reserved.

Objective: The 2-year, phase III trial designated Anti-vascular endothelial growth factor (VEGF) Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization (CNV) in Age-related Macular Degeneration (ANCHOR...).

... antiangiogenic drugs. Intervention: Patients were randomized 1:1:1 to verteporfin PDT plus monthly sham intraocular injection or to sham verteporfin PDT plus monthly intravitreal ranibizumab (0.3 mg or 0.5 mg) injection. The need for PDT (active or sham) retreatment was evaluated every 3 months using fluorescein...

...3 of 277 (1.1%) patients developed presumed endophthalmitis in the study eye (rate per injection = 3/5921 (0.05%)). Conclusions: In this 2-year study, ranibizumab provided greater clinical benefit...

...English Descriptors: Comparative study; Verteporfin; Photodynamic therapy; Treatment; Neovascularization; Ophthalmology; Immunomodulator; Antiangiogenic agent; Vascular endothelium growth factor; Photosensitizer; Age related macular degeneration
Broad Descriptors: Monoclonal antibody; Porphyrin derivatives; Eye disease; Retinopathy; Anticorps monoclonal; Derive de la porphyrine; Pathologie de l'oeil; Retinopathie; Anti-VEGF; Anticuerpo...

11/3,K/39 (Item 2 from file: 144) Links
Pascal
(c) 2009 INIST/CNRS. All rights reserved.

18923817 PASCAL No.: 08-0534730

Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration

ozone3.txt

SCHMIDT-ERFURTH U; WOLF S

Department of Ophthalmology, Universitätsklinik für Augenheilkunde und Optometrie, University of Vienna, Vienna, Austria; Klinik und Poliklinik für Augenheilkunde, Inselspital, University of Bern, Bern, Switzerland

PROTECT Study Group, Unknown

Journal: British journal of ophthalmology,

2008, 92 (12)

1628-1635

Language: English

Copyright (c) 2008 INIST-CNRS. All rights reserved.

Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age...

Objective: To evaluate safety of same-day administration of verteporfin and ranibizumab. Methods: Prospective, open-label, multicentre study; patients with predominantly classic (n...

.. months 3, 6 and 9, based on fluorescein angiography (FA). Ranibizumab 0.5 mg was administered at baseline and months 1, 2 and 3. Main outcome measure: The incidence of severe...

English Descriptors: Choroidal neovascularization; Verteporfin; Ranibizumab ; Human; Ophthalmology; Photosensitizer; Immunomodulator; Antiangiogenic agent; Vascular endothelium growth factor; Age related macular degeneration

Broad Descriptors: Porphyrin derivatives; Monoclonal antibody; Eye disease; Retinopathy; Derive de la porphyrine; Anticorps monoclonal; Pathologie de l'oeil; Retinopathie; Anti-VEGF; Porfirina...

11/3_K/40 (Item 3 from file: 144) Links
Pascal

(c) 2009 INIST/CNRS. All rights reserved.

18657740 PASCAL No.: 08-0250525

Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-related Macular Degeneration (FOCUS) : Year 2 Results

ANTOSZYK Andrew N; TUOMI Lisa; CHUNG Carol Y; SINGH Angele

Charlotte Eye, Ear, Nose and Throat Associates, Charlotte, North Carolina , United States; Genentech, Inc, South San Francisco, California, United States

FOCUS STUDY GROUP, United States

Journal: American journal of ophthalmology,

2008, 145 (5)

862-874

Language: English

Copyright (c) 2008 INIST-CNRS. All rights reserved.

... macular degeneration. . DESIGN: Two-year, multicenter, randomized, single-masked, controlled study. . METHODS: Patients received monthly

intravitreal injections of ranibizumab 0.5 mg (n = 106) or sham injections (n = 56). All patients received PDT on day zero, then quarterly as needed. Efficacy assessment...

... than PDT-alone patients (mean = 0.4 vs 3.0 PDT retreatments). Endophthalmitis and serious intraocular inflammation occurred, respectively, in 2.9% and 12.4% of ranibizumab + PDT patients and 0...

...English Descriptors: Combined treatment; Verteporfin; Photodynamic therapy; Neovascularization; Focus; Ophthalmology; Immunomodulator; Antiangiogenic agent; Vascular endothelium growth factor; Photosensitizer; Age related macular degeneration
Broad Descriptors: Monoclonal antibody; Porphyrin derivatives; Eye disease; Retinopathy; Anticorps monoclonal; Derive de la porphyrine; Pathologie de l'oeil; Retinopathie; Anti-VEGF; Anticuerpo...

11/3,K/41 (Item 4 from file: 144) Links
Pascal

(c) 2009 INIST/CNRS. All rights reserved.

18612804 PASCAL No.: 08-0202971

Pharmacotherapy for the Treatment of Choroidal Neovascularization Due to Age-Related Macular Degeneration

NOVACK Gary D
Pharmalogic Development, Inc, San Rafael, California 94903, United States
Journal: Annual review of pharmacology and toxicology
, 2008, 48
61-78

Language: English

Copyright (c) 2008 INIST-CNRS. All rights reserved.

Age-related macular degeneration (AMD) is a progressive, degenerative disease of the macula that threatens central vision. It initially occurs in a "dry" form, and...

...is substantially different than it was in 1997. Focal, photoagulating, laser therapy was replaced by intravenous verteporfin and then by intravitreal pegaptanib, which is now being replaced by intravitreal ranibizumab and off-label use of hevacizumab. Other than a ranibizumab versus verteporfin trial, there are no published comparative studies of the three approved pharmacological treatments for CNV. Although frequent intravitreal injections are accepted as a current standard of care, their use is still far from ideal...

... for improving therapy of CNV with respect to mechanism-targeted treatments, efficacy, and route of administration.

...English Descriptors: Treatment; Antineoplastic agent; Pegaptanib; Verteporfin; Immunomodulator; Ranibizumab; Antiangiogenic agent; Vascular endothelium growth factor; Choroidal neovascularization; Photosensitizer; Pharmacotherapy; Human; Review; Age related macular degeneration

Broad Descriptors: Eye disease; Retinopathy; Monoclonal antibody; Pegylated form; Oligonucleotide; Porphyrin derivatives;

Pathologie de l'oeil; Retinopathie; Anticorps monoclonal; Forme peglee;
Oligonucleotide...

11/3_K/42 (Item 5 from file: 144) Links

Pascal

(c) 2009 INIST/CNRS. All rights reserved.

14801589 PASCAL No.: 00-0482363

Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies : A new possibility for use in photodynamic therapy

VROUENRAETS Maarten B; VISSER Gerard W M; LOUP Christophe;
MEUNIER Bernard; STIGTER Marijke; OPPELAAR Hugo; STEWART Fiona A; SNOW
Gordon B; VAN DONGEN Guus A M S

Department of Otolaryngology/Head and Neck Surgery, University Hospital,
vrije Universiteit, Amsterdam, Netherlands; Radio Nuclide Center, Vrije
University, Amsterdam, Netherlands; Laboratoire de Chimie de Coordination
du CNRS, Toulouse, France; Division of Experimental Therapy, Netherlands
Cancer Institute/Antoni van Leeuwenhoek Huis, Amsterdam, Netherlands
Journal: International journal of cancer,

2000, 88 (1)

108-114

Language: English

Copyright (c) 2000 INIST-CNRS. All rights reserved.

Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies : A new possibility for use in photodynamic therapy
... in PDT, probably because they cannot readily pass the cell membrane
and reach the critical intracellular target. We used the model compound TrisMPyP- PHI CO SUB 2 H, a hydrophilic porphyrin...

... integrity on SDS-PAGE, full stability in serum *in vitro*, and optimal immunoreactivity when the sensitizer : Mab ratio was <=3. At higher molar ratios, the solubility of the conjugates decreased. In...

... conjugates were phototoxic to A431 cells, while the non-internalizing E48 conjugate and the unconjugated sensitizer were not.
Biodistribution data of conjugates with sensitizer; SUP 1 SUP 2 SUP 5 I-cMAB U36 ratios varying from I:I to...

English Descriptors: Squamous cell carcinoma; Head and neck; Established cell line; Photodynamic therapy; Photochemotherapy;
Photosensitizer; Porphyrin; Hydrophilic compound; Monoclonal antibody; Internalization; Targeting; Treatment; *In vitro*; Human; Vulva

Broad Descriptors: Malignant tumor; ENT disease; Vulvar diseases;
Female genital diseases; Tumeur maligne; ORL pathologie; Vulve pathologie;
Appareil genital femelle pathologie...

11/3_K/43 (Item 6 from file: 144) Links

Pascal

(c) 2009 INIST/CNRS. All rights reserved.

14767255 PASCAL No.: 00-0446207

Experimental photoimmunotherapy of hepatic metastases of colorectal cancer with a 17.1A Chlorin SUB e SUB 6 immunocconjugate

DEL GOVERNATORE M; HAMBLIN M R; SHEA C R; RIZVI I; MOLPUS K G;
TANABE K; HASAN T

Wellman Laboratories of Photomedicine, Department of Dermatology,
Massachusetts General Hospital, Harvard Medical School, Boston,
Massachusetts 02114, United States; Departments of Pathology and Medicine
(Dermatology), Duke University Medical Center, Durham, North Carolina 27710
, United States; Vincent Memorial Obstetrics and Gynecology Service,
Division of Gynecologic Oncology, Massachusetts General Hospital, Harvard
Medical School, Boston, Massachusetts 02114, United States; Department of
Surgical Oncology, Massachusetts General Hospital, Harvard Medical School,
Boston, Massachusetts 02114, United States
Journal: Cancer research : (Baltimore),
2000, 60 (15)
4200-4205

Language: English

Copyright (c) 2000 INIST-CNRS. All rights reserved.

Photoimmunotherapy (using a monoclonal antibody-targeted photosensitizer and red light) may be a strategy to overcome the limitations inherent in photodynamic therapy...

... of hepatic metastases of colorectal cancer in an orthotopic murine xenograft using the murine monoclonal antibody 17.1A conjugated to the photosensitizer chlorin SUB e SUB 6 , and (b) to compare the tumor response after the same...

... with a photoimmunoconjugate bearing a polycationic charge, mice were treated 3 h after i.v. injection of the polyamionic 17.1A chlorin SUB e SUB 6 conjugate or unconjugated photosensitizer. Red light was delivered into the liver tumor by an interstitial fiber, and tumor response ...

English Descriptors: Phototherapy; Immunotherapy; Interstitial; Photosensitizer; Monoclonal antibody; Porphyrin; Immunoconjugate; Combined treatment; Metastasis; Liver; Intravenous administration; Malignant tumor; Colon; Rectum; Red light; Animal; Mouse

French Descriptors: Phototherapie; Immunotherapie; Interstiel; Photosensibilisant; Anticorps monoclonal; Porphyrine; Immunoconjugue; Traitement associe; Metastase; Foie; Voie intraveineuse; Tumeur maligne; Colon; Rectum; Lumiere rouge; Animal; Souris; Porphyrine derive

Spanish Descriptors: Fototerapia; Inmunoterapia; Intersticial; Fotosensibilizante; Anticuerpo monoclonal; Porfirina; Immunoconjugado; Tratamiento asociado; Metastasis; Higado; via intravenosa; Tumor maligno; Colon; Recto; Luz roja; Animal; Raton

Broad Descriptors: Rodentia; Mammalia; Vertebrata; Hepatic disease; Digestive diseases; Intestinal disease; Colonic disease; Rectal disease; Rodentia; Mammalia; Vertebrata; Foie pathologie; Appareil digestif pathologie; Intestin pathologie; Colon pathologie; Rectum pathologie; Rodentia...

11/3_K/44 (ITEM 7 FROM FILE: 144) Links
Pascal
(c) 2009 INIST/CNRS. All rights reserved.

13921145 PASCAL No.: 99-0102920

Light-induced photoactivation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria

MICCOLI L; BEURDELEY-THOMAS A; DE PINIEUX G; SUREAU F; OUDARD S; DUTRILLAUX B; POUPON M F
Laboratoire de Cytogenetique Moleculaire et Oncologie, CNRS UMR 147,
Institut Curie, 75248 Paris, France; Laboratoire de Physico-Chimie
Biomoleculaire et Cellulaire, CNRS URA 2056, Universite Pierre et Marie
Curie, 75252 Paris, France
Journal: Cancer research : (Baltimore),
1998, 58 (24)
5777-5786
Language: English

Copyright (c) 1999 INIST-CNRS. All rights reserved.

... for glioma metabolism depends on hexokinase, which is mainly bound to mitochondria. A decrease in intracellular pH leads to a release of hexokinase-binding, which in turn decreases glucose phosphorylation, ATP content, and cell proliferation. Thus, intracellular pH might be a target for therapy of gliomas, and a search for agents able to modulate intracellular pH was initiated. Hypericin, a natural photosensitizer, displays numerous biological activities when exposed to light. Its mechanism and site of action at...

... oxygen-dependent photosensitization mechanism producing singlet oxygen. Hypericin is also able to induce a photogenerated intracellular pH drop, which could constitute an alternative mechanism of hypericin action. In human glioma cells...

...I h with 2.5 μg/ml hypericin, light exposure induced a fall in intracellular pH. In these conditions, mitochondria-bound hexokinase was inhibited in a light- and dose-dependent...

... with a decreased ATP content, a decrease of mitochondrial transmembrane potential, and a depletion of intracellular glutathione. Hexokinase protein was effectively released from mitochondria, as measured by an ELISA using a specific anti-hexokinase antibody. In addition to decreased glutathione, a response to oxidative stress was confirmed by the concomitant...

English Descriptors: Photosensitizer; Energy metabolism; Human; Malignant glioma; Established cell line; Tumor cell; Mitochondria; Enzyme inhibitor; pH; In...
Broad Descriptors: Nervous system diseases; Central nervous system disease; Malignant tumor; Transferases; Enzyme; Carbon-nitrogen ligases; Ligases; Systeme nerveux pathologie; Systeme nerveux central pathologie...

11/3,K/45 (Item 8 from file: 144) Links
Pascal

(c) 2009 INIST/CNRS. All rights reserved.

12952657 PASCAL No.: 97-0228109

Biodistribution of charged F(ab') SUB 2 photoimmunoconjugates in a
xenograft model of ovarian cancer

DUSKA L R; HAMBLIN M R; BAMBERG M P; HASAN T
Wellman Laboratories of Photomedicine, WEL 224, Harvard Medical School,
Massachusetts General Hospital, Boston, MA 02114, United States; Vincent
Gynecological Oncology Service, VBK 1, Harvard Medical School,
Massachusetts General Hospital, Boston, MA 02114, United States
Journal: British journal of cancer,
1997, 75 (6) 837-844

Language: English

Copyright (c) 1997 INIST-CNRS. All rights reserved.

... was attached site specifically to the F(ab') SUB 2 fragment of the
murine monoclonal antibody OC125, directed against human ovarian
cancer cells, via poly-L-lysine linkers carrying cationic or...

...1 SUP 2 SUP 5 I and compared with non-specific rabbit IgG PICs after
intraperitoneal (i.p.) injection into nude mice. Samples were
taken from normal organs and tumour at 3 h and...

English Descriptors: Malignant tumor; Ovary; Treatment;
Photosensitizer; Immunoconjugate; Combined treatment;
Pharmacokinetics; Minimal residual disease; Indication;
Heterograft; Established cell line; Animal; Mouse; Fab'-Fragment;
Animal model; Specificity; Target cell; Photodynamic therapy

...French Descriptors: Traitement associe; Pharmacocinetique; Maladie
residuelle imperceptible; Indication; Heterogrefffe; Ligne cellulaire
etablie; Animal; Souris; Fragment peptidique Fab'; Modele animal;
Specificite; Cellule cible; Ligne NIH:OVCAR 5; Phototherapie dynamique

...Spanish Descriptors: Tratamiento asociado; Farmacocinetica; Enfermedad
residual imperceptible; Indicacion; Heteroinjerto; Linea celular
establecida; Animal; Raton; Fragmento peptidico Fab'; Modelo
animal; Especificidad; Celula blanco

11/3,K/46 (Item 9 from file: 144) Links
Pascal

(c) 2009 INIST/CNRS. All rights reserved.

12547557 PASCAL No.: 96-0227612

Control of hypertrophic scar growth using antibody-targeted
photolysis

WOLFORT S F; REIKEN S R; BERTHIAUME F; TOMPKINS R G; YARMUSH M

Page 33

ozone3.txt

L Surgical Services, Massachusetts General Hospital, Department of Surgery, Harvard Medical School and the Shriners Burns Institute, Boston, Massachusetts 02114, United States
Journal: The Journal of surgical research, 1996, 62 (1)
17-22
Language: English

Control of hypertrophic scar growth using antibody-targeted photolysis

...no routinely effective form of therapy. In this study, we investigated the potential use of antibody-targeted photolysis (ATPL) in treating hypertrophic scars. An immunoconjugate consisting of a photosensitizer (Sn-chlorin e6) linked to a monoclonal antibody that binds to human myofibroblasts (PR2D3) was prepared, which in response to photoactivation produces singlet...

... fold in volume over a period of 15 days. Four days after implantation immunoconjugate was injected directly into scar implants and allowed to diffuse throughout for 24 hr before implants were...

English Descriptors: Hypertrophy; Scar; Treatment; Laser photolysis; Association; Monoclonal antibody; Fibroblast;

Photosensitizer; Result; Experimental study; Animal; Mouse

Broad Descriptors: Rodentia; Mammalia; Vertebrata; Skin disease;

Instrumentation therapy; Rodentia; Mammalia; Vertebrata; Peau pathologie;

Traitement instrumental; Rodentia; Mammalia; Vertebrata; Piel patologia; Tratamiento...

11/3_K/47 (Item 10 from file: 144) Links

Pascal
(c) 2009 INIST/CNRS. All rights reserved.

10633471 PASCAL No.: 93-0142747

Suppression of anti-interferon alpha -2a antibody formation in patients with mycosis fungoids by exposure to long-wave UV radiation in the A range and methoxsalen ingestion

KUZEL T M; ROENIGK H H JR; SAMUELSON E; ROSEN S T
Northwestern univ. medical school, cancer cent., div. dermatology,
Chicago IL, USA

Journal: Journal of the National Cancer Institute
1992, 84 (2)

} 119-121
Language: English

Suppression of anti-interferon alpha -2a antibody formation in patients with mycosis fungoids by exposure to long-wave UV radiation in the A range and methoxsalen ingestion

English Descriptors: Photosensitizer; Immunotherapy; Phototherapy;
Page 34

ozone3.txt

Combined treatment; Human; Intramuscular administration;
Oral administration; Subcutaneous administration; Cytokine;
Alpha interferon; Immune response; Antibody; Mycosis fungoïdes;
Sezary syndrome; Mycosis; Ultraviolet irradiation

French Descriptors: Photosensibilisant; Immunotherapie; Phototherapie;
Traitement associe; Homme; Voie intramusculaire; Voie orale; Voie
souscutanee; Cytokine; Interferon alpha; Repense immune; Methoxsalen;
Anticorps; Mycosis fungoïde; Sezary syndrome...

Spanish Descriptors: Fotosensibilizante; Inmunoterapia; Fototerapia;
Tratamiento asociado; Hombre; Via intramuscular; Via oral; Via
subcutanea; Citoquina; Interferon alfa; Respuesta immune; Anticuerpo;
Micosis fungoïdes; Sezary sindrome; Micosis...

Broad Descriptors: Skin disease; Infection; Peau pathologie;
Infection; Piel patologia; Infección

11/3,K/48 (Item 1 from file: 154) Links

Fulltext available through: STIC Full Text Retrieval Options
MEDLINE(R)

(c) format only 2009 Dialog. All rights reserved.

28784227 PMID: 18488222

Systemic antitumor protection by vascular-targeted photodynamic therapy involves
cellular and humoral immunity.

Preise Dina; Oren Roni; Glinert Itai; Kalchenko Vyacheslav; Jung Steffen; Scherz
Avigdor; Salomon Yoram
Department of Biological Regulation, The Weizmann Institute of Science, Rehovot,
Israel.

Cancer immunology, immunotherapy - CII (Germany) Jan 2009 , 58 (1) p71-84 ,
ISSN: 1432-0851--Electronic Journal Code: 8605732

Publishing Model Print-Electronic

Document type: Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Vascular-targeted photodynamic therapy (VTP) takes advantage of intravascular
excitation of a photosensitizer (PS) to produce cytotoxic reactive oxygen species
(ROS). These ROS are potent mediators of vascular....for the enhancement of host
antitumor immunity in the treatment of both local and disseminated disease. (

Descriptors: *Antibody Formation--drug effects--DE; *Bacteriochlorophylls
--pharmacology--PD; *Immunity, cellular--drug effects--DE; *Neoplasms--drug
therapy...

11/3,K/49 (Item 2 from file: 154) Links

Fulltext available through: STIC Full Text Retrieval Options
MEDLINE(R)

(c) format only 2009 Dialog. All rights reserved.

18447751 PMID: 18354841

Ranibizumab: new drug. Macular degeneration: second-line use due to risks.

Prescrire international (France) Feb 2008 , 17 (93) p3-6 , ISSN:
1167-7422--Print Journal Code: 9439295

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: HSR

Record type: MEDLINE; Completed

...treatment for subfoveal lesions due to neovascular age-related macular degeneration (AMD). It consists of intravenous injection of a photosensitizer, verteporfin, followed by local red laser activation. This treatment, sometimes repeated every 3 months, stabilises ... years in about 50% of patients. Adverse effects are generally acceptable. (2) Ranibizumab is an antibody fragment targeting vascular endothelial growth factor (VEGF). VEGF is implicated in the neovascularisation involved in age-related macular degeneration. Ranibizumab is injected into the vitreous in the same way as pegaptanib, the first VEGF antagonist to be... . verteporfin (statistically significant difference). These trials did not attempt to determine the optimal interval between intravitreal injections. (4) No trials have directly compared ranibizumab with pegaptanib; indirect comparisons suggest that ranibizumab is better than pegaptanib. (5) Intravitreal injection of ranibizumab can have local adverse effects, similar to pegaptanib. These include inflammatory reactions, infections, and elevated intraocular pressure. Arterial thromboses at distant sites, in particular strokes, have been reported with ranibizumab, at a higher frequency with 0.5 mg per injection (about 1%) than with 0.3 mg per injection. (6) When visual acuity continues to deteriorate in patients with age-related macular degeneration despite... .
Descriptors: ; Antibodies, Monoclonal--administration and dosage--AD; Antibodies, Monoclonal--adverse effects--AE; Drug Approval; France; Humans; Light Coagulation; Photocochemotherapy; Porphyrins--administration and dosage--AD; Porphyrins--adverse effects--AE; Porphyrins--therapeutic use --TU; Randomized Controlled Trials as...
Named Person:

11/3,K/50 (Item 3 from file: 154) Links

Fulltext available through: STIC Full Text Retrieval Options

MEDLINE(R)

(c) format only 2009 Dialog. All rights reserved.

17765677 PMID: 17185984

A human mab specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo.

Trachsel Eveline; Kaspar Manuela; Bootz Frank; Detmar Michael; Neri Dario
Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
Journal of investigative dermatology (United States) Apr 2007 , 127 (4) p881-6
, ISSN: 1523-1747--Electronic Journal Code: 0426720
Contract/Grant No.: CA69184; CA; NCI NIH HHS United States; CA92644; CA; NCI NIH HHS United States
Publishing Model Print-Electronic
Document type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

The antibody-based targeted delivery of bioactive agents to sites of angiogenesis is an attractive therapeutic strategy... . a marker of angiogenesis, is expressed in psoriatic lesions, and that the anti-EDB human antibody L19 can selectively localize to chronically inflamed skin in vivo. The L19-based delivery of... . By contrast, the L19-based targeted delivery of the proinflammatory cytokine IL2 or of the photosensitizer Sn(IV) chlorin e6 resulted in an increased swelling and reddening of inflamed skin. These... .

Descriptors: *Antibodies, Monoclonal--immunology--IM; *Antibody Affinity; *Dermatitis, Atopic--immunology--IM; *Drug Delivery Systems; *Fibronectins--immunology--IM; Animals; Chronic Disease; Dermatitis, Atopic--metabolism--ME; Dermatitis, Atopic--pathology--PA; Humans; Hypersensitivity, Delayed--immunology--IM; Hypersensitivity, delayed--metabolism--ME; Hypersensitivity, Delayed--pathology--PA; Interleukin-10-- administration and dosage--AD; Interleukin-10--pharmacology--PD; Interleukin-12-- administration and dosage--AD; Interleukin-12 --pharmacology--PD; Interleukin-2--administration and dosage--AD; Interleukin-2--pharmacology--PD; Light; Metalloporphyrins-- administration and dosage--AD; Metalloporphyrins--pharmacology--PD; Mice; Mice, Inbred Strains; Mice,

ozone3.txt

Transgenic; Photosensitizing Agents-- administration and dosage--AD;
Photosensitizing Agents --pharmacology--PD; Skin--drug effects--DE;
Skin--pathology--PA; Skin...
Named Person:

11/3,K/51 (Item 4 from file: 154) Links

Fulltext available through: STIC Full Text Retrieval Options

MEDLINE(R)

(c) format only 2009 Dialog. All rights reserved.

17045573 PMID: 16467106

Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications.

Chen Bin; Pogue Brian W; Luna Jorge M; Hardman Rulon L; Hoopes P Jack; Hasan Tayyaba

Department of Surgery, Dartmouth Medical School, Lebanon, New Hampshire, USA.
Clinical cancer research - an official journal of the American Association for
Cancer Research (United States) Feb 1 2006 , 12 (3 Pt 1) p917-23 , ISSN:
1078-0432--Print Journal Code: 9502500

Contract/Grant No.: P01CA84203; CA; NCI NIH HHS United States

Publishing Model Print

Document type: Comparative Study; In Vitro; Journal Article; Research Support,
N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

...s.c. and orthotopic MatLyLu rat prostate tumor models and endothelial cells in vitro, using photosensitizer verteporfin. Vascular permeability to macromolecules (Evans blue-albumin and high molecular weight dextran) was assessed with dye extraction (ex vivo) and intravital microscopy (in vivo) methods. Intravital microscopy was also used to monitor tumor vascular functional changes after vascular-targeting photodynamic therapy... (

Descriptors: ; ...Permeability--radiation effects--RE; Cell Line; Cells, Cultured; Cytoskeleton--chemistry--CH; Cytoskeleton--radiation effects--RE; Disease Models, Animal; Drug Evaluation, Preclinical; Endothelial Cells--drug effects--DE; Endothelial Cells--physiology--PH; Endothelial Cells--radiation effects--RE; Fluorescent Antibody Technique --methods--MT; Light; Mice; Photosensitivity Disorders; Photosensitizing Agents--administration and dosage--AD; Photosensitizing Agents --radiation effects--RE; Porphyrins--administration and dosage--AD; Porphyrins--radiation effects--RE; Rats

Named Person:

11/3,K/52 (Item 5 from file: 154) Links

Fulltext available through: STIC Full Text Retrieval Options

MEDLINE(R)

(c) format only 2009 Dialog. All rights reserved.

13856368 PMID: 10945630

Experimental photoimmunotherapy of hepatic metastases of colorectal cancer with a 17.1A chlorin(e6) immunoconjugate.

Del Gobbiatore M; Hamblin M R; Shea C R; Rizvi I; Molpus K G; Tanabe K K; Hasan T
Department of Dermatology, Massachusetts General Hospital, Harvard Medical School,
Boston 02114, USA.

Cancer research (UNITED STATES) Aug 1 2000 , 60 (15) p4200-5 , ISSN:
0008-5472--Print Journal Code: 2984705R

Contract/Grant No.: R01 AR40352; AR; NIAMS NIH HHS United States

Publishing Model Print

Document type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research
Support, U.S. Gov't, P.H.S.

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Photoimmunotherapy (using a monoclonal antibody-targeted photosensitizer and red light) may be a strategy to overcome the limitations inherent in photodynamic therapy. . . . of hepatic metastases of colorectal cancer in an orthotopic murine xenograft using the murine monoclonal antibody 17.1A conjugated to the photosensitizer chlorin(e6), and (b) to compare the tumor response after the same light dose was. . . . with a photoimmunoconjugate bearing a polycationic charge, mice were treated 3 h after i.v. injection of the polyanionic 17.1A chlorin(e6) conjugate or unconjugated photosensitizer. Red light was delivered into the liver tumor by an interstitial fiber, and tumor response . . . (

Descriptors: ; Animals; Combined Modality Therapy; Disease Models, Animal; HT29 Cells--pathology--PA; Humans; Liver Neoplasms, Experimental--secondary--SC; Mice; Mice, Nude..

Named Person:

11/3,K/53 (Item 1 from file: 156) Links

ToxFile

(c) format only 2009 Dialog. All rights reserved.

1028984 NLM Doc No: CRISP/2003/AR040352-08A1 Sec. Source ID:

CRISP/2003/AR040352-08A1

Experimental Photoimmunotherapy of Ovarian Cancer

HASAN T

THASAN@PARTNERS.ORG, MASSACHUSETTS GENERAL HOSPITAL, 55 FRUIT STREET, BOSTON, MA 02114

Source: Crisp Data Base National Institutes of Health

City or State: MASSACHUSETTS Zip Code: 02114

Pub. Year: 2003

Sponsoring Agency: U.S. DEPT. OF HEALTH AND HUMAN SERVICES; PUBLIC HEALTH SERVICE; NATIONAL INSTITUTES OF HEALTH, NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES

Award Type: Grant

Document type: Research

Languages: ENGLISH

Record type: Completed

DESCRIPTION (provided by applicant): Photoimmunotherapy (PIT) involves the administration of a photosensitizer (PS) conjugated to antibodies (Mab), followed by light activation of the photoimmunoconjugate (PIC). The systemic. . . . overexpression is associated with the aggressive and invasive phenotype and chemoresistant cells, hallmarks of recurrent disease and (iii) cancer cell proliferation is more dependent on signaling via this molecular pathway than. . . . and interactions with both target and non-target cells in vitro. Sub-cellular localization and intracellular processing will be investigated. The PICs will be compared to non-specific rabbit IgG PICs. . . . human ovarian cancer. The strategy will be to (i) establish the optimal conditions for PIC administration. (ii) Determine the toxicology of PIC/PIT and treat the mice at the maximum tolerated. . . . (

Enzyme No.: Identifiers: laboratory mouse; biological signal transduction; chemical synthesis; spectrometry; immunoglobulin G; epidermal growth factor; immunoconjugate; immunocytochemistry; monoclonal antibody; immunofluorescence technique; statistics /biometry; intermolecular interaction; neoplasm /cancer immunotherapy; ovary neoplasm; combination cancer therapy; photochemistry. . . . cell culture; cytotoxicity; confocal scanning microscopy; technology /technique development; SDS polyacrylamide gel electrophoresis; minimal residual disease

Gene Symbol:

11/3,K/54 (Item 1 from file: 399) Links

CA SEARCH(R)

(c) 2009 American Chemical Society. All rights reserved.

148302882

CA: 148(14)302882t

PATENT

Page 38

ozone3.txt

Cooperative reporter systems, components, and methods for analyte detection

Inventor (Author): Su, Wei Wen

Location: USA

Assignee: University of Hawaii

Patent: PCT International ; WO 200820823 A2 Date: 20080221
Application: WO 2006US20106 (20060523) *US 2005PV683921 (20050523) *US 2006PV778991 (20060301)

Pages: 44pp.

CODEN: PIXXD2

Language: English

Patent Classifications:

Class: G01N-000/A

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA
Designated Regional: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CT; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

11/3,K/55 (Item 2 from file: 399) Links

CA SEARCH(R)

(c) 2009 American Chemical Society. All rights reserved.

148152083 CA: 148(7)152083s PATENT

Photodynamic therapy comprising administration of a targeted photosensitizing agent, for treatment for eye disease such as diabetic retinopathy, macular degeneration, and malignant uveal melanomas

Inventor (Author): Chen, James C.

Location: USA

Assignee: Light Sciences Oncology, Inc.

Patent: United States ; US 7320786 B2 Date: 20080122

Application: US 2005297880 (20051207) *US 2000PV175689 (20000112) *us 2001760362 (20010112)

Pages: 15pp., Cont.-in-part of U.S. Ser. No. 760,362, abandoned.

CODEN: USXXAM

Language: English

Patent Classifications:

Class: 424009600

IPC8 + Level Value Position Status Version Action Source Office:

A61K-0009/00 A I F B 20060101 20080122 H US

A61K-0039/395 A I L B 20060101 20080122 H US

A01N-0043/38 A I L B 20060101 20080122 H US

11/3,K/56 (Item 3 from file: 399) Links

CA SEARCH(R)

(c) 2009 American Chemical Society. All rights reserved.

135209894 CA: 135(15)209894v PATENT

Antibody specific for the ED-B domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis

Inventor (Author): Neri, Dario; Tarli, Lorenzo; Viti, Francesca; Birchler, Manfred

Location: Switz.

Assignee: Eidgenoessische Technische Hochschule Zurich

Patent: PCT International ; WO 200162800 A1 Date: 20010830

Application: WO 2001EP2062 (20010223) *US 512082 (20000224)

Pages: 75 pp.

CODEN: PIXXD2

Language: English

ozone3.txt

Patent Classifications:

Class: C07K-016/18A; A61K-051/10B; G01N-033/53B; G01N-033/574B; G01N-033/577B; C07C-063/06B; A61P-035/00B

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

Designated Regional: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

11/3,K/57 (Item 4 from file: 399) Links

CA SEARCH(R)

(c) 2009 American Chemical Society. All rights reserved.

132290565 CA: 132(22)290565w PATENT

Photosensitizer conjugates for targeting intracellular pathogens

Inventor (Author): Hasan, Tayyaba; Gross, Jerome; Nau, Gerard J.

Location: USA

Assignee: The General Hospital Corporation

Patent: PCT International ; wo 200023117 A1 Date: 20000427

Application: WO 99US24124 (19991015) *US PV104584 (19981016) *US PV115976 (19990115)

Pages: 35 pp.

CODEN: PIXXD2

Language: English

Patent Classifications:

Class: A61k-049/00A; A61k-038/00B; A01N-037/18B; C12N-001/20B

Designated Countries: CA; JP

Designated Regional: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL;

PT; SE

11/3,K/58 (Item 1 from file: 135) Links

NewsRx Weekly Reports

(c) 2009 NewsRx. All rights reserved.

0000522729 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Medical findings published by Swiss Federal Institute of Technology,
Switzerland

Biotech Business Week, May 14, 2007, p.1851

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1114

...TEXT: of PKC-theta in the induction of autoimmune myocarditis induced by either Coxsackie B3 virus infection or immunization with alpha-myosin/CFA (experimental autoimmune myocarditis (EAM)).
PKC-theta-deficient mice did...

...of immune stimulation that might reconcile the differential requirements for PKC-theta in these two disease models. We found systemic

ozone3.txt

administration of the TLR ligand CpG restored EAM in PKC-theta-deficient mice. CpG could act...
... Zurich, Switzerland. Study 3: According to recently published research from Switzerland, targeted delivery of an antibody-photosensitizer conjugate permits selective occlusion of tumor blood vessels. "The irregular vasculature and high interstitial pressure...
...tumors of nutrients and oxygen and causing an avalanche of tumor cell deaths. The human antibody L19, specific to the EDB domain of fibronectin, a marker of angiogenesis, is capable of...
...payloads to the tumor neovasculature. "Here we show that a chemical conjugate of the L19 antibody with the photosensitizer bis(triethanolamine)Sn(IV) chlorin e6, after intravenous injection and irradiation with red light, caused an arrest of tumor growth in mice with subcutaneous tumors. By contrast, a photosensitizer conjugate obtained with an antibody of identical pharmacokinetic properties but irrelevant specificity did not exhibit a significant therapeutic effect," reported...
...blood vessels, have a significant anticancer therapeutic potential and encourage the use of anti body-photosensitizer conjugates for the therapy of superficial tumors and possibly other angiogenesis-related pathologies." Fabbrini and...
...International Journal of Cancer (Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate. Int J Cancer, 2006;118(7):1805-1813). For more information, contact D. Neri...
...Switzerland. Keywords: Zurich, Switzerland, Angiogenesis, Angiology, Cancer Therapy, Drug Delivery, Targeted Delivery, Tumor Blood Vessels, Antibody-Photosensitizer Conjugate Biotechnology, Fibronectin, Solid Cancers, Vascular Targeting. This article was prepared by Biotech Business Week...

11/3/K/59 (Item 2 from file: 135) Links
NewsRx Weekly Reports
(c) 2009 NewsRx. All rights reserved.
0000520595 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Recent Hokkaido University, Japan, study findings reported

Biotech Business Week, May 14, 2007, p.1655

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1127

...TEXT: the clinical features of gefitinib-responders. In the present study, we analyzed the response and disease progression of primary and metastatic lesions to gefitinib in responders and the results of
Page 41

gefitinib...

...received gefitinib and achieved either a complete or partial response. The best-response rate and disease-control rate against the initial chemotherapy for the gefitinib-responders were 27.3% and 77...

...and brain, while there was no obvious effect on bone metastasis. The primary lesion and intrapulmonary metastasis were the sites of major recurrence. Median progression-free survival was 13.8 months...

...months and median overall survival was 29.2 months. Some of the patients who experienced disease progression after responding to gefitinib were again sensitive to readministration of gefitinib following temporary cessation...

... established tumors in mice," wrote D. Wakita and colleagues, Hokkaido University. "C57BL/6 mice were intradermally (i.d.) inoculated with ovalbumin (OVA)-expressing EG-7 tumor cells; when the tumor size reached 7-8 mm, the tumor-bearing mice were i.d. injected near the tumor-draining lymph node (DLN) with liposomes encapsulated with unmethylated cytosine-phosphorothioate-guanine...

...be generated in the tumor DLN and subsequently migrated into the tumor site. In vivo antibody blocking experiments revealed that CD8+ T cells, but not CD4+ T, NK or NKT cells...

...434). For additional information, contact D. Wakita, Hokkaido University, Institute of Medical Genetics, Section of Disease Control, Division of Immunoregulation, Sapporo, Hokkaido 0600815, Japan. Study 3: Tumor angiogenesis is vulnerable to...

...pharmacokinetics of clinically applied benzoporphyrin derivative monoacid ring-A (BPD-MA; verteporfin), a second-generation photosensitizer, during a trial of photodynamic therapy (PDT) in nine dogs having naturally occurring neoplasms," scientists writing in the Journal of Veterinary Medicine Series A - Physiology Pathology Clinical Medicine report. "After injecting BPD-MA at 0.5 mg/kg intravenously, its mean half-life ($t_{1/2}$) was found to be 8.14+/-5.34 h, mean...

...Vet. Surgery, Sapporo, Hokkaido 0600818, Japan. Keywords: Hokkaido, Japan, Biotechnology, Pharmacokinetics, Pharmacology, Photodynamic Therapy, Photomedicine, Photosensitizer, Verteoporfin, Cancer Therapy, Animal Research, Neoplasm, Angiogenesis. This article was prepared by Biotech Business week...

11/3/K/60 (Item 3 from file: 135) Links
NewsRx Weekly Reports
(c) 2009 NewsRx. All rights reserved.

0000477238 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Reports from University of Munich, Germany, add new data to knowledge base

Science Letter, March 20, 2007, p.4565

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1070

Study 1: Scientists discuss in "Secondary non-response due to antibody formation in a child after three injections of botulinum toxin B into the salivary glands" new findings in sialorrhea. According to recent...

...Botulinum toxin (BTX) offers a new treatment option to reduce drooling in adults and children; Antibody formation against BTX is known to be one reason for clinical secondary non-response to...

...treated for the indication of drooling. After three successful treatment sessions, the fourth and fifth injections showed no clinical response. This was associated with the presence of antibodies against BTX-B ...

...only in patients treated for cervical dystonia but also in children treated for drooling. Subsequent injections with an adequate dose of BTX type A (BTX-A) did not show any clinical...

...impede clinical response."

Berweck and colleagues published their study in(Secondary non-response due to antibody formation in a child after three injections of botulinum toxin B into the salivary glands. Developmental Medicine & Child Neurology, 2007;49(1...

...beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris.

"Tonsillar infection with may induce several nonsuppurative autoimmune sequelae. The precise pathogenetic mechanisms behind this clinically well..."

...fluorescence imaging demonstrates the rate of colonic dysplasia in patients with long-standing inflammatory bowel disease (IBD) colitis may be lower than previously reported.

"Patients with long-standing IBD have an..."

...be missed by conventional colonoscopy. Endoscopic fluorescence imaging, using 5-aminolevulinic acid (5-ALA) as photosensitizer, has evolved as a new technique to differentiate between normal colonic mucosa and dysplasia. We...

...indeterminate colitis; mean age 43 years, range 21-78) with long-standing IBD colitis (median disease duration 14 years, range 3-40). All patients were in clinical remission. Patients were examined...

...their study in (Low frequency of colorectal dysplasia in patients with long-standing inflammatory bowel disease colitis: Detection by fluorescence endoscopy. Endoscopy, 2006;38(5):477-482).

For additional information, contact...

...Germany.

Keywords: Munich, Germany, 5-ALA, Colonoscopy, Colonic Dysplasia, Endoscopic Fluorescence Imaging, Gastroenterology, Inflammatory Bowel Disease, IBD, Medical Device, Ulcerative Colitis.

This article was prepared by Science Letter editors from staff...

ozone3.txt

0000475376 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers from Norwegian Radium Hospital, Oslo, Norway, detail new studies and findings

Life Science Weekly, March 20, 2007, p.5023

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1013

... cellular transcriptional activity, the effect of the photochemical treatment as used in PCI (with the photosensitizer disulfonated meso-tetraphenylporphyrin followed by illumination) on gene transcription in WDR adenocarcinoma cells was evaluated...
...in the corresponding normal tissue. The significance of acidic pH in the development of metastatic disease was investigated in the present work," scientists in Norway report.
"Human melanoma cells (A-07...

...22) were cultured in vitro at pH 6.8 or 7.4 (control) before being inoculated into the tail vein of BALB/c nu/nu mice for formation of experimental pulmonary...

...vitro by using Matrigel invasion chambers and angiogenesis was studied in vivo by using an intradermal assay. Protein secretion was measured by ELISA and immunocapture assays," described E.K. Rofstad and...

...general matrix metalloproteinase (MMP) inhibitor GM6001, the general cysteine proteinase inhibitor E-64, or blocking antibody against vascular endothelial growth factor-A (VEGF-A) or interleukin-8 (IL-8).
"Our study...

...01). In HPV-cases with high expression of p53, no p14 expression predicted the poorest disease-specific survival ($p<.01$). For the first time, we have shown that p14 expression indicates longer disease-specific survival in patients with vulvar carcinoma," explained S. Knopp and colleagues, Norwegian Radium Hospital...
...with HPV-tumors expressing high levels of p53, low p14 indicated the poorest 5-year disease-specific survival."

Knopp and colleagues published their study in American Journal of Clinical Pathology (p14...

11/3/K/62 (Item 5 from file: 135) Links
NewsRx Weekly Reports
(c) 2009 NewsRx. All rights reserved.

0000473076 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Reports highlight recent research from Hokkaido University, Japan

Biotech Business Week, March 19, 2007, p.1644
Page 44

ozone3.txt

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1038

... established tumors in mice," wrote D. Wakita and colleagues, Hokkaido University.

"C57BL/6 mice were intradermally (i.d.) inoculated with ovalbumin (OVA)-expressing EG-7 tumor cells. When the tumor size reached 7-8 mm, the tumor-bearing mice were i.d. injected near the tumor-draining lymph node (DLN) with liposomes encapsulated with unmethylated cytosine-phosphorothioate-guanine...

...be generated in the tumor DLN and subsequently migrated into the tumor site. In vivo antibody blocking experiments revealed that CD8+ T cells, but not CD4+ T, NK or NKT cells...

...434).

For additional information, contact D. Wakita, Hokkaido University, Institute of Medical Genetics, Section of Disease Control, Division of Immunoregulation, Sapporo, Hokkaido 0600815, Japan.

Study 3: Tumor angiogenesis is vulnerable to...

...pharmacokinetics of clinically applied benzoporphyrin derivative monoacid ring-A (BPD-MA; verteporfin), a second-generation photosensitizer, during a trial of photodynamic therapy (PDT) in nine dogs having naturally occurring neoplasms," scientists writing in the Journal of Veterinary Medicine Series A - Physiology Pathology Clinical Medicine report.

"After injecting BPD-MA at 0.5 mg/kg intravenously, its mean half-life ($t_{1/2}$) was found to be 8.14+/-5.34 h, mean...

...Vet. Surgery, Sapporo, Hokkaido 0600818, Japan.

Keywords: Hokkaido, Japan, Biotechnology, Pharmacokinetics, Pharmacology, Photodynamic Therapy, Photomedicine, Photosensitizer, Verteporphyrin, Cancer Therapy, Animal Research, Neoplasm, Angiogenesis.

This article was prepared by Biotech Business Week...

11/3/K/63 (Item 6 from file: 135) Links
NewsRx Weekly Reports
(c) 2009 NewsRx. All rights reserved.

0000431341 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Journal articles present study results from Hokkaido University, Japan

Life Science Weekly, February 6, 2007, p.2739

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1026

... induction of apoptosis in leukemia cells." "These reagents significantly inhibited 2CdA-induced elevation of the intracellular calcium concentration ($[Ca(2+)](i)$) in MOLT-4 cells, and 2CdA-induced apoptosis was partly...
...established tumors in mice," wrote D. Wakita and colleagues, Hokkaido University.

"C57BL/6 mice were intradermally (i.d.) inoculated with ovalbumin (OVA)-expressing EG-7 tumor cells. When the tumor size reached 7-8 mm, the tumor-bearing mice were i.d. injected near the tumor-draining Tymph node (DLN) with liposomes encapsulated with unmethylated cytosine-phosphorothioate-guanine..."

...be generated in the tumor DLN and subsequently migrated into the tumor site. In vivo antibody blocking experiments revealed that CD8+ T cells, but not CD4+ T, NK or NKT cells...

...434).

For additional information, contact D. Wakita, Hokkaido University, Institute of Medical Genetics, Section of Disease Control, Division of Immunoregulation, Sapporo, Hokkaido 0600815, Japan.

Study 3: Tumor angiogenesis is vulnerable to...

...pharmacokinetics of clinically applied benzoporphyrin derivative monoacid ring-A (BPD-MA; verteporfin), a second-generation photosensitizer, during a trial of photodynamic therapy (PDT) in nine dogs having naturally occurring neoplasms," scientists writing in the report.

"After injecting BPD-MA at 0.5 mg/kg intravenously, its mean half-life ($t_{1/2}$) was found to be 8.14+-5.34 h, mean...

...Vet. Surgery, Sapporo, Hokkaido 0600818, Japan.

Keywords: Hokkaido, Japan, Biotechnology, Pharmacokinetics, Pharmacology, Photodynamic Therapy, Photomedicine, Photosensitizer, Verteporphyrin, Cancer Therapy, Animal Research, Neoplasm, Angiogenesis.

This article was prepared by Life Science Weekly...

...DESCRIPTORS: Cancer Vaccines; Hokkaido; Hokkaido University; Japan
; Leukemia Vaccines; Neoplasm; O; Pharmacokinetics;
Pharmacology; Photodynamic Therapy; Photomedicine;
Photosensitizer; Verteporphyrin; All News

11/3/K/64 (Item 7 from file: 135) Links
NewsRx Weekly Reports
(c) 2009 NewsRx. All rights reserved.

0000399604 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Hokkaido University, Japan, researchers describe recent findings

Life Science Weekly, January 9, 2007, p.658

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:

... pharmacokinetics of clinically applied benzoporphyrin derivative monoacid ring-A (BPD-MA; verteporfin), a second-generation photosensitizer, during a trial of photodynamic therapy (PDT) in nine dogs having naturally occurring neoplasms," scientists writing in the Journal of Veterinary Medicine Series A - Physiology Pathology Clinical Medicine report.

"After injecting BPD-MA at 0.5 mg/kg intravenously, its mean half-life ($t_{1/2}$) was found to be 8.14+/-5.34 h, mean...

...established tumors in mice," wrote D. Wakita and colleagues, Hokkaido University.

"C57BL/6 mice were intradermally (i.d.) inoculated with ovalbumin (OVA)-expressing EG-7 tumor cells. When the tumor size reached 7-8 mm, the tumor-bearing mice were i.d. injected near the tumor-draining lymph node (DLN) with liposomes encapsulated with unmethylated cytosine-phosphorothioate-guanine...

...be generated in the tumor DLN and subsequently migrated into the tumor site. In vivo antibody blocking experiments revealed that CD8+ T cells, but not CD4+ T, NK or NKT cells...

...434).

For additional information, contact D. Wakita, Hokkaido University, Institute of Medical Genetics, Section of Disease Control, Division of Immunoregulation, Sapporo, Hokkaido 0600815, Japan.

Keywords: Hokkaido, Japan, CpG Oligonucleotides, Interferons, Liposomal...

11/3/K/65 (Item 8 from file: 135) Links
NewsRx Weekly Reports
(c) 2009 NewsRx. All rights reserved.

0000378869 (USE FORMAT 7 OR 9 FOR FULLTEXT)

New findings from Norwegian Radium Hospital, Oslo, Norway, detailed

Biotech Business Week, December 11, 2006, p.428

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1038

... SA and its MDR, P-glycoprotein (P-gp)-overexpressing derivative MES-SA/Dx5 with the photosensitizer disulfonated meso-tetraphenylporphine (TPPS(2a)) and broad spectrum illumination. The PCI of doxorubicin, the ribosome...
...differences in the uptake and efflux of TPPS(2a) between the cell lines. After adenoviral infection, PCI enhanced gene delivery in both cell lines," wrote P.K. Selbo and colleagues, Norwegian...

ozone3.txt

...01). In HPV-cases with high expression of p53, no p14 expression predicted the poorest disease-specific survival ($p<.01$). For the first time, we have shown that p14 expression indicates longer disease-specific survival in patients with vulvar carcinoma," explained S. Knopp and colleagues, Norwegian Radium Hospital...

...with HPV-tumors expressing high levels of p53, low p14 indicated the poorest 5-year disease-specific survival."

Knopp and colleagues published their study in American Journal of Clinical Pathology (p14...

...in the corresponding normal tissue. The significance of acidic pH in the development of metastatic disease was investigated in the present work," scientists in Norway report.

"Human melanoma cells (A-07...

...22) were cultured in vitro at pH 6.8 or 7.4 (control) before being inoculated into the tail vein of BALB/c nu/nu mice for formation of experimental pulmonary...

...vitro by using Matrigel invasion chambers and angiogenesis was studied in vivo by using an intradermal assay. Protein secretion was measured by ELISA and immunocapture assays," described E.K. Rofstad and...

...general matrix metalloproteinase (MMP) inhibitor GM6001, the general cysteine proteinase inhibitor E-64, or blocking antibody against vascular endothelial growth factor-A (VEGF-A) or interleukin-8 (IL-8).

"Our study...

...Tumor Physiol, N-0310 Oslo, Norway.

Keywords: Oslo, Norway, Angiogenesis, Chemotherapy, Matrix Metalloproteinase, Melanoma, Metastatic Disease, Oncology, Photodynamic Therapy, Proteomics, Cancer Therapy, Extracellular pH, Hyperthermia, Proteinase.

This article was prepared by...

DESCRIPTORS: Angiogenesis; Cancer Gene; Cancer Therapy; Chemotherapy; Extracellular pH; Hyperthermia; Matrix Metalloproteinase ; Melanoma; Metastatic Disease; Norway; Norwegian Radium Hospital; Oncology; Oslo; Photodynamic Therapy; Proteinase; Proteomics; All News; Professional News

11/3/K/66 (Item 9 from file: 135) Links
NewsRx weekly Reports
(c) 2009 NewsRx. All rights reserved.

0000377815 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers with Hokkaido University, Japan, discuss study findings

Health & Medicine Week, December 11, 2006, p.779

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1150

... gene could attenuate left ventricular (LV) remodeling in diabetes mellitus (DM). We induced DM by injection of streptozotocin (160 mg/kg ip) in male GSHPx transgenic mice (TG+DM) and nontransgenic...

...pharmacokinetics of clinically applied benzoporphyrin derivative monoacid ring-A (BPD-MA; verteporfin), a second-generation photosensitizer, during a trial of photodynamic therapy (PDT) in nine dogs having naturally occurring neoplasms," scientists writing in the Journal of Veterinary Medicine Series A - Physiology Pathology Clinical Medicine report.

"After injecting BPD-MA at 0.5 mg/kg intravenously, its mean half-life ($t_{1/2}$) was found to be 8.14+/-5.34 h, mean...

...established tumors in mice," wrote D. Wakita and colleagues, Hokkaido University.

"C57BL/6 mice were intradermally (i.d.) inoculated with ovalbumin (OVA)-expressing EG-7 tumor cells. When the tumor size reached 7-8 mm, the tumor-bearing mice were i.d. injected near the tumor-draining lymph node (DLN) with liposomes encapsulated with unmethylated cytosine-phosphorothioate-guanine...

...be generated in the tumor DLN and subsequently migrated into the tumor site. In vivo antibody blocking experiments revealed that CD8+ T cells, but not CD4+ T, NK or NKT cells...

...434).

For additional information, contact D. Wakita, Hokkaido University, Institute of Medical Genetics, Section of Disease Control, Division of Immunoregulation, Sapporo, Hokkaido 0600815, Japan.

Keywords: Hokkaido, Japan, CpG Oligonucleotides, Interferons, Liposomal...

11/3/K/67 (Item 10 from file: 135) Links
NewsRx Weekly Reports
(c) 2009 NewsRx. All rights reserved.

0000319606 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Recent findings from Canada, the United Kingdom and the United States illuminate research in cancer treatment

Cancer Vaccine Week, July 24, 2006, p.47

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
943

... by incubating in vitro expanded mouse squamous cell carcinoma SCCVII cells for one hour with photosensitizer benzoporphyrin derivative (BPD), then exposing to light (690 nm, 1 J/cm²) and finally...
...HeN mice with 2 x 10⁷ PDT-vaccine cells per mouse by a peritumoral

injection produced a significant therapeutic effect, including growth retardation, regression, and cures," said Mladen Korbelik and...

...mismatched tumor cell line. Vaccine cells retrieved from the treatment site at one hour post-injection were intermixed with dendritic cells (DC), exhibited heat shock protein 70 on their surface, and...

...Canada. mkorbelik@bccrc.ca.

Study 2: Human papillomavirus (HPV) vaccines show promise for low-grade intraepithelial disease.

According to a review from England, "The ability to generate human papillomavirus virus (HPV)-like...

...from proof-of-principle efficacy trials strongly suggest that they will protect against persistent HPV infection and cervical intraepithelial neoplasia."

"However, the duration of protection provided by these vaccines is not known, the antibody responses induced are HPV type-specific and immunization must occur pre-exposure to the virus..."

...alternative delivery systems might be needed for the developing world. Therapeutic vaccines for low-grade intraepithelial disease are realistic but high-grade disease presents major hurdles for immunotherapies."

Stanley published the review in Best Practice and Research in...

...Court Road, Cambridge CB2 1QP, England. mas@mole.bio.cam.ac.uk.

Study 3: Pretreatment photosensitizer dosimetry improves the consistency of tumor responses.

In a recent study, scientists in New Hampshire sought "to compensate for photosensitizer uptake variation in photodynamic therapy (PDT), via control of delivered light dose through photodynamic dose calculation based on online dosimetry of photosensitizer in tissue before treatment."

The "photosensitizer verteporfin was quantified via multiple fluorescence microprobe measurements immediately before treatment," explained X.D. Zhou...

...calculated on an individual animal basis, by matching the light delivered to provide an equal photosensitizer dose multiplied by light dose."

"This was completed for the lower quartile, median, and upper quartile of the photosensitizer distribution," the investigators said. "PDT-induced tumor responses were evaluated by the tumor regrowth assay..."

...lower quartile (CL-PDT), the median (CM-PDT), and the upper quartile (CU-PDT) of photosensitizer distribution."

"The CL-PDT group was significantly less effective compared with NC-PDT (noncompensated PDT..."

...CM-PDT, and CU-PDT treatment groups."

These findings suggest that "accurate quantification of tissue photosensitizer levels and subsequent adjustment of light dose will allow for reduced subject variation and improved..."

...and colleagues published their study in the International Journal of Radiation Oncology Biology Physics (Pretreatment photosensitizer dosimetry reduces variation in tumor response. Int J Radiat Oncol Biol Phys, 2006;64(4)...

...USA.

Keywords: Hanover, New Hampshire, United States, Dosimetry, Medical Device, Oncology, Photodynamic Therapy, Photodynamics, Photomedicine,

ozone3.txt

Photosensitizer, Treatment Planning, Verteporfin.
This article was prepared by Cancer Vaccine Week editors from staff
and...

DESCRIPTORS: Cancer Treatment; Cancer Vaccine; Dosimetry; Hanover;
Medical Device; New Hampshire; Oncology; Photodynamic
Therapy; Photodynamics; Photomedicine;
Photosensitizer; Treatment Planning; United
States; Vaccination; Verteporfin; All News; Professional
News

11/3,K/68 (Item 11 from file: 135) Links
NewsRx Weekly Reports
(c) 2009 NewsRx. All rights reserved.

0000305783 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers' data from Norwegian Radium Hospital, Oslo highlight new
research

Pharma Business Week, June 7, 2006, p.474

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1119

... experiments, using untargeted saporin, EGFR-negative cell lines and competition with EGF and anti-EGFR antibody were used to document selective uptake of the affinity toxin," wrote A. Weyergang and colleagues, Norwegian Radium Hospital.

According to researchers, "One limitation in administration of macromolecular-drugs is lysosomal degradation. PCI is a modality for cytosolic release of macromolecules...

...also exert a triple tumour-selectivity; utilization of an affinity toxin, preferential accumulation of the photosensitizer in neoplastic lesions, and site-directed light activation," study authors concluded.

Weyergang and colleagues published...

...a wide range of carcinomas, in many of which it correlated with poor differentiation, metastasis, disease progression, and poor survival. MM is a locally aggressive and highly lethal tumor of serosal...

11/3,K/69 (Item 12 from file: 135) Links
NewsRx Weekly Reports
(c) 2009 NewsRX. All rights reserved.

0000033416 (USE FORMAT 7 OR 9 FOR FULLTEXT)

ozone3.txt
"Combination Photoimmunotherapy and Cisplatin: Effects on Human Ovarian Cancer ex vivo."

Cancer Weekly, October 25, 1999, p.27

DOCUMENT TYPE: Research News LANGUAGE: English
RECORD TYPE: FULLTEXT

word Count:
400

..TEXT: is clinically resistant to cisplatin-based chemotherapy have little hope of a cure of their disease. Photoimmunotherapy, which involves the antibody-targeted delivery of a nontoxic photosensitizer that is activated to a cytotoxic state with visible light, may offer a new treatment option. Photoimmunotherapy may be applied intraperitoneally to target disseminated tumor. We tested the hypothesis that this treatment in combination with cisplatin...

...tumor samples obtained from 14 patients with ovarian cancer who were undergoing primary surgery. The photosensitizer chlorin e(6) was conjugated to the F(ab')₂ fragment of the murine monoclonal antibody OC-123, which is directed against the antigen CA 125. Cytotoxicity was measured by the...

11/3,K/70 (Item 1 from file: 357) Links

Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0454417 DBA Accession No.: 2008-12836 PATENT

Composition is useful for treating or protecting influenza viral infection, comprises inactivated influenza virus and carrier pharmaceutical composition comprising carrier and inactivated influenza virus, useful as vaccine for prevention of influenza virus infection

Author: RAVIV Y; VIARD M; BLUMENTHAL R; HOGAN R J; TOMPKINS S M

Patent Assignee: US DEPT OF HEALTH 2008

Patent Number: WO 200854481 Patent Date: 20080508 WPI Accession No.: 2008-N01181
(200876)

Priority Application Number: US 785781 Application Date: 20060324

National Application Number: WO 2007US7338 Application Date: 20070323

Language: English

Composition is useful for treating or protecting influenza viral infection, comprises inactivated influenza virus and carrier pharmaceutical composition comprising carrier and inactivated influenza virus, useful as vaccine for prevention of influenza virus infection

Abstract: ...The light is ultraviolet light or a visible light and an effective amount of a photosensitizer chromophore is included in the mixture. The photosensitizer chromophore is a porphyrin, chlorin, bacteriochlorin, purpurin, phthalocyanine, naphthalocyanine, merocyanines, carbocyanine, texaphyrin, or non-tetrapyrrole. The photosensitizer chromophore is fluorescein, eosin, bodipy, nitro-benzo-diazol (NBD), erythrosine, acridine orange, doxorubicin, rhodamine 123,... a mammalian cell but cannot fuse with the mammalian cell. The composition is formulated for administration to a mucosal surface. The mucosal surface is a nasal surface. The carrier is a... before or after light exposure. Preferred Amount: The inactivated virus is a vaccine against viral infection of a mammal.

ACTIVITY - Virucide. MECHANISM OF ACTION - Vaccine. Mice were challenged with 10 LD₅₀ ... H1N1, and were immunized either with PBS, B/Ann Arbor or INA-X31 (subcutaneous or intranasal). Iodonaphthyl azide (INA) treatment protects animals against influenza infection and death. ELISA assays at day 28 post-vaccination showed that serum antibody titers specific for X31 were equivalent in mice receiving either live or INA-treated X31... indicated that the INA inactivation procedure did not reduce influenza viral antigenicity. Moreover, when challenged intranasally with 10 LD₅₀ of heterologous influenza virus (A/PR/8, H1N1), the live or INA... X31 subcutaneously immunized animals exhibited significant weight loss and none survived past fifteen days post-infection. USE - The composition or the vaccine is useful for treating or protecting a mammal against influenza viral infection (claimed). ADMINISTRATION - The inactivated influenza virus is administered by oral, subcutaneous, intravenous, intramuscular, intraperitoneal, rectal, dermal, transdermal, intrathoracic, intrapulmonary, mucosal or intranasal route at a dose of 0.01-5 g, preferably 0.1-0.2 g...

E.C. Numbers:

Descriptors: pharmaceutical comp., carrier, inactivated influenza virus, appl. vaccine, influenza virus infection prevention virucide (27, 51)

Section: ...DISEASE-HIV and Other Virus Infections

11/3,K/71 (Item 2 from file: 357) Links

Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.
0449841 DBA Accession No.: 2008-08350 PATENT

New fluorochrome conjugate comprising a dendrimer or backbone, a protease cleavage site and at least two fluorochromes, useful in preparing a composition for detecting or treating e.g., cancer pharmaceutical composition comprising dendrimer, protease cleavage site and fluorochrome, useful in treatment of cancer, arteriosclerosis, Alzheimer disease and osteosarcoma

Author: WEISSLEDER R; TUNG C; CHOI Y

Patent Assignee: GEN HOSPITAL CORP 2007

Patent Number: WO 2007109364 Patent Date: 20070927 WPI Accession No.: 2008-H56867
(200848)

Priority Application Number: US 783959 Application Date: 20060320

National Application Number: WO 2007US7289 Application Date: 20070320

Language: English

...composition comprising dendrimer, protease cleavage site and fluorochrome, useful in treatment of cancer, arteriosclerosis, Alzheimer disease and osteosarcoma

Abstract: ...to the dendrimer or backbone at quenching positions, where at least one fluorochrome is a photosensitizer. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are:

(1) a method of treating a subject having a disorder characterized by unwanted cellular proliferation; (2) a method for selectively imaging two different target cells of a subject simultaneously; and (3) kit for treating a subject having a disorder characterized by unwanted cellular proliferation or for imaging a target cell or cells in a...to the dendrimer or backbone at quenching positions, where at least one fluorochrome is a photosensitizer. The backbone comprises a dendrimer. At least two fluorochromes are photosensitizers. The fluorochrome conjugate further... polypeptide comprises albumin. The branched polypeptide comprises multiple antigenic peptides. The branched polypeptide is an antibody or an antibody fragment. The synthetic polymer is polyglycolic acid, polylactic acid, poly(glycolic-colactic) acid, polydioxanone, polyvalero... or beuzoporphyrin. The fluorochrome conjugate further comprises a solubility enhancing group, where at least one photosensitizer associates with the solubility enhancing group to form a photosensitive moiety. The photosensitizer is a chlorin. The photosensitive moiety comprises chlorin e6 and polyethylene glycol. The photosensitizer is rose bengal or a porphyrin. At least two fluorochromes are near-infrared fluorochromes. At... in range of about 500-900 nm. At least two fluorochromes are a combination of photosensitizer fluorochromes and nonphotosensitizer fluorochromes. At least two fluorochromes are a combination of photosensitizer fluorochromes and quencher. The fluorochrome conjugate further comprises at least one targeting moiety. The fluorochrome ... cathepsin S enzymatic cleavage site. Preferred Kit: The kit for

treating a subject having a disorder characterized by unwanted cellular proliferation, or for imaging a target cell or cells in a... ...that facilitate the illumination of a fluorochrome conjugate. Preferred Method: Treating a subject having a disorder characterized by unwanted cellular proliferation comprises: (a) administering the fluorochrome conjugate to a subject; (b) allowing the fluorochrome conjugate to distribute within the... ...through (c) are repeated over time. The method further comprises detecting fluorescence emitted from the photosensitizer conjugate and constructing an image. The disorder is a cancer, tumor, neoplasm, vascularization, cardiovascular disease, intravasation, extravasation, metastasis, arthritis, infection, Alzheimer's Disease, blood clot, atherosclerosis, melanoma, or osteosarcoma. The disorder is cancer. The subject is a human. The method comprises: (a) administering to a subject the fluorochrome conjugate, where at least one fluorochrome is a photosensitizer having optical properties distinct from the other fluorochrome(s); (b) allowing the fluorochrome conjugate to... ...with a second light of a wavelength sufficient to produce cytotoxic singlet oxygen by the photosensitizer; and (f) detecting fluorescence emitted by the photosensitizer. The method further includes the step of activating the fluorochrome conjugate prior to step (c). Step (a) comprises administering the fluorochrome conjugate to cells undergoing unwanted proliferation in the subject. Selectively imaging two different target cells of a subject simultaneously comprises: (a) administering to a subject one or more fluorochrome conjugates, where the at least two fluorochromes emit... ...conjugate is useful in preparing a composition for detecting or treating a subject having a disorder characterized by unwanted cellular proliferation, e.g., cancer, vascularization, cardiovascular disease, intravasation, extravasation, metastasis, arthritis, infection, Alzheimer's Disease, blood clot, atherosclerosis, melanoma or osteosarcoma. ADMINISTRATION - The composition is administered via subcutaneous, intravenous, intramuscular or intraarterial route. No dosage details given. ADVANTAGE - The fluorochrome conjugate is initially quenched and, therefore, insensitive... ...and after treatment, and minimal side-toxicity due to the non-activated state of the photosensitizer conjugates in circulation. EXAMPLE - No suitable example given.(68 pages)

E.C. Numbers:

Descriptors: pharmaceutical comp., dendrimer, protease cleavage site, fluorochrome, appl. cancer, arteriosclerosis, Alzheimer disease, osteosarcoma therapy cytostatic antirheumatic cardiant arteriosclerotic neuroprotective protein sequence enzyme tumor chromosome-21 21q21.3...

Section: ...DISEASE-Cancer; DISEASE-Cardiovascular... ...DISEASE-Central Nervous System

11/3,K/72 (Item 3 from file: 357) Links

Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0447358 DBA Accession No.: 2008-05867 PATENT

New recombinant binding protein comprises a derivative of the Src homology 3 domain of the FYN kinase, useful for preparing a medicament for treating or diagnosing cancer recombinant fusion protein produced by vector mediated gene expression in host cell, useful in pharmaceutical composition for diagnosis of cancer

Author: GRABULOVSKI D; NERI D

Patent Assignee: EIDGENOESSISCHE TECH HOCHSCHULE ZUERICH 2008

Patent Number: WO 200822759 Patent Date: 20080228 WPI Accession No.: 2008-F36389
(200835)

Priority Application Number: EP 200617336 Application Date: 20060821

National Application Number: WO 2007EP7324 Application Date: 20070820

Language: English

Abstract: ...preferably a component selected from Alexa Fluor or Cy dyes. The component is also a photosensitizer, preferably bis(triethanolamine)Sn(IV) chlorine 6 (SnChe6). The component is also a pro-coagulant... ...comprises a component modulating serum half-life, preferably a component selected from polyethylene glycol (PEG), immunoglobulin and albumin-binding peptides. ACTIVITY - Cytostatic. No biological data given. MECHANISM OF ACTION - Gene Therapy... ...of cancer, and for preparing a diagnostic means for the diagnosis of cancer (all claimed).

ozone3.txt

ADMINISTRATION - Administration can be through oral or parenteral, including subcutaneous, intramuscular, or intravenous route. No dosage details given. EXAMPLE - No suitable example given.(37 pages)

E.C. Numbers:

Section: ...GENETIC TECHNIQUES and APPLICATIONS-Gene Expression Techniques and Analysis; DISEASE-Cancer

11/3,K/73 (Item 4 from file: 357) Links

Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0431973 DBA Accession No.: 2007-18280 PATENT

New annexin variant that binds to at least one phospholipid and is bound to a recognizable compound, useful for pretargeting in therapy and diagnosis, or for treating or diagnosing neoplastic, autoimmune, or cardiovascular diseases involving vector-mediated gene transfer and expression in host cell for use in neoplastic disorder, autoimmune disorder and cardiovascular disease diagnosis

Author: REUTELINGSPERGER C; MOONEN P; VERMAIRE A

Patent Assignee: MOSAMEDIX BV 2007

Patent Number: WO 200769895 Patent Date: 20070621 WPI Accession No.: 2007-526434
(200751)

Priority Application Number: EP 2005111982 Application Date: 20051212

National Application Number: WO 2006NL50315 Application Date: 20061212

Language: English

...diseases involving vector-mediated gene transfer and expression in host cell for use in neoplastic disorder, autoimmune disorder and cardiovascular disease diagnosis

Abstract: ...substituted. Preferred Method: Delivering a diagnostic compound to a target cell in a subject comprises administering to the subject a composition comprising at least one annexin variant, and administering to the subject a composition comprising at least one complex of a compound (B) recognizing... ...or its combination. Delivering a pharmaceutical compound to a target cell in a subject comprises administering to the subject a composition comprising at least one annexin variant, and administering to the subject a composition comprising at least one complex of a compound (B) recognizing... ...is selected from a toxin, an enzyme, an enzyme inhibitor, a lipid, a carbohydrate, an immunoglobulin or its fragment, an immunoconjugate, a chemotherapeutic compound, a photosensitizer, a radionuclide, a cell death inducing agent, a cell death inhibiting agent, a fibrinolytic compound... ...acids and aptamers, a receptor or its part, a receptor ligand or its part, an antibody or its fragment, or an antigen. Detecting the presence or absence of cells or cell particles expressing phospholipids comprises: (A) administering to a subject a composition comprising at least one complex comprising a recognizable compound A and an annexin or an annexin variant; (B) administering to a subject a composition comprising at least one complex comprising a compound B recognizing...

E.C. Numbers:

Descriptors: recombinant annexin prep., isol., vector-mediated gene transfer, expression in host cell, appl., neoplastic disorder, autoimmune disorder , cardiovascular disease diagnosis (26, 36)

Section: ...GENETIC TECHNIQUES and APPLICATIONS-Gene Expression Techniques and Analysis; DISEASE-Cancer... ...DISEASE-Cardiovascular; DISEASE-Autoimmune Disease-

11/3,K/74 (Item 5 from file: 357) Links

Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0427490 DBA Accession No.: 2007-13428 PATENT

New monospecific antibody that binds an epitope of a mammalian dipeptidyl peptidase IV (DPPIV), useful for treating a patient suffering from a growth or proliferative disorder involving angiogenesis monoclonal antibody production against mammal enzyme protein via cell culture for disease therapy

Author: CHRISTOPHER R J; COVINGTON P

Patent Assignee: CHRISTOPHER R J; COVINGTON P 2007
Patent Number: US 20070060528 Patent Date: 20070315 WPI Accession No.: 2007-388195
(200736)

Priority Application Number: US 531495 Application Date: 20060913
National Application Number: US 531495 Application Date: 20060913

Language: English

New monospecific antibody that binds an epitope of a mammalian dipeptidyl peptidase IV (DPPIV), useful for treating a patient suffering from a growth or proliferative disorder involving angiogenesis monoclonal antibody production against mammal enzyme protein via cell culture for disease therapy

Abstract: DERWENT ABSTRACT: NOVELTY - A monospecific antibody, which specifically binds an epitope of a mammalian DPPIV (also known as CD26), is new. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are: (1) a bispecific antibody with binding specificity for a first epitope and a second epitope, where the first epitope is the epitope bound by the monospecific antibody; (2) an immunoconjugate comprising the monospecific antibody joined to a therapeutic agent; (3) an immunoconjugate comprising a bispecific antibody with binding specificity for a first and second epitope, the first epitope is an epitope of human DPPIV; (4) a pharmaceutical composition for inhibiting angiogenesis comprising an amount of monospecific antibody, bispecific antibody, or immunoconjugate, and a pharmaceutical carrier; (5) a method of treating a patient suffering from a growth or proliferative disorder involving angiogenesis; (6) a continuous cell line, which produces the monospecific antibody; (7) a method of inhibiting cancer invasion and angiogenesis in a solid tumor in a... by immunohistochemistry; and (8) a method of stimulating angiogenesis in a mammal suffering from a disease or disorder that may be remedied by an increased blood supply. BIOTECHNOLOGY - Preferred Antibody: The antibody inhibits angiogenesis. The antibody is a monoclonal or a polyclonal antibody. Preferably, the monoclonal antibody is an IgG2a. The mammalian DPPIV is human DPPIV. The antibody is monoclonal antibody E19 or E26, or antibody that specifically binds the epitope bound by monoclonal antibody E19 or E26. The antigen-binding fragment is selected from F(ab')², F(ab'), or Fv. The second epitope is an epitope of seprase, an epitope of MT1-MMP, an epitope of MMP-2, or an epitope of alpha(3)beta(1)-integrin. The antibody is also a chimeric antibody or a humanized antibody, where the humanized antibody has the immunoreactivity characteristics of monoclonal antibodies E19 or E26. Preferred Immunoconjugate: The immunoconjugate specifically binds the epitope bound by monoclonal antibody E19 or E26. It also comprises an antigen binding fragment of monoclonal antibody E19 or E26. The immunoconjugate also comprises a humanized antibody or a single chain antibody. The therapeutic agent is an anti-tumor drug, a cytotoxin, a radioactive agent, a photosensitizer, a second antibody, or an enzyme. Preferred Method: Treating a patient suffering from a growth or proliferative disorder involving angiogenesis comprises administering an amount of monospecific antibody, bispecific antibody, or immunoconjugate above. The method is administered in combination with a chemotherapy regimen. The monoclonal antibody specifically binds the epitope recognized by monoclonal antibody E3 or F4. Inhibiting cancer invasion and angiogenesis in a solid tumor in a patient ... normal tissue do not express levels of the DPPIV-seprase complex detectable by immunohistochemistry, comprises administering to the patient a composition comprising a cancer invasion- and angiogenesis-inhibiting amount of anti-DPPIV monoclonal antibody, where the DPPIV-seprase complex expressed on the surface of vascular endothelial cells and invading cancer cells involved in cancer invasion and angiogenesis is contacted by the antibody resulting in inhibition of cancer invasion and limiting the blood supply to the tissue of... solid tumor. The anti-DPPIV antibodies inhibit binding of collagen to the DPPIV-seprase complex. Administration is conducted in conjunction with chemotherapy, or with administration of a cytotoxin conjugate. In the method above, the patient is a human. Stimulating angiogenesis in a mammal suffering from a disease or disorder that may be remedied by an increased blood supply comprises administering to the mammal a composition comprising an angiogenesis-stimulating amount of a DPPIV modulator, where the blood supply to the affected tissue is increased. The disease or disorder is a cardiovascular disease, a diabetic ulcer, a retinopathy, or a non-healing wound.

Preferred Cell Line: The cell... compositions, and methods are useful for treating a patient suffering from a growth or proliferative disorder involving angiogenesis, and for stimulating angiogenesis in a mammal suffering from a disease

or disorder selected from cardiovascular disease, a diabetic ulcer, a retinopathy, or a non-healing wound. ADMINISTRATION - The cancer invasion and angiogenesis-inhibiting amount of anti-DPPIV monoclonal antibody is 0.1-300 mg/kg. Administration can be through intravenous, transdermal, intramuscular, or oral route (all claimed). EXAMPLE - No suitable example given.(41 pages)

E.C. Numbers:

Descriptors: mammal dipeptidyl-peptidase-IV-specific monospecific antibody, monoclonal antibody, humanized antibody, single chain antibody, hybridoma continuous cell culture, angiogenesis, appl. growth, proliferative disorder, cancer, cardiovascular disease, diabetic ulcer, retinopathy, non-healing wound therapy animal tumor antibody engineering cytostatic antitumor vulnerary (26, 26)
Section: ...BIOMANUFACTURING AND BIOCATALYSIS-Animal/Plant Cell Culture; DISEASE-Cancer... ...DISEASE-Cardiovascular; DISEASE-Endocrine/Metabolic SystemDISEASE-Other Diseases

11/3,K/75 (Item 6 from file: 357) Links

Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0408924 DBA Accession No.: 2006-22420 PATENT

Humanized L243 antibody binding human leukocyte antigen-DR, useful for treating cancer and immune disorders for use in sarcoma, glioma, skin cancer, autoimmune disease, leukemia, lymphoma, metabolic disease, neurodegenerative disease, immune-dysregulatory disorder, neoplastic disorder, autoimmune disorder, immune dysregulation disorder, metabolic disorder, neurodegenerative disease, dermatomyositis, myasthenia gravis, systemic lupus erythematosus, Addison disease, rheumatoid arthritis, multiple sclerosis, ulcerative colitis, anemia, amyloidosis and Alzheimer disease therapy

Author: GOLDENBERG D M; HANSEN H J; QU Z; CHANG C

Patent Assignee: IMMUNOMEDICS INC 2006

Patent Number: WO 200694192 Patent Date: 20060908 WPI Accession No.: 2006-621629
(200664)

Priority Application Number: US 657695 Application Date: 20050303

National Application Number: WO 2006US7598 Application Date: 20060303

Language: English

Humanized L243 antibody binding human leukocyte antigen-DR, useful for treating cancer and immune disorders for use in sarcoma, glioma, skin cancer, autoimmune disease, leukemia, lymphoma, metabolic disease, neurodegenerative disease, immune-dysregulatory disorder, neoplastic disorder, autoimmune disorder, immune dysregulation disorder, metabolic disorder, neurodegenerative disease, dermatomyositis, myasthenia gravis, systemic lupus erythematosus, Addison disease, rheumatoid arthritis, multiple sclerosis, ulcerative colitis, anemia, amyloidosis and Alzheimer disease therapy

Abstract: DERVENT ABSTRACT: NOVELTY - A humanized L243 (hL243) antibody binding to an epitope of human leukocyte antigen (HLA)-DR on HLA-DR+ cells, is new. DETAILED DESCRIPTION - A humanized L243 (hL243) antibody comprises: (a) a heavy chain variable domain, in which the complementary determining region (CDR)1... .27, 38, 46, 68 and 91 of the variable domain are from the mouse monoclonal antibody mL243 heavy chain and the remainder of the immunoglobulin framework domains are from one or more human heavy chains; and/or (b) a light... . residues 37, 39, 48 and 49 of the variable domain are from the mouse monoclonal antibody mL243 light chain and the remainder of the immunoglobulin framework domains are from one or more human light chains, where the antibody has the ability to bind to at least one epitope of HLA-DR (human leukocyte... .of the HLA gene cluster of major histocompatibility complex) on HLA-DR+ cells, and the antibody causes or leads to killing of the cells in a manner where neither cytotoxic addends... .INDEPENDENT CLAIMS are included for the following: (1) a pharmaceutical composition (C1) comprising the hL243 antibody; (2) a pharmaceutical composition (C2) comprising the hL243 antibody conjugated to one or more peptides, lipids, polymeric carriers, micelles, nanoparticles or their combinations, and... .3) treating (M1) a condition associated with undesired proliferation of cells expressing HLA-DR, by administering the pharmaceutical composition (C1) to a patient suffering from the disease; (4) treating (M2) a

patient using the pharmaceutical composition (C2); (5) kit comprising the pharmaceutical composition (C2); (6) treating (M3) a disorder in a subject, by administering to the subject, a "naked" polyvalent protein complex, comprising three binding sites, at least one....7) treating (M4) a condition associated with proliferation of cells expressing HLA-DR, by: (a) administering an effective amount of a bispecific antibody or its fragment comprising at least one arm that specifically binds HLA-DR and at... .binds a targetable conjugate, where the one arm that binds HLA-DR is an hL243 antibody or its fragment, and the targetable conjugate comprises a hapten moiety and a therapeutic agent, and administering the targetable conjugate to a patient with the condition; (b) administering to a subject with the condition, an effective amount of a bispecific antibody or its fragment comprising one arm that specifically binds HLA-DR and one arm that... .to a tumor-associated antigen, where one arm that binds HLA-DR is an hL243 antibody or its fragment; or (c) administering to a subject having the condition an effective amount of a antibody or its fragment that specifically binds HLA-DR, where the HLA-DR specific antibody is an hL243 antibody or its fragment, and administering to the subject before, after or simultaneously with the anti-HLA-DR antibody an effective amount of an antibody or its fragment that binds to a tumor-associated antigen.

WIDER DISCLOSURE - Also disclosed as new are: (A) nucleic acid molecules encoding the hL243 antibody or its conjugates; (B) expression vector comprising the nucleic acid molecules; and (C) host cells comprising the nucleic acid molecules.

BIOTECHNOLOGY - Preparation (disclosed): The antibody is prepared by standard recombinant methods.

Preferred Composition: The composition (C1) further comprises one or....antigens, where the additional binding molecule is given before, with or after the humanized L243 antibody. The pharmaceutical composition (C2) is an immunoconjugate. The antibody is conjugated to one or more lipids. The composition further comprises one or more additional... .4,8,11-tetraacetic acid (TETA), Tscg-Cys, Tscs-Cys or their mixtures. The hL243 antibody has at least one specificity for HLA-DR, where the remaining specificity is for a....The effector comprises a radionuclide, an enzyme, an immunomodulator or an anti-angiogenic agent. The antibody is conjugated to one or more therapeutic agents, diagnostic agents or their mixtures.

Preferred Method: In (M2), the administered composition (C2) comprises one or more agents for photodynamic therapy or diagnostic agents. The agent for photodynamic therapy is a photosensitizer. The diagnostic agent is used for performing positron emission tomograph (PET). The diagnostic agent comprises... .or contrast agents for X-ray or computed tomography (CT). The method (M2) further involves administering an additional composition which comprises a therapeutic agent, a diagnostic agent or their mixtures, where the additional composition comprises an immunoconjugate which is a humanized L243 antibody conjugated to one or more lipids, polymeric carriers, micelles, nanoparticles or their combinations, and one or more effectors. The humanized L243 antibody or its fragment is conjugated to the therapeutic agent, diagnostic agent or their mixtures by....a B-cell malignancy. The tumor-associated antigen is CD20. The anti-tumor-associated antigen antibody or its fragment comprises a humanized antibody or its fragment.

ACTIVITY - Cytostatic; Immunosuppressive; Muscular-Gen.; Neuroprotective; Dermatological; Metabolic; Endocrine-Gen; Antiinflammatory; Antiarthritic.... a xenograft model of human non-Hodgkin's lymphoma. Severe combined immunodeficiency (SCID) mice were injected with 2.5x10⁶ Raji cells. Therapy with hL243gamma4P or mL243 was initiated one day-post tumor cell administration. Both groups of mice were injected with saline or with non-specific control antibody, hMNI14 had a median survival time (MST) of 17 days. All the groups of mice treated with either humanized or murine L243 had significantly improved life span compared to mice injected with saline or hMNI14. In the group of animal treated with various doses of mL243.... .are chosen from carcinomas, melanomas, sarcomas, gliomas and skin cancers. The condition is an autoimmune disease, leukemia or lymphoma, metabolic disease, neurodegenerative disease or one of immune-dysregulatory disorders. For treating disorder in a subject, where the disorder is a neoplastic, autoimmune or immune dysregulation disorder, metabolic disorder, or neurodegenerative disease (claimed), where the autoimmune disease include dermatomyositis, myasthenia gravis, systemic lupus erythematosus, Addison's disease, rheumatoid arthritis, multiple sclerosis, ulcerative colitis, IgA nephropathy, Sjogren's syndrome, pernicious anemia, etc., metabolic disease such as amyloidosis, and neurodegenerative disease such as Alzheimer's disease.

ADMINISTRATION - The composition (C2) is administered

intravenously, subcutaneously or intramuscularly at a dose of 20-2000 mg. The composition (C2) is administered before, during, simultaneously, or after the administration of the additional composition (claimed). The composition (C1) is administered at a dose of 0.01-100 mg/kg body weight by parenteral route. ADVANTAGE - The humanized L243 antibody specifically binds HLA-DR, inhibits proliferation of HLA-DR+ cells, induces expression and release of... hinge region of the gamma4 sequence to avoid formation of half-molecules when the IgG4 antibody was expressed in mammalian cell cultures. The human gamma4 hinge region sequence between PstI and... obtained after 2-3 weeks. The supernatant from colonies was obtained and screened for human antibody secretion by ELISA using GAH-IgG, F(ab')2 fragment-specific antibody. Positive cell clones were expanded and hL243 and hL243gamma4P were purified from the cell culture...

E.C. Numbers:

Descriptors: human recombinant leukocyte antigen-humanized antibody, monoclonal antibody prep., isol., vector-mediated gene transfer, expression in host cell, apl., carcinoma, melanoma, sarcoma, glioma, skin cancer, autoimmune disease, leukemia, lymphoma, metabolic disease, neurodegenerative disease, immune-dysregulatory disorder, neoplastic disorder, autoimmune disorder, immune dysregulation disorder, metabolic disorder, neurodegenerative disease, dermatomyositis, myasthenia gravis, systemic lupus erythematosus, Addison disease, rheumatoid arthritis, multiple sclerosis, ulcerative colitis, anemia, amyloidosis, Alzheimer disease therapy animal mammal antibody engineering tumor cytostatic, immunosuppressive neuroprotective dermatological antiinflammatory antirheumatic antiulcer nephrotropic antianemic nootropic DNA sequence protein...

Section: ...GENETIC TECHNIQUES and APPLICATIONS-Gene Expression Techniques and Analysis; DISEASE-Cancer....DISEASE-Blood and Hematopoietic Cells; DISEASE-Central Nervous System....DISEASE-Endocrine/Metabolic System; DISEASE-Autoimmune Disease-....DISEASE-Other Diseases

11/3/K/76 (Item 7 from file: 357) Links

Fulltext available through: STIC Full Text Retrieval Options
Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.
0394742 DBA Accession No.: 2006-08238

Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate plasmid-mediated gene transfer and expression in HEK-293 cell for recombinant single chain antibody production for use in disease therapy

Author: FABBRINI M; TRACHSEL E; SOLDANI P; BINDI S; ALESSI P; BRACCI L; KOSMEHL H; ZARDI L; NERI D; NERI P

Corporate Affiliate: Swiss Fed Inst Technol Univ Siena Helios Klinikum Erfurt Ist Giannina Gaslini

Corporate Source: Neri D, Swiss Fed Inst Technol, ETH Honggerberg, Dept Chem and Appl Biosci, Wolfgang Pauli Str 10, HCI G396, CH-8093 Zurich, Switzerland

Journal: INTERNATIONAL JOURNAL OF CANCER (118, 7, 1805-1813) 2006

ISSN: 0020-7136

Language: English

Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate plasmid-mediated gene transfer and expression in HEK-293 cell for recombinant single chain antibody production for use in disease therapy

Abstract: ...tumors of nutrients and oxygen and causing an avalanche of tumor cell deaths. The human antibody L19, specific to the EBD domain of fibronectin, a marker of angiogenesis, is capable of... payloads to the tumor neovasculature. Here we show that a chemical conjugate of the L19 antibody with the photosensitizer bis(triethanolamine)Sn(IV) chlorin e6, after intravenous injection and irradiation with red light, caused an arrest of tumor growth in mice with subcutaneous tumors. By contrast, a photosensitizer conjugate obtained with an antibody of identical pharmacokinetic properties but irrelevant specificity did not exhibit a significant therapeutic effect. These... blood vessels, have a significant anticancer

therapeutic potential and encourage the use of anti body-photosensitizer conjugates for the therapy of superficial tumors and possibly other angiogenesis-related pathologies. (c) 2005...

E.C. Numbers:

Descriptors: recombinant single chain antibody, scFv(L19), SIP(L19) prep., immunoconjugate construction, plasmid pcDNA3.1-mediated gene transfer, expression in HEK-293 cell, affinity chromatography, tumor mouse animal model administration, immunofluorescence, appl. cancer, age-related macular degeneration, rheumatoid arthritis immunotherapy cell culture embryo kidney animal...

Section: ...GENETIC TECHNIQUES and APPLICATIONS-Gene Expression Techniques and Analysis; DISEASE-Cancer... ...DISEASE-Central Nervous System; DISEASE-Autoimmune Disease-

11/3,K/77 (Item 8 from file: 357) Links

Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0378448 DBA Accession No.: 2005-24154 PATENT

Conjugate useful as primary therapeutic agent for treating diseases e.g., infectious disease and autoimmune disease, comprises one or more moieties having ribonucleolytic activity, and one or more folate receptor ligands recombinant RNA-ase conjugate construction for use in disease diagnosis, RNA interference and gene therapy

Author: HANSEN H J; MCBRIDE W J; GOLDENBERG D M; ROSSI E A; CHANG C K

Patent Assignee: IMMUNOMEDICS INC 2005

Patent Number: WO 200569994 Patent Date: 20050804 WPI Accession No.: 2005-564084 (200557)

Priority Application Number: US 538396 Application Date: 20040122

National Application Number: WO 2005US2193 Application Date: 20050124

Language: English

Conjugate useful as primary therapeutic agent for treating diseases e.g., infectious disease and autoimmune disease, comprises one or more moieties having ribonucleolytic activity, and one or more folate receptor ligands recombinant RNA-ase conjugate construction for use in disease diagnosis, RNA interference and gene therapy

Abstract: ...conjugated to nitrilotriacetic acid residues, and nickel cations; and (2) treating and/or diagnosing a disease, comprising: (a) administering a binding molecule, having one arm that binds a targeted tissue and another arm that... ..composition and allowing the composition to clear non-localized binding molecules from circulation, and (c) administering a targetable construct comprising C1.

BIOTECHNOLOGY - Preferred Conjugate: In (I), the one or more moieties... ...more arms that specifically bind the peptide. Preferred Kit: K1 further comprises an implement for administering the therapeutic agent, one or more additional therapeutic agents or diagnostic agents. ACTIVITY - Antibacterial; Fungicide...

...data is given. MECHANISM OF ACTION - None given. USE - C1 is useful for treating a disease, by administering C1 as a primary therapeutic agent, and optionally an additional therapeutic agent or a diagnostic... ...is anti-sense or interference RNA. The binding molecule is multivalent, multispecific or bi-specific antibody. The antibody comprises MAb 679, MAb 734, MAb Mu-9, and/or MN-14. When the disease is a malignant disease, the binding molecule specifically binds an antigen chosen from carcinoembryonic antigen, tenascin, epidermal growth factor... ...factor receptors, vascular endothelial growth factor receptors, gangliosides, and/or HER2/neu receptors. When the disease is a cardiovascular disease, then the binding molecule is specific for granulocytes, lymphocytes, monocytes, fibrin or their mixture. The cardiovascular disease includes myocardial infarction, ischemic heart disease, atherosclerotic plaques, fibrin clots, and/or embolism. The infectious disease is caused by e.g. Microsporum, Trichophyton, Epidermophyton, Sporothrix schenckii, Cryptococcus neoformans, Candida albicans, HIV....Streptococcus agalactiae, Legionella pneumophila, Streptococcus pyogenes, Escherichia coli, Pneumococcus, Hemophilus influenzae B, Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus, Tetanus, helminth, malaria parasite, Mycoplasma arthritidis, and/or M.pneumoniae. The autoimmune disease is

e.g. idiopathic thrombocytopenic purpura, dermatomyositis, Sydenham's chorea, myasthenia gravis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, diabetes mellitus, Takayasu's arteritis, Addison's disease, rheumatoid arthritis, multiple sclerosis, sarcoidosis, ulcerative colitis, IgA nephropathy, polyarteritis nodosa, ankylosing spondylitis, Goodpasture's... .cell arteritis/polymyalgia, pernicious anemia, rapidly progressive glomerulonephritis, psoriasis, and/or fibrosing alveolitis. When the disease, is a metabolic or neurological disease, then the binding molecule specifically binds an amyloid deposit. The drug includes aplidin, azaribine, anastrozole... .anti-angiogenic agent is angiostatin, endostatin, baculostatin, canstatin, and/or maspin. The method also involves administering a diagnostic agent, preferably photosensitizer, preferably benzoporphyrin monoacid ring A (BPD-MA), tin etiopurpurin (SnET2), sulfonated aluminum phthalocyanine (AlSPC) and... .agents for performing an ultrasound imaging. The liposome is gas-filled. The method further involves administering Zn, Al³⁺, Ga, Lu, Pd, B, Gd, Ur, Mn, Fe, Cr, Cu, Co, Ni, Dy... .Ni²⁺, Cu²⁺, Nd³⁺, Sm³⁺, Yb³⁺, Gd³⁺, V²⁺, Tb³⁺, Dy³⁺, Ho³⁺, and/or Er³⁺. (All claimed.) ADMINISTRATION - (I) or C1 is administered by parenteral route such as intravenous route. The dosage of (I) is 0.01-300 mg, preferably 0.1-10 mg... .

E.C. Numbers:

Descriptors: ...conjugate construction, antisense RNA, RNA interference, MAb 679, MAb 734, MAb Mu-9, MN-14 antibody, carboxylesterase, glucuronidase, carboxypeptidase, beta-lactamase, phosphatase, nuclease, protease, lipase, appl. Microsporum sp., Trichophyton sp., Epidermophyton... .Streptococcus agalactiae, Legionella pneumophila, Streptococcus pyogenes, Escherichia coli, pneumococcus, Hemophilus influenzae-B, Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus, Tetanus, helminth, malaria parasite, Mycoplasma arthritidis, Mycoplasma pneumoniae... .chorea, myasthenia gravis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, diabetes mellitus, Takayasu arteritis, Addison disease, rheumatoid arthritis, multiple sclerosis, sarcoidosis, ulcerative colitis, IgA nephropathy, polyarteritis nodosa, ankylosing spondylitis, Goodpasture syndrome... .dorsalis, giant cell arteritis, polymyalgia, pernicious anemia, rapidly progressive glomerulonephritis, psoriasis, fibrosing alveolitis, metabolic, neurological disease diagnosis, therapy leuko virus retro virus AIDS Tenti virus herpes virus (24, 39)

11/3/K/78 (Item 9 from file: 357) Links

Dowker Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0357477 DBA Accession No.: 2005-03181 PATENT

Photosensitizer immunoconjugate composition useful for reducing tumor cell growth and/or proliferation, comprises antibody, polyethylene glycolylated polyglutamate chain and photosensitizer molecule indirectly linked to antibody for use in cancer therapy

Author: HASAN T

Patent Assignee: GEN HOSPITAL CORP 2004

Patent Number: WO 200499375 Patent Date: 20041118 WPI Accession No.: 2005-039270
(200504)

Priority Application Number: US 466574 Application Date: 20030430

National Application Number: WO 2004US13430 Application Date: 20040430

Language: English

Photosensitizer immunoconjugate composition useful for reducing tumor cell growth and/or proliferation, comprises antibody, polyethylene glycolylated polyglutamate chain and photosensitizer molecule indirectly linked to antibody for use in cancer therapy

Abstract: DOWKER ABSTRACT: NOVELTY - Photosensitizer immunoconjugate composition (I) comprises an antibody, a polyethylene glycol (PEG)ylated polyglutamate chain and a photosensitizer molecule, where the PEGylated polyglutamate chain is attached to a non-antigen binding region of the antibody, and a photosensitizer molecule such that the photosensitizer molecule is indirectly linked to the antibody through the PEGylated polyglutamate chain. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following: (1) detecting a target cell in a subject, involving

localizing a photosensitizer immunoconjugate composition comprising an antibody indirectly linked to a photosensitizer by a PEGylated polyglutamate chain to the target cell, light activating the composition to illuminate... .2) reducing tumor cell growth and/or proliferation in a subject, involving (a) providing a photosensitizer immunoconjugate composition comprising an antibody indirectly linked to photosensitizer by a PEGylated polyglutamate chain to the tumor cell, where the antibody binds with specificity to an epitope present on the surface of a tumor cell, and... .species, and inhibiting the tumor cell growth and/or proliferation, optionally (b) providing a second antibody to the tumor cell, where the antibody binds with specificity to a second epitope present on the surface of a tumor cell... .growth and/or proliferation of the tumor cell; and (3) preparing (M1) an indirectly linked photosensitizer immunoconjugate composition, involving preparing a PEGylated polyglutamate chain, attaching photosensitizer to a PEGylated polyglutamate chain, optionally activating the photosensitizer-PEG-polyglutamate composition to create a suitable reactive group, activating an antibody to create a suitable reactive group, and attaching a PEGylated polyglutamate chain to a non-antigen binding region of an antibody, where the antibody is indirectly linked to the photosensitizer through the PEGylated polyglutamate chain. BIOTECHNOLOGY - Preferred Composition: In (I), the antibody is chosen from whole native antibodies, bispecific antibodies, chimeric antibodies, fusion polypeptides, polyclonal antibodies, monoclonal antibodies and humanized monoclonal antibodies. The antibody is tumor specific or tumoricidal antibody. The tumor-specific antibody binds to an epitope on tumors derived from tissues chosen from breast, prostate, colon, lung... .intestine, liver, pancreas, ovary, uterus, cervix, testes, dermis, bone, blood and brain. The tumor specific antibody is chosen from IMC-C225, EMD 72000, BIWA 1, trastuzumab, rituximab, tositumomab, 2C3, rhuMab, vascular... .B8, 17F.11, anti-p75 interleukin (IL)-2R and anti-p64 IL-2R. The tumoricidal antibody is chosen from IMC-C225, EMD 72000, OvaRex Mab B43.13, anti-ganglioside G(D2) antibody ch14.18, CO17-1A, trastuzumab, rhuMab, VEGF, sc-321, AF349, BAF349, AF743, BAF743, MAB 743... .anti-p75 IL-2R, anti-p64 IL-2R, and 2A11. The immunoconjugate comprises upto 100 photosensitizer molecules. The photosensitizer molecule is chosen from porphyrins, hydroporphyrins, benzoporphyrins, chlorines, bacteriochlorins, purpurins, porphyrenes, verdins, phorbides, pheophorbides, texaphyrins... .rose Bengal and fluorescein. The porphyrin is benzoporphyrin monoacid derivative.

Preferred Method: In (M1), the photosensitizer -PEG-polyglutamate composition is activated with hydrazine to form a hydrazide on the carboxylic acid terminus of a glutamate residue, and purified by column chromatography. The antibody is activated by oxidation of the hydroxyl groups on the carbohydrates of the hinge region of the antibody, and purified by column chromatography. The activated antibody is conjugated to the activated photosensitizer-PEG-polyglutamate composition by forming an amide bond between the oxidized hydroxyl group in the hinge region of the activated antibody and a hydrazide group of the activated photosensitizer-PEG-polyglutamate. The photosensitizer -PEG-polyglutamate is linked to a lysine residue in the hinge region of the antibody. ACTIVITY - Cytostatic. The effect of photosensitizer immunoconjugates (PICs) to inhibit tumor growth was determined in vivo. A known xenograft model animal of intra -peritoneal epithelial ovarian carcinoma was utilized for measurement of the effects of photodynamic therapy (PDT)... .derived from human ovarian carcinoma cells with all of the inherent biological properties of human disease. The mice were maintained under specific pathogen-free conditions. Intraperitoneal PDT in the nude mice was performed. On day 10 and 20 after tumor cell injection, mice in treatment groups were injected with 1 mg/kg body weight of the PICs and irradiated with a total of... .were examined pathologically through hematoxylin and eosin staining. Animals were also weighed before tumor cell injection, and before sacrifice at day 21. Tumoricidal response was assessed by comparing the extent of gross residual disease in treated animals to the extent of disease in untreated controls. From the results it was seen that administration of indirectly linked C225-CMA with photoactivation at a high fluence rate resulted in a... .detecting a target cell such as tumor cell growth and/or proliferation in a neoplastic disease chosen from melanoma, neuroblastoma, glioma, sarcoma, lymphoma, ovarian, prostate, colorectal and small cell lung cancers. (I) is useful for reducing tumor cell growth and/or proliferation in a subject (Claimed). ADMINISTRATION - (I) is administered at a dosage of 0.01-500 mg/m², preferably 0.1-10 mg/m², orally, intranasally, topically or parenterally

(intramuscularly, subcutaneously, intraperitoneally, intravenously or transdermally). ADVANTAGE - (I) has low non-specific toxicity, high targeted phototoxicity, optimal antigen binding, high solubility, minimal aggregation and/or minimal contamination with unconjugated free photosensitizer molecules. (I) enables 40-50 photosensitizer molecules to be conjugated to a single antibody molecule, which provides 10-fold excess of photosensitizer, advantageously allowing for lower doses to be used in patients. (52 pages)

E.C. Numbers:

Descriptors: photosensitizer immunoconjugate composition monoclonal antibody, humanized antibody, appl. melanoma, neuroblastoma, glioma, sarcoma, lymphoma, cancer therapy antibody engineering cytostatic tumor (24, 05)

Section: ...DISEASE-Cancer

11/3,K/79 (Item 10 from file: 357) Links

Dowker Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0350216 DBA Accession No.: 2004-22508 PATENT

Treating ocular disease, e.g., proliferative diabetic retinopathy or iris, corneal or choroidal neovascularization by administering a conjugate of a benzoporphyrin and an anti-VEGF antibody and irradiating the subject with light verteporfin and vascular endothelial cell growth factor-specific monoclonal antibody administration for use in gene therapy

Author: GLICKMAN R D; MAYO G L; MCKINNON S J; MELENDEZ R F; KUMAR N C

Patent Assignee: UNIV TEXAS SYSTEM 2004

Patent Number: WO 2004080284 Patent Date: 20040923 WPI Accession No.: 2004-677340
(200466)

Priority Application Number: US 452655 Application Date: 20030307

National Application Number: WO 2004US6985 Application Date: 20040308

Language: English

Treating ocular disease, e.g., proliferative diabetic retinopathy or iris, corneal or choroidal neovascularization by administering a conjugate of a benzoporphyrin and an anti-VEGF antibody and irradiating the subject with light verteporfin and vascular endothelial cell growth factor-specific monoclonal antibody administration for use in gene therapy

Abstract: DÉRVENT ABSTRACT: NOVELTY - Treating a subject with ocular disease comprises administering to the subject a conjugate of a benzoporphyrin and an anti-VEGF antibody and irradiating the subject with light, symptoms of the ocular disease being reduced as compared to a control lacking the conjugate. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a photosensitizer-antibody conjugate comprising VISUDYNE linked bound to an anti-VEGF polyclonal antibody. BIOTECHNOLOGY - Preferred Method: Treating a subject with ocular disease comprises administering to the subject a conjugate of a benzoporphyrin and an anti-VEGF antibody and irradiating the subject with light, symptoms of the ocular disease being reduced as compared to a control lacking the conjugate. The benzoporphyrin is verteporfin. The verteporfin is VISUDYNE. The anti-VEGF antibody is a polyclonal or monoclonal antibody. The ocular disease is proliferative diabetic retinopathy or iris, corneal, occult-choroidal or classic-choroidal neovascularization. The reduced symptom is neovascularization. The administration is via intravenous injection of the conjugate by contact with an ophthalmic solution of the conjugate. The light is.... data given. MECHANISM OF ACTION - Gene therapy. USE - The method is useful in treating ocular disease e.g. proliferative diabetic retinopathy or iris, corneal, occult-choroidal or classic-choroidal neovascularization (claimed). ADMINISTRATION - The administration is via intravenous or ophthalmic route (claimed). No dosage details given. (45 pages)

E.C. Numbers:

Descriptors: benzoporphyrin, verteporfin, vascular endothelial cell growth factor-specific, polyclonal antibody, monoclonal antibody conjugate comp. administration, light irradiation, appl. ocular disease, proliferative diabetic retinopathy, iris, corneal, occult-choroidal, classic-choroidal neovascularization gene therapy protein (23, 45)

Section: ...GENETIC TECHNIQUES and APPLICATIONS-Gene Expression Techniques and

11/3,K/80 (Item 11 from file: 357) Links

Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0346832 DBA Accession No.: 2004-19124 PATENT

New pancreatic carcinoma-specific antigen 3C4-Ag primarily localized on the surface of rat and human pancreatic cancer cells, but not detected in normal, non-proliferating cells, useful in diagnosis and treatment of pancreatic cancer pancreas carcinoma-specific humanized antibody production useful for cancer diagnosis and therapy

Author: MICHL J; BRADU S M; HANNAN R; PINCUS M R

Patent Assignee: UNIV NEW YORK STATE RES FOUND 2004

Patent Number: WO 200465547 Patent Date: 20040805 WPI Accession No.: 2004-571676
(200455)

Priority Application Number: US 440699 Application Date: 20030117

National Application Number: WO 2004Us1196 Application Date: 20040116

Language: English

...non-proliferating cells, useful in diagnosis and treatment of pancreatic cancer pancreas carcinoma-specific humanized antibody production useful for cancer diagnosis and therapy

Abstract: ...2) an immunologically active fragment of the pancreatic carcinoma-specific antigen 3C4-Ag; (3) an antibody or its binding portion having specificity to pancreatic carcinoma specific antigen 3C4-Ag; (4) a murine hybridoma cell line that produces a monoclonal antibody specifically immunoreactive with the 3C4-Ag antigen; (5) a monoclonal antibody, mAb3C4, secreted by the hybridoma cell line; (6) detecting pancreatic cancer in an animal subject... ...a cell, tissue, or fluid sample from the subject with (the binding portion of) an antibody that binds to 3C4-Ag; (b) detecting antibody-antigen complex in the sample; and (c) correlating the detection of elevated levels of antibody-antigen complex in the sample with the presence of pancreatic cancer; (7) a diagnostic kit....3C4-Ag in a cell, tissue or fluid sample from a patient comprising: (a) the antibody or its binding portion specific for 3C4-Ag or its immunologically active fragment; (b) a conjugate of a specific binding partner for the antibody or its binding portion; and (c) a label for detecting the bound antibody; (8) treating pancreatic cancer in a patient by administering an effective amount of an antibody or its binding portion which specifically binds to 3C4-Ag or its immunologically active fragment, where the antibody or binding portion is conjugated or linked to a therapeutic drug or toxin; (9) a pharmaceutical composition comprising the antibody or its binding portion, and a carrier. BIOTECHNOLOGY - Preferred Antibody: The antibody or its binding portion binds to both the 43.5 kDa and 26-38 kDa forms of the 3C4-Ag antigen. The antibody is polyclonal or monoclonal. The monoclonal antibody mAb3C4 is preferably in a humanized form. The antibody is labeled with a fluorophore, chemilumiphore, chemiluminescer, photosensitizer, suspended particles, radioisotope or enzyme. The antibody is conjugated or linked to a therapeutic drug or toxin. The therapeutic drug or toxin... ...Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu (SEQ ID NO:1). The antibody comprises a penetratin sequence from antennapedia protein having a sequence of: Lys-Lys-Trp-Lys... ...Immunotoxin. USE - The antigen and methods are useful for detecting and treating pancreatic cancer (claimed). ADMINISTRATION - Dosage is 1-5000 mg/m². Administration is oral, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, intraarterial, intralesional. (112 pages)

E.C. Numbers:

Descriptors: human, rat, unglycosylated, pancreas carcinoma-specific antigen 3C4, mouse, 3C4-specific, labeled monoclonal antibody, humanized antibody , prep., hybridoma, appl., pancreas cancer, diagnosis, therapy animal mammal antibody antibody engineering cell culture cytostatic protein sequence (23, 39)

Section: ...GENETIC TECHNIQUES and APPLICATIONS-Gene Expression Techniques and Analysis; DISEASE-Cancer... ...DIAGNOSTICS-Antibody-Based Diagnostics; THERAPEUTICS-Protein Therapeutics

11/3, K/81 (Item 12 from file: 357) Links

Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0338210 DBA Accession No.: 2004-10502 PATENT

Novel monoclonal antibody e.g. Immu31 antibody useful for treating hepatocellular carcinoma, hepatoblastoma, germ cell tumors, carcinoma and other AFP-producing tumors involving expression in hybridoma and reverse transcription-polymerase chain reaction for use in therapy and as a drug target

Author: HANSEN H; QU Z; GOLDENBERG D M

Patent Assignee: IMMUNOMEDICS INC; MCCALL J D 2004

Patent Number: WO 200413180 Patent Date: 20040212 WPI Accession No.: 2004-238603 (200422)

Priority Application Number: US 399707 Application Date: 20020801

National Application Number: WO 2003GB3325 Application Date: 20030801

Language: English

Novel monoclonal antibody e.g. Immu31 antibody useful for treating hepatocellular carcinoma, hepatoblastoma, germ cell tumors, carcinoma and other AFP-producing tumors...

Abstract: DERWENT ABSTRACT: NOVELTY - A monoclonal antibody or its fragment (MB) that binds an alpha-fetoprotein (AFP) antigen, is new. DETAILED DESCRIPTION...
...Mab and framework region of the heavy or light chain variable region of a human antibody and the heavy or light chain constant region of a human antibody; (2) a diagnostic/detection or therapeutic immunoconjugate (IC) comprising an antibody component that comprises MB or CC, or an antibody fusion protein or its fragment that comprises MB or CC, where the antibody component is bound to at least one of diagnostic/detection or therapeutic agent; (3) a multivalent, multispecific antibody or its fragment (MF) comprising one or more antigen binding sites having affinity toward a... antigen and one or more hapten binding sites having affinity towards hapten molecules; (4) an antibody fusion protein or its fragment (AF) comprising at least two of MB, such as first monoclonal antibody e.g., MB and second monoclonal antibody other than the MB; (5) a DNA sequence (DS) comprising a nucleic acid encoding monoclonal antibody chosen from any one of MB and AF, where the second monoclonal antibody is chosen from CEA, EGP-1, EGP-2, MUC-1, MUC-2, MUC-3, MUC...
..K) useful for treating or identifying diseased tissues in a subject, comprising a bi-specific antibody or its fragment having at least one arm that specifically binds a targeted tissue and... bears at least one epitope recognizable by the at least one of the bi-specific antibody or its fragment and IC, optionally, a clearing composition useful for clearing non-localized antibodies... least one epitope recognizable by the at least one other arm of the bi-specific antibody or its fragment, and a prodrug, when the enzyme is capable of converting the prodrug to a drug at the target site. BIOTECHNOLOGY - Preferred Antibody: MB is a Immu31 antibody. MB is a humanized, chimeric or a full human antibody or its fragment. MB comprises complementarity-determining regions (CDRs) of a murine anti-AFP MAb...
...the framework (FR) regions of the light and heavy chain variable regions of a human antibody and the light and heavy chain constant regions of a human antibody. The CDRs of the light chain variable region of the humanized AFP Mab comprises CDR1... at least one amino acid substituted from the corresponding FRS of the murine anti-AFP antibody or its fragment. The amino acid from the murine MAB is at least one amino... 354 nucleotides as given in specification. Preferred Chain: In CC, the fragment is chosen from Fv, F(ab')2, Fab' and Fab. Preferred Immunoconjugate: IC comprises at least one photoactive diagnostic/detection agent. The photoactive diagnostic agent... factor (CSF), an interferon (IFN), a stem cell growth factor, erythropoietin, thrombopoietin and/or an antibody. The lymphotoxin is tumor necrosis factor (TNF), the hematopoietic factor is an interleukin (IL), the... 47, Fe-59, Cu-64, Cu-67, Se-75, etc., and its combinations. Preferred Multispecific Antibody: MF is a human antibody or chimerized antibody. MF further comprises IC. Preferred Fusion Protein: AF further comprises IC. The second monoclonal antibody is a carcinoma-associated antibody. Preferred Kit: In (K), the targetable conjugate is chosen from: (a) DOTA-Phe-Lys(HSG)... a MRI image-enhancing agent or a fluorescent label. Preferred Uses: IC is useful in intraoperative, endoscopic, or intravascular tumor detection/diagnosis. IC is useful for close-range lesion detection, during an operative, intravascular, laparoscopic

or endoscopic procedure which involves injecting IC to a subject parenterally, conducting the procedure within 48 hours of the injection, scanning the accessed interior of the subject at close range with a detection unit for detecting the presence of the labeled antibody or its fragment, and locating the sites of accretion of the labeled antibody or its fragment by detecting elevated levels of the labeled antibody or its fragment at such sites with the detection units. IC comprises a radioisotope that... .MF is useful for treating or diagnosing/detecting a malignancy in a subject which involves administering MF to a subject, waiting a sufficient amount of time for an amount of the non-binding protein to clear the subject's blood stream, and administering to the subject a carrier molecule having a diagnostic agent, a therapeutic agent or its combination, that binds to a binding site of the antibody. AF is useful for detecting or treating tumors expressing AFP in a mammal, imaging malignant tissue or cells in a mammal, intraoperatively identifying/disclosing diseased tissues expressing AFP, endoscopic identification of diseased tissues expressing AFP or intravascular identification of diseased tissues expressing AFP in a subject, which involves administering an effective amount of AF and administering a targetable conjugate chosen from targetable conjugate as mentioned in (K). The method further involves administering to the subject a clearing composition, and allowing the composition to clear non-localized antibodies or antibody fragments from circulation. AF is useful for screening for a targetable conjugate which involves contacting... .and analyzing the mixture. AF is useful for detection of lesions during an endoscopic, laproscopic, intravascular catheter or surgical procedure which involves injecting a subject with AF (e.g., F(ab)2 or F(ab')2, where AF has a first antibody binding site which specifically binds to a AFP antigen and has a second antibody binding site which specifically binds to a hapten, and permitting the antibody fragment to accrete at target sites, optionally clearing non-targeted antibody fragments using a galactosylated anti-idiotype clearing agent if AF is not largely cleared from circulation within 24 hours of injection and injecting a bivalent labeled hapten, which quickly localizes at the target site and clears through the... .accreted label at the target sites with detection units, within 48 hours of the first injection, and conducting the procedure, where the detection is performed without the use of a contrast....targetable conjugate comprises at least two HSG haptens. The first targetable conjugate comprises a prodrug, administering a second targetable conjugate which comprises a carrier portion which bears at least one epitope recognizable by at least one other arm of the bi-specific antibody or antibody fragment, and an enzyme capable of converting the prodrug to a drug or of reconverti... .comprises one or more agents for photodynamic therapy. The agent for photodynamic therapy is a photosensitizer which is chosen from benzoporphyrin monoacid ring A (BPD-MA), tin etiopurpurin (SnET2), sulfonated aluminum... .other arm that specifically binds a targetable conjugate is a human, chimeric or humanized Immu31 antibody or a fragment of a human, chimeric or humanized Immu31 antibody. The targeted tissue is a tumor. The tumor produces or is associated with AFP. The Immu31 antibody or its fragment comprises the Fv of monoclonal antibody Immu31. The bispecific antibody is AF which is trivalent, and incorporates the Fv of an antibody reactive with AFP. MB, MF or AF is useful diagnosing or detecting a malignancy in... .MF or AF is useful for treating a malignancy in the subject. The second monoclonal antibody in the above method is either MB or a native monoclonal antibody or its fragment. The second monoclonal antibody is immunocoujugated to a therapeutic or diagnostic/detection agent. The anti-AFP antibody is chosen from a subhuman primate anti-AFP antibody, murine monoclonal anti-AFP antibody, chimeric anti-AFP antibody, human anti-AFP antibody, and humanized anti-AFP antibody. The chimeric, human and humanized anti-AFP antibody constant and hinge regions comprise constant and hinge regions of a human IgG1. The anti-AFP antibody or its fragment is administered before, in conjunction with, or after a second conjugated antibody reactive with a second tumor marker expressed by the malignancy is administered to the subject. The first binding site of the anti-AFP antibody or its fragment is present in a multivalent, multispecific fusion protein or chemical conjugate and... .binding site is reactive with a tumor marker substance other than AFP. The anti-AFP antibody or its fragment is administered before, concurrently, or after at least one therapeutic or diagnostic/detection agent. The therapeutic or diagnostic/detection agent is conjugated to an antibody that targets a tumor marker that is expressed by the malignancy. MB, CC, MF or... .AF is useful for treating

or diagnosing/detecting a malignancy in a subject which involves administering MB, CC, IC, MF or AF, formulated in a vehicle. MB, CC, IC, MF or... ...a target which involves providing an immunoconjugate that comprises MB, CC, IC, MF or AF and administering the above composition to the subject in combination with carrier molecule. The diagnostic/detection agent... ...a liposome that comprises a humanized Immu31 or its fragment. ACTIVITY - Cytostatic. MECHANISM OF ACTION - Antibody therapy. No biological data given. USE - IC is useful in intraoperative, endoscopic, or intravascular tumor detection/diagnosis. IC is useful for close-range lesion detection, during an operative, intravascular, laparoscopic or endoscopic procedure. AF is useful for detecting or treating tumors expressing AFP in a mammal, imaging malignant tissue or cells in a mammal, intraoperatively identifying/disclosing diseased tissues expressing AFP, endoscopic identification of diseased tissues expressing AFP or intravascular identification of diseased tissues expressing AFP in a subject. AF is useful for screening for a targetable conjugate. AF is useful for detection of lesions during an endoscopic, laparoscopic, intravascular catheter or surgical procedure. (K) is useful for treating and identifying diseased tissues in a... ...useful for treating hepatocellular carcinoma, hepatoblastoma, germ cell tumors, carcinoma and other AFP-producing tumors. ADMINISTRATION - MB is administered by parenteral (claimed) or subcutaneous route. Dosage ranges from 20-2000 milligrams protein per dose. EXAMPLE - To elucidate Immu31 monoclonal antibody, the following test was done. The VH and Vkappa genes of Immu31 was obtained by... ...PCR reactions using the first strand cDNA as templates were then carried out to amplify immunoglobulin (Ig) VH and Vkappa genes. The Vkappa sequence of Immu31 was amplified by using the... .

E.C. Numbers:

Descriptors: alpha-fetoprotein antigen monoclonal antibody, humanized antibody, Fab, Fab', F(ab')2, Fv prep., expression in hybridoma, reverse transcription-polymerase chain reaction, appl. hepatocellular carcinoma, hepatoblastoma, germ cell tumor, carcinoma therapy, drug target antibody engineering cell culture DNA amplification cancer tumor cytostatic (23, 21)

Section: ...GENETIC TECHNIQUES and APPLICATIONS-Gene Expression Techniques and Analysis; DISEASE-Cancer...

11/3/K/82 (Item 13 from file: 357) Links

Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0331271 DBA Accession No.: 2004-03563 PATENT

New compound, useful for preparing a composition for diagnosing or treating tumor or infections caused by fungus, virus, parasite, bacterium, protozoan or mycoplasm for use in cancer and fungus, virus, parasitic, bacterium, protozoan and mycoplasm infection diagnosis and gene therapy

Author: GOLDENBERG D M; HANSEN H; LEUNG S; MCBRIDE W J; QU Z

Patent Assignee: IMMUNOMEDICS INC; MCCALL J D 2003

Patent Number: WO 200397105 Patent Date: 20031127 WPI Accession No.: 2004-042533 (2004)

Priority Application Number: US 150654 Application Date: 20020517

National Application Number: WO 2003GB2110 Application Date: 20030516

Language: English

Abstract: ...Pseudomonas endotoxin. The diagnostic agent includes one or more agents for photodynamic therapy, preferably a photosensitizer consisting of benzoporphyrin monoacid ring A (BPD-MA), tin etiopurpurin (SnET2), sulfonated aluminum phthalocyanine (AlSPc.....fragments. Preferred Method: Diagnosing or treating a disease or condition that may lead to a disease comprises: (a) administering to the subject a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targetable tissue and at least one other arm that specifically binds a targetable construct; (b) optionally, administering to the subject a clearing composition, and allowing the composition to clear non-localized antibodies or antibody fragments from circulation; and (c) administering to the subject a targetable construct comprising the compound. The bi-specific antibody or antibody fragment has at least one other arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct and the

targetable construct are administered at substantially the same time. The therapeutic cation emits particles and/or positrons having 20... . .least one arm that specifically binds a targeted tissue or targetable construct is a monoclonal antibody, human, chimeric or humanized antibody or its fragment. The bi-specific antibody or antibody fragment further comprises a therapeutic nuclide. The bi-specific antibody comprises the Fv of Mab Mu-9 and the Fv of Mab 679. Mu-9 and/or 679 are chimerized or humanized or human Mu-9 and 679. The bi-specific antibody comprises one or more of the CDRs of Mu-9 or 679. The bi-specific antibody is a fusion protein. The bi-specific antibody comprises the Fv of Mab MN-14 and the Fv of Mab 679. MN-14, and/or 679 are chimerized or humanized or are human MN-14 and 679. The bi-specific antibody comprises one or more of the CDRs of MN-14 or the CDRS of 679. The fusion protein is trivalent, and incorporates the Fv of an antibody reactive with CSAP. The bi-specific antibody incorporates a Class-III anti-CEA antibody and the Fv of 679. The targetable construct comprises one or more radioactive isotopes useful for killing diseased... . .BNCT of the diseased tissue. The targetable construct comprises an enzyme. The method further comprises administering to the subject a drug which the enzyme is capable of converting to a toxic... . .the target site. Detecting or treating target cells, tissues or pathogens in a mammal comprises administering the bi-specific antibody or antibody fragment comprising at least one arm that specifically binds a target and at least one other arm that specifically binds a targetable construct and administering a targetable construct comprising the compound; where the target includes a target cell, tissue, pathogen... . .Streptococcus pyogenes, Escherichia coil, Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus, Hemophilus influenzae B, Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus, Mycobacterium tuberculosis or Tetanus toxin. The parasite is... . .ovis, Taenia saginata or Mesocestoides corti. Treating or identifying diseased tissues in a subject comprises administering to the subject a bi-specific antibody or antibody fragment, a targetable construct comprising the compound or optionally, a clearing composition, and allowing the composition to clear non-localized antibodies or antibody fragments from circulation. The subject comprises humans, primates, equines, canines or felines. Imaging normal tissue in a mammal comprises administering bi-specific antibody or targetable construct comprising the compound. The normal tissue is tissue from the ovary, thymus, parathyroid, endometrium, bone marrow or spleen. intra-operatively identifying diseased tissues in a subject comprises administering bi-specific antibody or antibody fragment and a targetable construct comprising the compound. Endoscopic or intravascular identification of diseased tissues in a subject comprises administering bi-specific antibody or antibody fragment and a targetable construct comprising the compound. ACTIVITY - Cytostatic; Viricide; Antifungal; Antiparasitic; Antibacterial; Protozoacide...

E.C. Numbers:

Section: ...GENETIC TECHNIQUES and APPLICATIONS-Gene Expression Techniques and Analysis; DISEASE-Cancer... . .DISEASE-HIV and Other Virus Infections; DISEASE-Infectious Disease (non-viral)

11/3,K/83 (Item 14 from file: 357) Links
Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.
0311847 DBA Accession No.: 2003-12987 PATENT

New polypeptide comprising alpha-helix and attached therapeutic or diagnostic groups, useful e.g. for treating cancer, with groups arranged for minimal interference vector-mediated recombinant protein gene transfer and expression in host cell for use in gene therapy

Author: DEONARAIN M P; STAFFORD S
Patent Assignee: PHOTOBIOTICS LTD 2003

Patent Number: WO 200315825 Patent Date: 20030227 WPI Accession No.: 2003-278519
(200327)

Priority Application Number: GB 200120022 Application Date: 20010816

National Application Number: WO 2002GB3813 Application Date: 20020816

Language: English

Abstract: ...diseases, e.g. cancer; age-related macular degeneration; microbial infections; arthritis; immune disorders and cardiovascular disease, most particularly in photodynamic therapy where (A) is a photosensitizer. ADMINISTRATION - (I) are administered by inhalation, orally, by injection, topically etc. No dosage details given. ADVANTAGE - (I) provide targeted delivery of therapeutic and diagnostic... ...subcellular compartments). EXAMPLE - essentially standard recombinant DNA methods were used to produce a single-chain Fv (scFv)-4 helix bundle, mutated to incorporate Cys at optimal positions and to replace any ...
E.C. Numbers:

Descriptors:vector-mediated gene transfer, expression in host cell, appl. cancer age-related macular degeneration, infectious disease, arthritis, immune disorder, cardiovascular disease diagnosis, prevention, therapy, gene therapy tumor (22, 21)
Section: ...GENETIC TECHNIQUES and APPLICATIONS-Gene Expression Techniques and Analysis; DISEASE-Cancer... ...DISEASE-Cardiovascular; DISEASE-Central Nervous System... ...DISEASE-HIV and Other Virus Infections; DISEASE -Endocrine/Metabolic System... ...DISEASE-Infectious Disease (non-viral); DIAGNOSTICS-Molecular Diagnostics

11/3/K/84 (Item 15 from file: 357) Links
Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.
0300355 DBA Accession No.: 2003-02139 PATENT

Introducing molecule into cell cytosol for treating cancer, comprises contacting cell with photosensitizing agent, irradiating cell and contacting molecule with cell, before, substantially at same time or after irradiation DNA transfer and expression in host cell for drug delivery evaluation and gene therapy

Author: BERG K; PRASMICKAITE L; HOGSET A; SELBO P K
Patent Assignee: NORWEGIAN RADIUM HOSPITAL RES FOUND; JONES E L 2002
Patent Number: WO 200244396 Patent Date: 20020606 WPI Accession No.: 2002-636438 (200268)

Priority Application Number: GB 200114695 Application Date: 20010615
National Application Number: WO 2001GB5299 Application Date: 20011129

Language: English

Abstract: ...same time or after irradiation, where irradiation is performed before uptake of MO into any intracellular compartment, preferably the one containing PA, is new. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included.... ...performed on cells *in vitro* or *in vivo*. The transfer molecule is a protein, peptide, antibody, antigen or their fragments, or a cytotoxic drug, or a nucleic acid molecule that is.... ...were minced to homogeneity by a scalpel and 20 micro liters of the solution was injected subcutaneously on the right hip of each mouse. The tumor size was measured two or.... ...A stock solution of AlPcs2a was diluted to 1.25 mg/ml in PBS and injected intraperitoneally to a final concentration of 10 mg/kg when the tumors had reached a volume of approximately 100 mm³. 48 hour after the injection of AlPcs2a the tumors were exposed for 16 minutes to red light. Immediately after light exposure gelonin was injected intratumorally. The mice were kept in the dark for 1 week after the injection of AlPcs2a. The tumors were illuminated with a 150 W halogen lamp filtered with a.... ...molecule into the cytosol of a cell. (M) is useful for treating or preventing a disease, disorder or infection (such as cancer), in a patient by introducing a transfer molecule into one or more cells *in vitro*, *in vivo* or *ex vivo* by (M), and where necessary administering the cells to the patient. The method is a gene therapy method and the transfer...or other infections, psoriasis, solar keratosis, wound healing, fracture healing, wart or an inherited genetic disorder such as cystic fibrosis, Gorlin's syndrome, ataxia telangiectasia and metabolic disorders. (I) is useful.... ...a composition or medicament for use in therapy, preferably cancer therapy, gene therapy or vaccination. ADMINISTRATION - The transfer molecule is administered at a dose of 0.1-5 mg/kg. The photosensitizing agent is administered at a dose of 10-50 microgram/ml or 0.05-20 mg/kg body....
...photochemical treatment may be performed after surgical exposure of the lesion followed by e.g., intratumoral injection or other local administration of the transfer molecule. (M) is more independent of exact timing of treatment, i.e....
...were seeded out into 6-well plates. The next day 20 microgram/ml of the

photosensitizer AlPcs2a (aluminum phthalocyanine with 2 sulfonate groups on adjacent rings) was added, and the cells... 3 minutes before the treatment with the adenoviral vector AdHCMV-lacZ at a multiplicity of infection (MOI) of 1 for 30 minutes. This vector contained a beta-galactosidase reporter gene. For...
E.C. Numbers:

Descriptors: adeno virus vector-mediated protein, peptide, antibody, antigen, cytotoxic drug, DNA transfer, beta-galactosidase reporter gene transfer, expression in antigen-presenting cell, liposome, sulfonated tetraphenylporphine, di-, tetrasulfonated aluminum phthalocyanine, amphiphilic photosensitizer, 5-aminolevulinic acid, 5-aminolevulinic acid ester photosensitization agent treatment, cell irradiation, mouse cancer animal model, appl. drug delivery evaluation, cancer, rheumatoid arthritis, atherosclerosis, cardiovascular disease, virus infection, psoriasis, solar keratosis, fracture healing, wart, inherited genetic disorder, cystic fibrosis, Gorlin syndrome, ataxia telangiectasia, metabolic disorder therapy, gene therapy, vaccine, nucleic acid vaccine, vulnerability act. enzyme EC-3.2.1.23...

Section: ...DISEASE-Cancer; DISEASE-Cardiovascular... ...DISEASE-HIV and Other virus Infections; DISEASE -Neuromuscular System... ...DISEASE-Endocrine/Metabolic System; DISEASE-Autoimmune Disease-... ...DISEASE-Other Diseases; PHARMACEUTICALS-Vaccines

11/3/K/85 (Item 16 from file: 357) Links

Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0298769 DBA Accession No.: 2003-00553 PATENT

Introducing a molecule into a cell for treating cancer, by contacting cell with photosensitizing agent, contacting cell with molecule to be introduced which is associated with viral carrier, and irradiating the cell photosensitizing agent, transfer molecule and virus vector expression in host cell use in disease therapy and gene therapy

Author: HOGSET A; BERG K; MAELANDSMO G M; ENGE SAETER B O; PRASMICKAITE L

Patent Assignee: NORWEGIAN RADIUM HOSPITAL RES FOUND; JONES E L 2002

Patent Number: WO 200244395 Patent Date: 20020606 WPI Accession No.: 2002-575278
(200261)

Priority Application Number: GB 200114696 Application Date: 20010615

National Application Number: WO 2001GB5281 Application Date: 20011129

Language: English

...the cell photosensitizing agent, transfer molecule and virus vector expression in host cell use in disease therapy and gene therapy

Abstract: ...inflammation inhibitor, an angiogenesis inhibitor, a protein inducing vessel formation, a coagulation initiating protein, an intracellular antibody or a recombinant immunotoxin. The nucleic acid molecule is 20-10000 bases in length. The... ...bacteriophage, an influenza virus, Sendai virus, vaccinia virus or Baculovirus. The photosensitizing agent localizes to intracellular compartments, particularly endosome or lysosome. The photosensitizing agent is separate from the viral carrier, and... ...therapy vector encoding the HSV-tk gene and subjected to PCI-treatment. 2 days after infection, different concentrations of ganciclovir (GCV) was added, and the cells were incubated further for 3....of GCV was observed for 3 different doses of GCV in cells receiving the AlPcs2a photosensitizer, Adv-TK and GCV. In comparison no such effect was seen in control cells receiving only photosensitizer treatment, in cells receiving photosensitizer and GCV, or in cells receiving photosensitizer and Adv-TK, but no GCV. This showed that the light-induced increase in GCV... ...molecule into a cell, preferably mammalian cell. (M) is useful for treating or preventing a disease, disorder or infection (such as cancer, rheumatoid arthritis, atherosclerosis, a viral or other infections, psoriasis, solar keratosis, wound, fracture, wart or an inherited genetic disorder), in a patient by gene therapy by introducing a transfer molecule into one or more cells in vitro, in vivo or ex vivo by (M), and where necessary administering the cells to the patient, where 10 to the power 10 to the power 15 virus particles are administered in vivo. The gene therapy is achieved by targeted killing of specific cells, targeted inhibition... ...cytosol of a cell and for vaccination. (M) is useful for treating an inherited genetic disorder such as cystic fibrosis, Gorlin's syndrome, ataxia

ozone3.txt

telangiectasia and metabolic disorders. ADMINISTRATION - The photosensitizing agent is administered at dose of 0.05-500 micro-g/ml, preferably 0.05-20 mg/kg. (II) is administered by intramuscular, subcutaneous, intraperitoneal, intratumoral, intravenous or topical route or by inhalation. ADVANTAGE - (M) improves both the efficiency and the specificity...light are affected, and the internalization of viral carriers is more efficient than standard viral infection in terms of the proportion of cells in which the transfer molecule is introduced and....seeded out into 6-well plates. The next day 20 micro-g/ml of the photosensitizer AlPC52a (aluminum phthalocyanine with 2 sulfonate groups on adjacent rings) was added, and the cells.....3 minutes before the treatment with the adenoviral vector AdHCMV-lacZ at a multiplicity of infection (MOI) of 1 for 30 minutes. This vector contained beta-galactosidase reporter gene. For...

E.C. Numbers:

Descriptors: ...triple helix formation, prodrug activation enzyme, recombinant immunotoxin, liposome, appl. cancer, rheumatoid arthritis, atherosclerosis, virus infection, psoriasis, solar keratosis, wound, fracture, wart, inherited genetic disorder, cystic fibrosis, Gorlin syndrome, ataxia telangiectasia, metabolic disorder therapy, drug screening, gene therapy RNA enzyme parvo virus orthomyxo virus paramyxo virus pox virus...

Section: ...GENETIC TECHNIQUES and APPLICATIONS-Gene Expression Techniques and Analysis; DISEASE-Cancer.... ...DISEASE-HIV and Other Virus Infections; DISEASE-Cardiovascular.... ...DISEASE-Respiratory System; DISEASE-Endocrine/Metabolic System

11/3/K/86 (Item 17 from file: 357) Links

Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0286785 DBA Accession No.: 2002-08632 PATENT

Use of substituted indole-3-acetic acid derivatives for the manufacture of a medicament for the treatment of neoplastic diseases vector-mediated horseradish peroxidase gene transfer, expression in host cell and antibody for prodrug activation and gene therapy

Author: WARDMAN P; FOLKES L K; DACHS G U; ROSSITER S; GRECO O

Patent Assignee: CANCER RES VENTURES LTD 2002

Patent Number: WO 200202110 Patent Date: 20020110 WPI Accession No.: 2002-154686
(200220)

Priority Application Number: GB 200016162 Application Date: 20000630

National Application Number: WO 2001GB2872 Application Date: 20010628

Language: English

...treatment of neoplastic diseases vector-mediated horseradish peroxidase gene transfer, expression in host cell and antibody for prodrug activation and gene therapy

Abstract: ...R7 is an electron withdrawing group. INDEPENDENT CLAIMS are also included for the following: (1) antibody directed enzyme/prodrug therapy (ADEPT), polymer directed enzyme/prodrug therapy (PDEPT) involving peroxidase as a... .by the gene and (I); (3) photodynamic therapy (PDT) involving (I) in conjunction with a photosensitizer; (4) a two component system for the treatment of neoplastic disease comprising: a vector encoding and capable of expressing the peroxidase enzyme in a tumor cell and (I); and (5) a two component system for the treatment of neoplastic disease comprising: a tumor directed antibody or polymer linked to the peroxidase enzyme and (I). ACTIVITY - Cytostatic. Human bladder carcinoma T24... .renal, liver, head, ovary, neck, brain and lung tumors, and small cell carcinomas and melanomas. ADMINISTRATION - In ADEPT, GDEPT and PDEPT, (I) are administered parenterally (preferably intramuscularly) or intratumorally. For PDT (I) are administered dermally (preferably subcutaneously) or topically. Dosage is (0.1-200, preferably 10-100) mg/kg...

E.C. Numbers:

Descriptors: plasmid PRK34-HRP-mediated horseradish peroxidase gene tranfer, expression in human bladder carcinoma T24 cell, antibody, appl. substituted indole-3-acetic acid prodrug activation, leukemia, mamma, bowel, colon, kidney, liver, head...

Section: ...GENETIC TECHNIQUES and APPLICATIONS-Gene Expression Techniques and

Analysis; DISEASE-Cancer... ...DISEASE-Blood and Hematopoietic Cells

11/3,K/87 (Item 18 from file: 357) Links
Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.
0280564 DBA Accession No.: 2002-04705 PATENT

Treating tumor-bearing or precancerous subject, and inducing memory cytotoxic T-lymphocyte response specific to tumor in a subject, comprises administering CD40 binding protein along with photodynamic therapy to subject -photosensitizer, FasL, CD30L, TRAIL, tumor necrosis factor-alpha, Flt3L administration useful for tumor therapy

Author: Fanslow III W C; Thomas E K
Corporate Source: Seattle, WA, USA.

Patent Assignee: Immunex 2001

Patent Number: WO 200180888 Patent Date: 20011101 WPI Accession No.: 2002-066404 (200209)

Priority Application Number: US 199545 Application Date: 20000425

National Application Number: WO 2001US13616 Application Date: 20010425

Language: English

...subject, and inducing memory cytotoxic T-lymphocyte response specific to tumor in a subject, comprises administering CD40 binding protein along with photodynamic therapy to subject - photosensitizer, FasL, CD30L, TRAIL, tumor necrosis factor-alpha, Flt3L administration useful for tumor therapy

Abstract: ...a memory cytotoxic T lymphocyte response specific to tumor in a tumor-bearing subject, involving administering a CD40 binding protein (I) to the subject in conjunction with photodynamic therapy (PDT), is new. PDT includes administering photosensitizers to the tumor-bearing subject and exposing the subject to light that is absorbed by the photosensitizer. The method further involves administering an active agent selected from FasL, CD30L, TRAIL and tumor necrosis factor (TNF)-alpha. The method further involves administering Flt3L to mobilize dendritic cells, and administering soluble oligomeric CD40L to the subject. The method further involves obtaining hematopoietic or progenitor cells... ...obtain dendritic cells and infusing the dendritic cells into the subject. (I) is selected from antibody to CD40, CD40L, and an oligomeric soluble CD40L fusion protein. The antibody is selected from monoclonal antibody HuCD40-M2 (ATCC HB11459) and antibodies having an antigen binding domain of HuCD40-M2. (24pp)

E.C. Numbers:

Descriptors: T-lymphocyte induction, mouse EMT6 cell inoculation, monoclonal antibody HuCD40-M2, antibody, native, recombinant CD40 binding protein, photodynamic therapy, photosensitizer, FasL, CD30L, TRAIL, tumor necrosis factor-alpha, Flt3L administration, dendrite cell, light, fusion protein, antibody, appl. tumor therapy, immunotherapy DNA sequence protein sequence mammal animal lymphokine antitumor cytokine protein (Vol...

Section: ...Gene Expression Techniques and Analysis; DISEASE-

11/3,K/88 (Item 19 from file: 357) Links
Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.
0276761 DBA Accession No.: 2002-00263 PATENT

An antibody, with specific affinity for a characteristic epitope of the ED-B domain of fibronectin for the treatment of diseases characterized by vascular proliferation

- antibody engineering for antibody production for use in therapy and diagnosis of cancer

Author: Neri D; Tarli L; Viti F; Birchler M
Corporate Source: Zurich, Switzerland.

Patent Assignee: Eidgenoessische-Tech.Hoch-Schule-Zurich 2001

Patent Number: WO 200162800 Patent Date: 20010830 WPI Accession No.: 2001-541701

ozone3.txt

(200160)

Priority Application Number: US 512082 Application Date: 20000224
National Application Number: WO 2001EP2062 Application Date: 20010223

Language: English

An antibody, with specific affinity for a characteristic epitope of the ED-B domain of fibronectin for... - antibody engineering for antibody production for use in therapy and diagnosis of cancer

Abstract: An antibody (AB) with specific affinity for a characteristic epitope of the ED-B domain of fibronectin, where the antibody has improved affinity to ED-B is claimed. Also claimed are: rapid angiogenesis targeting comprising an antibody with specific affinity for a characteristic epitope of the ED-B domain of fibronectin, the antibody having improved affinity for the ED-B domain; a diagnostic kit comprising an antibody (AB); conjugates comprising (AB) and a molecule capable of inducing blood coagulation and blood vessel occlusion; and therapy of angiogenesis related pathologies where the conjugate injected a radionuclide; therapy of angiogenesis related pathology, where the conjugate injected is a photosensitizer and a radionuclide; and 3-(trimethylstanny)benzoic acid. The AB is useful for diagnosis and therapy of tumors characterized by vascular proliferation. Therapy of angiogenesis related pathologies involves injecting the conjugates of AB and a molecule capable of inducing blood coagulation and blood vessel ...

E.C. Numbers:

Descriptors: fibronectin-specific antibody prep., antibody engineering, appl. tumor diagnosis, therapy, angiogenesis-related pathology therapy (Vol.21, No.1)

Section: ...Antibody-Based Diagnostics; GENETIC TECHNIQUES AND APPLICATIONS ...

...Gene Expression Techniques and Analysis; DISEASE-

11/3,K/89 (Item 1 from file: 315) Links

ChemEng & Biotec Abs

(c) 2009 DEHEMA. All rights reserved.485565 CEABA Accession No.: 1995-05-007949

Document Type: Journal

Original Title: Antibody-targeted photolysis of bacteria in vivo

Author: Yarmush, M.L; Berthiaume, F; Reiken, S.R; Toner, M; Tompkins, R.G

Corporate Source: Massachusetts General Hospital, Boston, MA 02114, USA

Publication: Bio/Technology , Volume: 12 , Issue: 7 , Pages: 703-706

CODEN: BTCHDA ISSN: 0733-222X

Availability: C19950507949

Publication Year: 1994 Language: English

Original Title: Antibody-targeted photolysis of bacteria in vivo

Author:

Abstract(English): The efficacy of antibody-targeted photolysis to kill bacteria in vivo using specific antibacterial photosensitizer (PS) immunoconjugates was evaluated. After infecting the dorsal skin of mice with *Pseudomonas aeruginosa*, both specific and nonspecific tin (IV) chlorin e6-monoclonal antibody conjugates were injected at the infection site. After a 15 min incubation period, the site was exposed to 630 nm light...

Abstractor(English):

Descriptors (English): DISEASE THERAPY; MONOCLONAL ANTIBODY; PHOTOLYSIS

11/3,K/90 (Item 1 from file: 149) Links

TGG Health&Wellness DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

03757691 Supplier Number: 182004389 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Skin directed therapy for Mycosis fungoides: A review.(Disease/ Disorder overview)

Berthelot, Cindy; Rivera, Allison; Duvic, Madeleine

Journal of Drugs in Dermatology , 7 , 7 , 655(12)

July ,

2008

Document Type: Disease/Disorder overview Publication Format: Magazine/Journal

ISSN: 1545-9616

Language: English

Record Type: Fulltext Target Audience: Academic; Trade

Word Count: 10323 Line Count: 00910

Skin directed therapy for Mycosis fungoides: A review.(Disease/ Disorder overview)

...treated with topical modalities with high response rates. More aggressive systemic treatment of early disease does not alter survival or cure the disease and could accelerate progression by causing immunosuppression. Topical corticosteroids, mechlorethamine, and carbamustine have been the...

...presently unknown, several potential contributing factors have been investigated including persistent antigen stimulation, chemical exposure, infection, smoking, certain medications, and sun exposure.(4-12) Mycosis fungoides, in some cases, may be...

...on symptomatic relief of pruritus, cosmetic improvement, reduction in skin tumor burden, and rate of disease progression. Because early MF is caused by the accumulation of skin-homing epidermotropic lymphocytes, treatment...

...remissions. The support of this strategy is that a more aggressive systemic treatment of early disease using systemic chemotherapy does not alter overall survival.(28) Importantly, 2 recent studies have shown that the overall survival of treated patients with stage IA disease does not differ from that of age, sex, and race matched control population, with only 10% to 15% of these patients experiencing disease progression. (24,29,31) In patients with stage IA disease, 80% experience complete resolution of lesions after initial therapy, and half are disease-free after 5 years.(30)

Topical corticosteroids and chemotherapy has been the mainstay of early...

...32)	1961	unspecified	2	0	100	0
--------	------	-------------	---	---	-----	---

CR=complete response; PR=partial response; PD=progressive disease; "fluocinolone under occlusion"; '0.5% triamcinolone
Despite the prevalent use of corticosteroids for the treatment...

...controversial. (48), (49) Therefore, it is advisable to use the lowest potency corticosteroids to achieve disease responsiveness while avoiding these adverse effects.

Advantages of topical corticosteroids are the low cost, availability ...

...results. (54), (60) Effectiveness is seen predominately in patients with patch-stage or plaque-stage disease, as nitrogen mustard may not adequately penetrate far enough into the reticular dermis to clear...

...52	43	5	23	32
-------	----	---	----	----

(A) (54)

CR=complete response; PR=partial response; PI)=progressive disease; Mo=duration in months until CR; 5y=disease free survival
at 5 years ((dagger) 4 year disease free survival); (section) T1 as 20% BSA, T2 as < 20% BSA; *NO differentiation between stages...

...included (all patients are NO).

ozone3.txt

In 1 study, freedom-from- progression ion rates in T1 disease at 5 and 10 years were 92% and 85% and in T2, 83% at 5 and 10 years, respectively. (54) One third of T1 patients enjoy long-term disease-free survival with complete responses of up to 14 years, as reported by Vonderheid.(60...)

...electron beam (TSEB), nitrogen mustard has been helpful to prolong remissions, especially in more aggressive disease. (62) The frequency of nitrogen mustard application is often decreased from daily to several times...

...therapy. There is no systemic absorption of nitrogen mustard used topically. Reactions experienced with systemic administration such as myelosuppression, gastrointestinal desquamation, neurotoxicity, and teratogenicity have not been observed with topical...

...effects. It is used most often as second-line or third-line treatment for refractory disease.

Retinoids and Retinoids

Retinoids are vitamin A derivatives that modulate proliferation and differentiation of keratinocytes...

...2003 < 20% BSA 16 0 63 1

CR=complete response; PR=partial response; PD=progressive disease

; * no differentiation between stages in report of response.

Bexarotene

Topical bexarotene (Targretin (R)) is a...

...mucinosis, and psoriasis. (83-86)

Bexarotene 1% gel was approved by the Food and Drug Administration (FDA) for treatment of refractory IA and IB skin lesions. (87-89) Response to topical...

...in 21% of 67 patients. (89) An additional 42% of patients experienced partial remissions, and disease progressed in 16%. Patients with no previous therapy for the mycosis fungoides responded at all.

...response rates by physician's global assessment of clinical condition, composite assessment of index lesion disease severity, and primary end point classification were 44%, 46%, and 54%, respectively. (91)

Adverse events...

...patients including irritation, pruritis, pain, and vesiculobullous rash. (88-89) Less common reactions include headache, infection, edema, and hyperlipidemia. Irritation is managed by decreasing frequency of application or using low property...

...likely delineate its role as a second-line or third-line topical agent for refractory disease.

Other Topical Treatments

Methotrexate

Methotrexate is a potent competitive inhibitor of dihydrofolate reductase, thereby selectively...

...improvement. Four additional patients improved less than 50%, and there were no individuals with progressive disease. Improvement in induration, pruritus, scaling, and erythema was also reported.

Safety data indicates methotrexate-laurocapram...

...factor (IL-2) and thus prevents T-cell activation, decreases cytokine production, and down regulates immunoglobulin E (IgE) receptors.(117), (118) Tacrolimus also blocks super-antigen induced T-cell

proliferation caused...135-138)

Local reactions, especially erythema or irritation are common but pruritis, burning, pain, tenderness, infection, ulceration, impetigo, or postinflammatory discoloration may also occur. (139) Severe reactions such as bleeding, crusting...

...occur in patients on a more intensive regimen. Severe reactions may be due to super-infection with *S aureus*. Local reactions often resolve within 1 to 2 days after cessation or decreased...

...efficacious dosing regimen.

Localized Phototherapy

Photodynamic Therapy

Photodynamic therapy (PDT) involves the activation of a photosensitizer by light of the appropriate wavelength, leading to the formation of reactive oxygen species. Singlet...

...5 to 6 hours penetrates tumors and is converted into protoporphyrin IX, a potent endogenous photosensitizer. After activation by an FDA-approved blue-light therapy device, protoporphyrin IX induces apoptosis.

Limited...

...The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients. J Clin Invest. 1995;95:547-554.

(7.) Pawson R...

...1313.

(31.) van Doorn R, Van Haselen CW, Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients.

Arch Dermatol 2000;136:504-510.

(32.) Lebwohl...

...2001; 6:4-11.

(88). Liu HL, Kim YH. Bexarotene gel: a Food and Drug Administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2002;138...

...Chemother. 1998;42:789-794.

(142.) Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human Papillomavirus. Arch Dermatol...

11/3/K/91 (Item 2 from file: 149) Links

TGG Health&Wellness DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

02584360 Supplier Number: 131937665 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases.

Trent, Jennifer T.; Kerdel, Francisco A.

Dermatology Nursing , 17 , 2 , 97(12)

April ,

2005

Publication Format: Magazine/Journal; Refereed

ISSN: 1060-3441

Language: English

Record Type: Fulltext; Abstract Target Audience: Professional

Word Count: 7613 Line Count: 00659

Author Abstract: ...diseases such as psoriasis, hidradenitis suppurativa, pyoderma gangrenosum, Behcet's syndrome, and graft versus host disease. The efficacy of these

agents has proven impressive and short-term side effects have been...

Text:

...syndrome.

5. Describe the use of TNF(alpha) in the treatment of graft versus host disease.

Tumor necrosis factor alpha (TNF(alpha)) is a cytokine involved in various activities in the...

...inhibitors of TNF(alpha) were born. More recently, adalimumab (Humira(R)), a fully humanized monoclonal antibody to TNF(alpha), has also joined this group (Weinblatt et al., 2003). Various studies and...

...the treatment of psoriasis and psoriatic arthritis, hidradenitis suppurativa, pyoderma gangrenosum, and graft versus host disease will be discussed.

Psoriasis

Psoriasis is a chronic, inflammatory disease which can affect the skin, tendons, ligaments, and joints (Gottlieb, 2001; Gottlieb & Bos, 2002; Lebwohl...).

...pustular account for 10%, 3%, and 3% of patients respectively. Cutaneous lesions usually precede joint disease in 70% of patients with psoriasis.

Psoriatic arthritis, a seronegative arthropathy, can affect upwards of ...

...be performed. This is to ensure that the patient does not harbor undiagnosed collagen vascular disease/photosensitivity. Also, since psoralen, which is ingested prior to UVA exposure, is a photosensitizer and can cause hepatotoxicity, liver function tests should be obtained.

In patients afflicted with severe...

...Inhibition of T-cell activation/proliferation has been achieved with several therapies, including a monoclonal antibody to anti-CD4, anti-CD80, anti CD25 (dacomitinib), anti-CD11a (efalizumab), and anti-CD2 (sifilizumab...).

...Finally, inhibition of cytokines is accomplished with infliximab (Remicade(R)), a chimeric mouse-human monoclonal antibody which inhibits TNF(alpha) (see Figures 1 & 2); etanercept (Enbrel(R)), a fusion protein which inhibits TNF(alpha) (see Figures 3-6); adalimumab (Humira(R)), a fully humanized monoclonal antibody to TNF(alpha); and anti-IL8.

(FIGURES 1-6 OMITTED)

Infliximab (Remicade(R)). Infliximab is a chimeric monoclonal IgG antibody which inhibits TNF(alpha) activity and triggers complement mediated lysis of TNF(alpha) expressing cells...

...blocks membrane-bound TNF(alpha). It is FDA approved for the treatment of Crohn's disease and rheumatoid arthritis (RA) at intravenous doses of 5 mg/kg and 3 mg/kg respectively. The infusion is given over...

...and has a half life of 8 to 10 days (Williams & Griffiths, 2002). Crohn's disease without fistulas is treated with one dose of infliximab at 5 mg/kg, while the...

...day 84.

Drawbacks are few and include headache, diarrhea, rash, pharyngitis, rhinitis, cough, upper respiratory infection, and urinary tract

infection (LaDuca & Gaspari, 2001; Lebwohl, 2003; Mease, 2002; Provenzano et al., 2003; Van Den Bosch et...)

...70 cases of TB developing after the use of infliximab, 40 of which had extrapulmonary disease. The incidence of TB with infliximab is much higher than with etanercept. This reactivation of...

...macrophage apoptosis after the use of infliximab. Patients are required by the Food and Drug Administration to have a negative purified protein derivative (PPD) test and negative chest radiograph prior to...

...efficacy, the development of infusion reactions, chest pain, bronchospasm, and anaphylactic shock. The rate of antibody formation is inversely related to dose and decreases with the addition of low-dose methotrexate...

...contraindications to the use of infliximab include congestive heart failure, demyelinating disorders, lupus, lymphoma/malignancy, antibody formation to infliximab, hypersensitivity to murine products, and sepsis. Infliximab is a pregnancy class B...

...adult rheumatoid (RA) and psoriatic arthritis (PA) at doses of 25 mg twice a week administered subcutaneously.

It was noted that in the treatment of patients with PA, their psoriasis improved...

...enrolled 60 recalcitrant psoriatic arthritis patients in a double-blind placebo controlled study comparing subcutaneous injections of etanercept 25 mg twice a week to placebo. Patients continued on methotrexate. After 12...

...none of the placebo patients improved. Only 20 of the patients reported side effects, namely injection site reactions, but no significant side effects were noted. After 4 months of followup, five...

...a 75% reduction in PASI scores at 24 weeks.

The most common side effect was injection site reactions (Gottlieb et al., 2002; Mease et al., 2000a; Mease, Goffe, & Betz, 2000b). Other uncommon side effects were upper-respiratory infections, headache, rhinitis, abdominal pain, vomiting, pharyngitis, nausea, gastrointestinal infection, and rash. Antibody formation is less likely to occur in etanercept-treated patients compared to infliximab (Lebwohl, 2003...).

...Extensive scarring can lead to decreased mobility, and vaginal, urethral, and anal strictures. Secondary bacterial infection with *Staphylococcus*, *Streptococcus*, *Pseudomonas*, and *Escherichia* is common and produces a foul-smelling odor. Rarely...

...of HS suggests a genetic component.

More recently, the association of HS with Crohn's disease has been elucidated (Katsanos et al., 2002). It was then postulated that these two conditions...

...et al., 1999). Daily use of antibacterial soaps or Burrow's soaks should be utilized. Intralesional or systemic steroids, cyclosporin, isotretinoin, and cyproterone have been used with minimal success. Oral antibiotics...

...PG is associated with other conditions in up to 75% of patients, including inflammatory bowel disease (Crohn's disease or ulcerative colitis), arthritis (rheumatoid or seronegative), monoclonal gammopathy (usually IgA

...IL-8 is overproduced in PG. Laboratory studies have shown that when IL-8 is injected into human skin xenografts, which are grafted onto mice, PG like ulcers develop. This suggests...

...of inflammation.

Treatment. There is no specific treatment available for PG. For limited or mild disease, topical or intralesional steroids may be utilized (Tan et al., 2001). For more severe or widespread disease, a variety of systemic therapies can be used, such as systemic steroids, cyclosporin, mycophenolate mofetil...

...in the pathogenesis of PG, and PG is often found in association with Crohn's disease, several patients reported in the literature were treated successfully with infliximab (Ljung et al., 2002...

...their dosing schedule, but gave two to five infusions of infliximab. Mimouni et al. (2003) administered infliximab at weeks 0, 2, 4, 8, 10, and then every 6 to 8 weeks...

...skin lesions, eye findings, or positive pathergy test (Travis, Czajkowski, McGovern, Watson, & Bell, 2001). Ocular disease is the most frequent cause of morbidity, with blindness occurring in 25% of patients (Sfikakis...

...solely on clinical findings. Death may occur from neurologic involvement, bowel perforation, vasculitis, and cardiopulmonary disease.

Pathogenesis. While the pathogenesis of BS remains largely unknown, several theories have been offered, such...

...circulating immune complexes have been recovered from serum of patients with BS and correlate with disease activity (Freedberg et al., 1999). It is thought that these immune complexes trigger a neutrophilic...

...types: mucocutaneous and systemic (Freedberg et al., 1999; Sfikakis, 2002; Travis et al., 2001). Mucocutaneous disease has responded to topical and intralesional glucocorticoids, topical anesthetics, thalidomide, dapson, interferon alpha, and colchicine. Systemic disease requires more aggressive treatment with the use of prednisone alone or in combination with cyclosporin...use of etanercept were not sustained after 6 months post-treatment followup.

Graft versus Host disease

Graft versus host disease (GVHD) is a condition which can occur after bone marrow or organ transplantation, or blood...

...and photopheresis. PUVA, retinoids, and topical steroids may be of some use for chronic cutaneous disease.

Infliximab. Rivkina and Stump (2002) reported four cases of GVHD treated with infliximab at 10...

...involvement.

Other Off-Label Uses of Infliximab

Patients with Sneddon-Wilkinson, a chronic superficial pustular disorder; toxic epidermal necrolysis, a rare hypersensitivity reaction to certain medications which leads to loss of the epidermis; and sarcoidosis, a systemic granulomatous disease, have been successfully treated with infliximab (Baughman, Lower, & Du Bois, 2003; Fischer, Fielder, Marsch, & Wohlraub...

...Luftl, Schuler, & Hertl, 2001).

Other Off-Label Uses of Etanercept

Patients with scleroderma, an inflammatory disease

characterized by systemic sclerosis; cicatricial pemphigoid, a chronic autoimmune blistering disease; histiocytosis X, a systemic disease characterized by infiltration with Langerhans cells; and Wegener's granulomatosis, an autoimmune granulomatous vasculitic disease, have been successfully treated with etanercept (Henter et al., 2001; Saché et al., 2002; Sapadin...

...the pathogenesis of psoriasis, psoriatic arthritis, hidradenitis suppurativa, pyoderma gangrenosum, Behcets, and graft versus host disease have led to the development of revolutionary anti-TNF(alpha) biologic therapies, which target this...

...K., Ippoliti, C., et al. (May, 2000) Infliximab for the treatment of graft versus host disease in allogeneic transplant recipients. Paper presented at 36th Annual Meeting of the American Society of...

...M., et al. (1999, December). Infliximab for the treatment of steroid refractory graft versus host disease in allogeneic transplant recipients. Paper presented at American Society of Hematology Annual Meeting, New Orleans...

...Tsianos, E.V. (2002). Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. American Journal of Gastroenterology, 97(8), 2155-2156.
Keane, J., Gershon, S., Wise, R...

...F., Aivado, M., et al. (2001). Treatment of severe steroid refractory acute graft versus host disease with infliximab, a chimeric human/mouse anti-TNF(alpha) antibody. Bone Marrow Transplantation, 28(1), 47-49.

Kurschat, P., Rubbert, A., Poswig, A., Scharffetter-Kochanek...

...Banco, A., Ciccia, F., Ferrante, A., et al. (2003). Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behcet's syndrome. Annals of the...

...O., Fausa, O., Vatn, M.H., & Hellstrom, P.M. (2002). Pyoderma gangrenosum associated with Crohn disease: Effect of TNF(alpha) blockade with infliximab. Scandinavian Journal of Gastroenterology, 37(9), 1108-1110...

...S., Hidalgo, V., & Schlincker, A. (2001). Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet, 358(9293), 1644.
Mussack, T., Landauer, N., Ladurner, R., Schiemann, U., Goetzberger, M., Burchardi, C., et al. (2003). Successful treatment of cervical esophageal perforation in Behcet's disease with drainage operation and infliximab. American Journal of Gastroenterology, 98(3), 703-704.
Newland, M...

...A.A., Mortimer, P.S., & Staughton, R.C.D. (1991). Hidradenitis suppurativa in Crohn's disease. British Journal of Dermatology, 125(4), 384-386.

Person, J.R., & Bernhard, J.D. (1986...).

...Moli, C., & Rinaldi, F. (2003). Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: An open pilot study. Annals of Rheumatic Diseases, 62(7), 680-681.

Rivkina, A.M., & Stump, L.S. (2002). Infliximab in graft versus host disease. American Journal of Health-System Pharmacy, 59, 1271-1275.

Rozenbaum, M., Rosner, I., & Portnoy, E...

ozone3.txt

...of scleroderma. Archives of Dermatology, 138(1), 99-105.
Sfikakis, P.P. (2002). Behcet's disease: A new target for anti-tumour necrosis factor treatment. Annals of the Rheumatic Diseases, 61
...
...P., & Markomichelakis, N.N. (2001). Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet, 358(9278), 295-296.
Smith, K.J., & Skelton, H.G. (2001). Rapid onset of...
...George, J., & Lebwohl, M.G. (2001). Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Archives of Dermatology, 137(7), 930-933.
Travis, S.P.L., Czajkowski, M., McGovern, D...
...Apostolopoulou, K.A. (2002). Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scandinavian Journal of Gastroenterology, 37(7), 863-865.
Triolo, G., Vadala, M...
...A., Ferrante, A., Ciccia, F., Giardina, E., et al. (2002). Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Annals of the Rheumatic Diseases, 61(6), 560-561.
Tsianos, E.V., Dalekos, G.N., Tzermias, C., Merkouropoulos, M., & Hatzis, J. (1995). Hidradenitis suppurativa in Crohn's disease. Journal of Clinical Gastroenterology, 20(2), 151-153.
Tutuncu, Z., Morgan, G.J., & Kavanaugh, A...
...E.M. (2000). Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: An open pilot study. Annals of Rheumatic...
...M. (2001). Infliximab: A novel highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Archives of Dermatology, 137(12), 1571-1574.
Weinblatt, M.E., Keystone, E.C., Furst, D...
...C.A., et al. (2003). Adalimumab, a fully humanized anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis...

Special Features:

Descriptors: Behcet's disease--... Behcet's disease--

Geographic Codes:

11/3/K/92 (Item 3 from file: 149) Links
TGG Health&Wellness DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

02294857 Supplier Number: 95914053 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Catalytic antibody bridges innate and adaptive immunity. (Perspectives: immunology).

Nathan, Carl
Science , 298 , 5601 , 2143(2)
Dec 13 ,
2002

Publication Format: Magazine/Journal; Refereed
ISSN: 0036-8075

Language: English

Record Type: Fulltext Target Audience: Academic

Word Count: 1552 Line Count: 00140

Catalytic antibody bridges innate and adaptive immunity. (Perspectives: immunology).

Text:

...when it comes to outright destruction, antibodies call on the innate immune system for help. Antibody, when combined into complexes with antigen, can activate the complement enzyme cascade that disrupts microbial membranes. In addition, antibody forms a bridge between the pathogen and the immunoglobulin receptors (FcRs) of phagocytic cells of the innate immune system (neutrophils and macrophages), triggering ingestion...

...the innate and adaptive immune system with their discovery of a new way in which antibody contributes to the innate immune system's arsenal. They demonstrate that antibody can kill bacteria by catalytically converting relatively nontoxic ROI supplied by phagocytes into a more toxic form. In effect, antibody acts as a supercharger, taking electronically excited molecular dioxygen (singlet (O.₂.sub.2) or (sup...)...

...in which phagocytes kill microbes with ROI.

Wentworth, Lerner, and colleagues have already established that antibody molecules can catalyze the production of (H.₂O₂)(O.₂.sub.2) from (sup.1...).

...sub.2.sup.*)) (4). To produce (sup.1)(O.₂.sub.2.sup.*), this group irradiated antibody solutions with ultraviolet light in the presence of a photosensitizer. In their new study, Wentworth et al. (1) reveal a biological counterpart to the ultraviolet...

...they use ingenious heavy-isotope chemistry to demonstrate three biological sources of (O.₂.sub.3)--antibody that comes into contact with (sup.1)(O.₂.sub.2.sup.*), activated phagocytes, and inflamed tissues. These sources may be interrelated; in fact, the investigators postulate that cell-bound antibody molecules are responsible for converting phagocyte-derived (sup.1)(O.₂.sub.2.sup.*)) into (H... radical that is generated from them might damage B cells or even cause oncogenic mutations. Immunoglobulin E (IgE) is a class of antibody that binds to cells antigen-nonspecifically via specialized receptors (Fc_(epsilon)R)s) on mast cells...

...to mast cell activation by catalyzing formation of more potent oxidants. Furthermore, cells can bear antibody molecules when antibody is directed against an antigen on the cell surface, as in some forms of autoimmunity and immunotherapy. For example, patients with rheumatoid arthritis or an inflammatory bowel disorder called Crohn's disease may benefit from injection of antibodies against the cytokine tumor necrosis factor (TNF); those with rheumatoid arthritis may also benefit from injection of soluble TNF receptors. It is assumed that both reagents work by neutralizing TNF. However, TNF-specific antibody may also bind to activated macrophages, mast cells, and T cells that express TNF on...

...surface (6). Antibodies against leukocyte surface molecules can trigger production of ROI. Then, cell-bound antibody might convert these ROI into toxic forms, injuring the cells to which the antibody is attached and ameliorating inflammatory disease.

ozone3.txt

Immune complex disorders are also settings in which antibody is brought into proximity with (sup.1)(O.sub.2.sup.*). For example, antigen-antibody complexes can accumulate in the glomeruli of the kidney and fix complement, attracting and activating phagocytes. In rheumatoid arthritis, affected joints contain rheumatoid factor, an antigen-antibody complex in which the antigen is itself antibody. The rheumatoid joint also holds large numbers of neutrophils that respond to TNF by releasing...

...Wentworth et al. (3) work leaves critical questions open for future investigation. The receptors for antibody (FcRs) expressed by neutrophils are not thought to retain antibody in the absence of antigen. Thus, the display of nonspecific antibody on the neutrophil surface suggested by the Wentworth et al. study requires explanation. The extent to which cell-bound antibody contributes to (O.sub.3) production by phagocytes or to their antibacterial activity has not...

...3) has not been defined or compared with the amounts of those products produced by antibody or by phagocytes with and without phagocyte-bound, bacteria-bound, or soluble antibody. It is not clear whether production of (O.sub.3) leads to more (sup.)OH...

...host defense is clear, because people genetically deficient in this enzyme are highly susceptible to infection (9). An even wider role for phox is revealed when a partially compensating enzyme, nitric...

...offers a facile route to (sup.)OH production. Perhaps we will come to regard the antibody molecule as the seventh component of the phox complex (see the figure), as well as...

...sup.)NO NOX synthases Killing; signaling (7)
CO Heme oxygenase Signaling (72)
(O.sub.3) Antibody
Killing (3); signaling?
References and Notes
(1.) C. Nathan, M. U. Shiloh, Proc. Natl. Acad...

11/3/K/93 (Item 4 from file: 149) Links
TGG Health&Wellness DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

01835731 Supplier Number: 54710309 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Acne: update on therapeutic choices.(includes related article on acne-causing pathogens)

Rothe, Marti Jill; Grant-Kels, Jane M.
Consultant , 39 , 4 , 1061(1)
April ,
1999

Publication Format: Magazine/Journal; Refereed

ISSN: 0010-7069

Language: English

Record Type: Fulltext; Abstract Target Audience: Professional
Word Count: 5510 Line Count: 00492

...page 1054). When we initially evaluate a patient, we briefly explain the pathogenesis of the disease (Box) and summarize available treatment options according to the manner in which they block the...

...tests are normal, but the patient has menstrual irregularities or
Page 83

ozone3.txt

evidence of androgen-related skin disease. More avid binding of dihydrotestosterone to its receptor or increased conversion of normal concentrations of...doxycycline is significantly more photosensitizing than minocycline, which has only rarely been reported as a photosensitizer. We generally advise patients receiving photosensitizing therapy to avoid or minimize sun exposure between 10...

...13) recommend avoiding minocycline therapy in patients with systemic lupus erythematosus (SLE), hepatic or renal disease, or a family history of SLE. Avoid prescribing the tetracycline class of antibiotics for patients...

...Suspect it when acne flares (particularly around the nose and mouth) in a patient whose disease has been controlled with long-term antibiotic therapy. Treatment options include ampicillin, TMP-SMX, and...

...nitrogen, and creatinine levels; complete blood cell count; and chest film.

* Suspected late reactions: antinuclear antibody titer and alanine aminotransferase and aspartate aminotransferase levels.(18)
Whether oral antibiotics decrease the effectiveness...successful treatment requires a cumulative dose of 120 to 150 mg/kg, which can be administered over a period of 4 to 7 months.(22) Initiating therapy at lower dosages with...

11/3/94 (Item 5 from file: 149) Links

TGG Health&Wellness DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

01674362 Supplier Number: 19051130 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Staff responsibilities for phototherapy administration. (includes continuing education test)

Sheik, Joan; McClelland, Patricia B.; Morgan, Pamela; Leach, Eileen Enny; Nankin, Marlene

Dermatology Nursing , v8 , n6 , p393(12)

Dec ,

1996

Publication Format: Magazine/Journal

ISSN: 1060-3441

Language: English

Record Type: Fulltext; Abstract Target Audience: Professional

Word Count: 5293 Line Count: 00577

Staff responsibilities for phototherapy administration. (includes continuing education test)

Author Abstract: ...is quality patient education. The opportunities to implement this responsibility are as endless as the disease itself.

Text:

...with the dispensing of information that helps the patient understand and cope with his/her disease, including the fact that many of the diseases are chronic and incurable.

The information has been culled from the collective experience of the Dermatology Nurses' Association (DNA) Phototherapy Administration Symposium staff, information from the DNA Phototherapy Administration Symposium manual and DNA's Phototherapy Administration Guidelines for Nurse Phototherapists and Phototechnicians, and books and articles written by phototherapy

specialists (Abel...

...both practitioner and staff to understand not only the physical aspects of the patient's disease, but also the overall effect of any previous treatment and any emotional impact upon the...

...and giving of information (see Figure 1).

Figure 1. Pathophysiology and Treatment of Photoresponsive Diseases
Disease Treated With Ultraviolet Light PUVA UVA UVB
Psoriasis X X X Parapsoriasis X X Vitiligo...

...an Intake Interview

Presenting complaint. Patients should be questioned about the initial onset of the disease, any precipitating factors such as streptococcal infection, and the treatment history. This history should include the type of treatment, frequency of use...

...Many treatments are judged as a failure when in fact there was a failure to administer the therapies properly. This is generally the result when unrealistically conservative caps are place on...

...or phototherapy doses.

Discussion of the family should include how they affect the patient's disease. Are they a positive support system? Do they induce stress? Are they knowledgeable about the disease and how it affects the patients' physical and emotional well-being?

Allergies. Investigating allergies or...

...preparations that were a part of previous psoriasis therapies and the overall effect upon the disease. The implications of other medications are also important. Are any of the current medications an...

...medical background provides valuable information that can influence the rhyme and reason of the current disease. For instance, a previous history of persistent polymorphous light reactions will make consideration of phototherapy concerning family medical history. Areas of discussion should include the patient's presenting disease as well as history of skin cancers and of photodermatoses. A family history of a...

...by someone of the opposite gender.

Lifestyle questions should include the impact that a skin disease has upon the patient's daily living. Do you experience discrimination? Do you feel restricted...

...several small areas of skin to incremental doses of UVB. For PUVA testing, patients are administered psoralen and 1 to 2 hours later are exposed to WA in the same manner...

...to the patient's condition may influence their ability to function and to manage their disease. Many nurses have noted that objective observations have not only been helpful in the ultimate...impedes the penetration of medications and ultraviolet light. Debridement should not be vigorous because the disease may be exacerbated by the trauma (Koebner phenomenon). A multistep approach is advised. What isn...

...off, they should be clipped because subsequent injury could cause a flare-up or an infection. The best time to apply emollients and/or medications is after bathing. Moist skin requires...of many weeks or months of therapy and not an instant miracle. WB is usually administered 3 to 5 times weekly and topical preparations are customarily a part of the treatment...

...unaware of this, so it must be reinforced.

Psoralen and UVA therapy (PWA) are usually administered 2 to 3

times weekly and topical preparations are optional and often omitted. The avoidance...

...of education regarding PWA is that it is a marriage of two elements, a chemical photosensitizer (psoralen) and longwave ultraviolet light. One without the other is not PWA. Even though this...

...requirements are not mandatory and they vary from practice to practice. Chemistry, CBC, and antinuclear antibody (ANA) are the most routinely requested.

If an informed consent is required as a facility...

...reference.

Methotrexate or retinoids are often introduced for difficult cases of psoriasis. These are either administered independently or in combination with UVB or PWA. Regular laboratory studies are customarily required for...

...be appropriate for the level of need demonstrated by the extent and severity of their disease. Accepting the fact that not every patient can have complete clearing or find themselves in...

...retinoids)

Cyclosporine
Experimental drug programs
Climate-therapy

Photographs are helpful in establishing a baseline of disease activity. They should also be taken periodically to document treatment response and ultimate progress. Patients...

...factors. Very few patients are aware that psoriasis is aggravated by several factors including:

- * Streptococcal infection
- * Medications (beta-blockers,
- * lithium, prednisone)
- * Excessive intake of alcoholic beverages
- * Abrasion
- * Stress

* Overexposure to ultraviolet...the Dermatology Nurses' Association (DNA) and the National Psoriasis Foundation; however, the majority of people administering phototherapy have been trained by a coworker. Unfortunately, much misinformation is included with appropriate information ...

...be the standard for any phototherapy program (see Figure 7).

Figure 7. Phototherapy Guidelines
Phototherapy Administration Guidelines for Nurse
Phototherapists and Phototechnicians
Phototherapy administration and supervision. Phototherapy should be administered by staff who are supervised by a dermatologist familiar with photomedicine. Patients must never be in a position of administering their own treatments in a clinic setting. Policies should be established that are clear-cut...

...or

blistering

Table 5. Response to Therapy

Grade	Criteria	% Improvement Compared to Original Extent of Disease
		Page 86

ozone3.txt

-1	Psoriasis worse	0
0	No change	0
1	Minimal improvement; slightly less...	5-20

...Clearing; complete flattening of
plaques including borders; 95
plaques may be outlined by
pigmentation

Every administrator of phototherapy must be knowledgeable of
treatment protocols and equipment operation. Not all equipment is...

...and complex, it takes a certain type of individual to staff a unit
treating this disease. They must be committed, caring, and
empathetic because patients not only need medical intervention, they...

...for the psoriatic patient. Areas of nursing responsibility should
include:

- * Patient education
- * Patient assessment
- * Phototherapy administration and supervision
- * Patient resource and support system
- * Treatment implementation and management
- * Unit maintenance

In general...

...psoriasis with systemic drugs. *Dermatology Nursing*, 7(2), 107-118.
*Dermatology Nurses' Association. (1996a). Phototherapy
administration symposium manual.* Pitman, NJ: Author. *Dermatology
Nurses' Association. (1996b). Phototherapy administration guidelines
for nurse phototherapists and phototechnicians.* Pitman, NJ: Author.

Galloway, G.A., & Lawson, G.B...Walters has arrived at the office
for her UVB treatment. Before her treatment can be administered, the
nurse must assess all the following except:

a. The time lapse since last treatment...

...his primary care physician for phototherapy. A staff member is taking
his medical history. Which disease might eliminate phototherapy as a
treatment option?

- a. Alopecia areata
- b. Eosinophilia folliculitis
- c. Mycosis...

...application, and use of emollients.
d. All of the above.

Joan Sherk, RN, is Clinical Administrator, Leone Dermatology
Centers, Arlington Heights and Bloomingdale, IL.

Patricia B. McClelland, RN, is Nurse Manager...

Special Features:

Descriptors: ...Administration and dosage

Geographic Codes:

ozone3.txt
01532439 Supplier Number: 14485686 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Melanoma. (Research Report) (Pamphlet)

Pamphlet by: U.S. Department of Health and Human Services , p1(30)
Feb ,

1992 ,

Document Type: Pamphlet Publication Format: Pamphlet

Language: English

Record Type: Fulltext Target Audience: Consumer

Word Count: 9885 Line Count: 00829

...is the body's outer covering. It protects the body from heat and light, injury, infection, and many chemicals. The largest organ of the body, the skin also regulates body temperature...

...than lung, liver, or bone cancer) to indicate that they are part of a single disease and are not new cancers originating in these organs. Treatment for cancer that has spread...

...estimated that 32,000 new cases of cutaneous melanoma and 6,500 deaths from this disease occurred in the United States in 1991. The incidence of melanoma in this country...

...skin (such as blacks, Hispanics, or Asians), and many more of them die of the disease as well. In the United States, the incidence among whites increased by almost 75 percent...

...5-year survival rate for patients with localized melanoma is 91 percent. For patients whose disease has spread to other sites in the region of the original cancer, the 5-year...for people who were severely sunburned as children.

* People with xeroderma pigmentosum, a rare hereditary disease in which the skin and eyes are extremely sensitive to light, are much more likely...

...addition, people with certain types of atypical nevi may have an increased risk for this disease.

Atypical nevi are generally larger than ordinary moles and have irregular borders that fade into...

...with atypical nevi may be at increased risk for melanoma, most do not develop this disease. The risk of developing melanoma is greatest for persons with many such nevi who are...rated in strength from 2 to 15 or higher. The U.S. Food and Drug Administration (FDA) requires that this rating, the sun protection factor (SPF), be printed on the container ...

...tissue for microscopic examination by a pathologist (a doctor who specializes in the diagnosis of disease by studying cells and tissues removed from the body). The pathologist determines whether cancer is...

...If melanoma is diagnosed, the physician conducts additional tests to determine the stage of the disease. The staging of melanoma provides information about the depth to which the cancer has penetrated...

...a patient's microstage is related to his or her prognosis (probable outcome of the disease). Dr. Alexander Breslow, of The George Washington University School of Medicine, grouped melanomas by thickness...

Clinical Staging--In this original staging system, melanomas are classified into three stages: localized disease (stage 1), regional

metastasis (stage II), and distant metastasis (stage III). However, many doctors believe...

...by incorporating tumor thickness and level of invasion as well as the extent of the disease.

TNM Staging--The American Joint Committee on Cancer has developed a staging system based on Clark's levels, Breslow's categories of tumor thickness, and the extent of the disease. Specifically, it uses coded descriptions of primary tumor size (T), lymph node involvement (N), and...

...classified as MX, when the presence of metastases cannot be determined; M0, when no distant disease is found; or M1, when there are metastases in skin, subcutaneous tissue, or lymph nodes...

...statistically significant difference in the length of time stage IB and stage II patients remain disease free or in the length of their survival.

Regional lymph nodes, or those affected by disease, are removed following wide excision for stage III melanoma. For more advanced disease (stage IV), surgical removal of metastatic tumors and affected lymph nodes may help relieve symptoms such as pain.

Chemotherapy--Some melanoma patients treated with surgery face a high risk of disease recurrence. To improve the outlook for these patients, researchers are evaluating the use of ...kill undetectable cancer cells that remain in the body after surgery.

A new method of administering adjuvant chemotherapy is under investigation to determine whether it is effective for patients with stage

...of the drugs. The drug most commonly used for perfusion is melphalan.

A similar technique, intra-arterial regional infusion, also is being studied in patients whose disease is limited to an arm or a leg. Again, normal blood circulation to and from...

...infused directly into the main artery of the limb. The drugs most commonly used for intra-arterial regional infusion are dacarbazine (DTIC) and cisplatin.

Researchers are also evaluating chemotherapy in the...

...However, no drug or drug combination has produced long-term survival for patients with widespread disease. Therefore, clinical trials with anticancer drugs and biological agents are continuing, and patients with advanced disease should consider participating in these trials to evaluate new treatments. Most clinical trials involve combinations...

...such treatment does not appear to improve long-term survival. In cases in which the disease has spread to the lung, gastrointestinal tract, bone, or brain (stage IV), radiation may provide relief from such symptoms as pain.

Recurrent Disease--Treatment for recurrent melanoma depends on prior therapy, the location and extent of recurrence, the...to distant parts of the body. Clinical trials should be considered for patients with recurrent disease.

Followup Care--Because melanoma patients are at high risk for the development of new melanomas...

...This form of melanoma is even rarer in blacks and Asians.

The causes of this disease are not well understood. One study suggests that sunlight plays a role in the development...

...inflammation also may occur.

Diagnosis--Diagnostic procedures for ocular melanoma also depend upon where the disease begins. The doctor may suspect melanoma of the

iris if he or she detects a...

ozone3.txt

...diagnosis of ocular melanoma is made, it is necessary to determine the extent of the disease in order to plan treatment. The patient has a full medical examination, which includes blood...substance that makes cells more sensitive to light (photosensitizing agent) to destroy tumor tissue. When injected into the body, HPD collects in tumor cells, sensitizing them to light. Doctors then expose the cancer to a laser beam. This activates the photosensitizer and produces a toxic reaction that destroys the tumor.

Patients with advanced ocular melanomas may...

...interferons, see page 14.)

Rehabilitation and Followup--Treatment results, side effects, and evidence of metastatic disease may not appear for several months to years following the initial therapy. It is therefore...

...substances to stimulate or restore the ability of the body's immune system to fight disease more effectively. Also called immunotherapy.

Biopsy: The surgical removal of a small piece of tissue...

...of the eyeball.

Epidemiologic: Relating to epidemiology, the study of the incidence and spread of disease in a population.

Epidermis: The outer layer of the skin. Melanocytes, basal cells, and squamous...after diagnosis.

Fluorescein angiography: The process of taking pictures of blood vessels that have been injected with a special dye. The dye allows the blood vessels to show up on the...

...of the eye through a special camera used to view the inner eye.

Glaucoma: A disease of the eye in which there is a buildup of pressure in the eye. If...

...bleeding.

Immune system: The complex group of organs and cells that defend the body against infection and disease.

Incidence: The rate at which a disease occurs within a population. Cancer incidence is usually expressed in terms of the number of ...

...of those blood cells that are an important part of the body's immune system.

Intra-arterial regional infusion: Treatment with anticancer drugs in which the drugs are put directly into...

...a melanoma and by noting the deepest level of skin invaded by the tumor.

Monoclonal antibody: A laboratory-produced antibody that can target a specific antigen. They can be made in large quantities in the...

...absorbs a large portion of the sun's ultraviolet radiation.

Pathologist: A specialist who diagnoses disease by studying how tissues and cells look under a microscope.

Photocoagulation: A process using a...the vascular tunic. Ocular melanocytes are located in the uvea.

Vaccine: A preparation of a disease-causing agent or a similar substance that is given to patients to stimulate the immune system to fight disease or to prevent subsequent disease. For example, scientists are conducting studies to determine whether a vaccine composed of irradiated melanoma...

...prevent the return of the cancer.

Vascular tunic: See Uvea.

ozone3.txt

Xeroderma pigmentosum: A rare, inherited disease in which the skin and eyes are extremely sensitive to the sun. Many spots similar...

...91-1136.

Coleman, D.J., et al. "Ultrasonic Hyperthermia and Radiation in the Management of Intraocular Melanoma," American Journal of Ophthalmology, Vol. 10 1 (6), 1986, pp. 635-642.

DeVita, V...

11/3/K/96 (Item 7 from file: 149) Links

TGG Health&Wellness DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

01303557 Supplier Number: 11287608 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Out of control: new cancer agents strive to restore order. (includes related articles on anticancer treatments) (Cover Story)

Starr, Cynthia

Drug Topics , v135 , n17 , p36(9)

Sept 9 ,

1991

Document Type: Cover Story Publication Format: Magazine/Journal

ISSN: 0012-6616

Language: English

Record Type: Fulltext Target Audience: Trade

Word Count: 6500 Line Count: 00528

...This is particularly true for childhood leukemias, testicular cancer in young men, and Hodgkin's disease. Warning that "you have to be careful with numbers," he added that the survival rate...

...such as heart attack more frequently and are thus living long enough to develop the disease. As the population ages, the incidence climbs, he observed. "We will have to get a...

...biochemical, molecular, genetic, pharmacologic, and physiologic terms," Mark Pearson, executive director of cancer and inflammatory disease research at Du Pont Pharmaceuticals, told Drug Topics. "Ten years ago, we really didn't...that doesn't happen."

While the genes that influence cell growth are involved in the disease, cancer is not frequently a "genetic" or inherited disease. There are "really very few" cancers in which the predisposition to malignancy is passed from...

...The technique employs therapeutic versions of materials normally manufactured by activated members of our natural infection-fighting forces, according to Michael Bookman, a member of the department of medical oncology at...

...sarcoma.

Genentech's interferon gamma-1b or Actimmune, approved for the treatment of chronic granulomatous disease, is under study in renal cell carcinoma, Jaffe reported. The company is also experimenting with... its ability to provoke a melanoma-specific immune response.

Classified as "active specific immunotherapy," the injectable is "like any vaccine program," explained Ribi's Jeffrey McDowell, corporate information manager.

"It's..."

...magnet-to-metal-like affinity antibodies have for a particular antigen.

These agents wed an antibody that has been developed to pick out a unique protein on tumor cells with "some..."

...is precisely what Genentech is attempting to do with an anti-HER-2/neu monoclonal antibody product. Preclinical studies indicated that the MAB can induce an anticancer effect. Presumably, it works...

...depriving tumor tissue of whatever nutritive factors it requires to flourish.

The agent was also administered in a phase I clinical trial to a small number of women who had failed...that put the patient at risk of lung, liver, and other toxicities have to be administered. Nova's approach, he said, puts the drug where it needs to be without exposing...

...Inc. have modified L-asparaginase with polyethylene glycol. The goal is to be able to administer the chemotherapeutic to hypersensitive children with acute lymphoblastic leukemia.

Hypersensitivity to L-asparaginase is a...

...emerging technology, called photodynamic therapy, uses laser light to selectively destroy tumors. Patients are first injected with a photosensitive dye that primarily collects in tumor cells. Then physicians use a laser...sunlight or even very bright focused light. One company, U.S. Bioscience, is experimenting with intratumoral injection of the photosensitizer, in order to help reduce the therapy's burn potential.

while all of the information...

...Adozelesin, The Upjohn Co.: In phase I for treatment of solid tumors and leukemia, this intravenous compound appears to interact with a very specific part of the DNA sequence. The anthrapyrazoles...in phase III studies as a treatment for metastatic breast cancer. Galamustine, Unimed Inc.: This intravenously administered alkylating agent is in phase I trials in patients with breast cancer, lung cancer, and...

...protein is under evaluation in lung, breast, melanoma, bladder, colon, and pancreatic cancers. It is administered intravenously. PEG-I-asparaginase, Enzon Inc.: A polyethylene glycol-modified version of L-asparaginase, the agent...

...Myers Squibb Co.: Derived from the bark of the Pacific yew tree, taxol is an intravenously administered compound in phase III development for recurrent ovarian cancer. TLC D-99, Pfizer Inc.: Under development by The Liposome Co. Inc. and Pfizer, this intravenously administered liposomal doxorubicin will be marketed by the latter. It is in phase II studies for...

...or Carrisyn, Carrington Laboratories: Just about to enter phase I clinical trials, acemannan is an injectable, plant-derived polysaccharide aimed at stimulation of the immune system. Alfa leukoferon (alpha interferon), Viragen...

...believed to stimulate the immune system. A limited number of patients are receiving the drug intravenously in Florida. Bropirimine, Upjohn: In phase II for treatment of bladder cancer, the oral compound...

...effect on the immune system. The mechanism is unclear. imuVert, Cell Technology Inc.: This subcutaneously administered Serratia marcescens extract is to be used as a general immune system stimulator. It is...

...suppression. interferon gamma-1b or Actimmune, Genentech Inc.: Already approved for treatment of chronic granulomatous disease, the drug is in phase II trials as a single-agent treatment for renal cell...

ozone3.txt

...as well as colorectal, ovarian, and bladder cancers. Cetus is experimenting with several routes of administration. Melaccine, Ribi immunochem Research inc.: Labeled as a theraccine," Melaccine is a therapeutic vaccine aimed...

..It is entering phase III clinicals. Thymosin alpha 1, Alpha 1 Biomedicals inc.: A subcutaneously administered immunomodulating agent, thymosin alpha 1 is being used to normalize T cell responses in patients...delivered locally, such as gastrointestinal and ovarian types. MONOCLONAL ANTIBODIES Anti-HER-2/neu monoclonal antibody, Genentech: This agent has been used in a small phase I trial that included women...

...phase II. The MABs are given IV except in ovarian cancer, where they're used intraperitoneally. 17-1Aor Panorex, Centocor Inc.: This "naked" MAB is in late phase II trials for...

..sodium or Photofrin, Lederle Laboratories: Used in conjunction with laser light to destroy tumors, the injectable agent is in phase III studies of patients with lung, bladder, and esophageal cancers. USB...

...from Eastman Kodak Co., this light-sensitive dye is in preclinicals. USB is also studying intratumoral delivery of a light-sensitive hematoporphyrin derivative.

MISCELLANEOUS Buserelin, Hoechst-Roussel Pharmaceuticals: Company will not...

...Merck Pharmaceutical: Aimed at hypoxic tumors generally larger ones with (a deranged circulation), this radiation sensitizer is used to improve the efficacy of radiotherapy. It is in phase III. ICI 176334...

11/3/K/97 (Item 8 from file: 149) Links

TGG Health&Wellness DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

00800003 Supplier Number: 09112524 (USE FORMAT 7 OR 9 FOR FULL TEXT) Sexually transmitted disease (STD) (venereal disease) prevention for everyone. (pamphlet)

Pamphlet by: American Foundation for the Prevention of Venereal Disease , p1(27) Annual ,

1988

Document Type: pamphlet Publication Format: Pamphlet

Language: English

Record Type: Fulltext Target Audience: Consumer

Word Count: 10821 Line Count: 00921

Sexually transmitted disease (STD) (venereal disease) prevention for everyone. (pamphlet)

Text:

INTRODUCTION TO SEXUALLY TRANSMITTED DISEASE (STD) PREVENTION

...extensive group now identified as "sexually transmitted diseases" (STDs).

Today, for a better understanding of disease prevention, the STDs should not be categorized solely by their mode of transmission, but

must...

...of communicable diseases.

STD PREVENTION and PERSONAL HYGIENE INFORMATION are an integral part of overall disease prevention and should be taught as vital to individual and collective health to all persons...

...and teach the techniques of STD PREVENTION.

The American Foundation For The Prevention Of Venereal Disease, Inc., (originally incorporated in 1967 as The New York Alliance For The Eradication Of Venereal Disease, Inc.), is a non-profit agency dependent on public support through tax-deductible contributions, considering...

...college and university health services.

Over a million copies of our widely acclaimed guide, VENEREAL DISEASE PREVENTION FOR EVERYONE, retitled beginning with the thirteenth revised English edition SEXUALLY TRANSMITTED DISEASE (STD) (VENEREAL DISEASE) PREVENTION FOR EVERYONE, are in use around the world.

Being a charitable organization, we furnish...

...reproduce this booklet or complete chapters thereof may be requested in writing.

PERSONAL HYGIENE AND DISEASE PREVENTION
WASHING

It is vital to individual and collective health that everyone learn the importance...

...female mucous membranes, especially those of the genito-urinary (GU) system, are highly susceptible to infection by some of these germs from the rectum, which may cause urethritis (inflammation of the...

...be greatly aided by the bidet, a low bathroom fixture designed to facilitate washing for disease prevention and proper cleansing after toilet. Not everyone, unfortunately, has been informed on the advantages... of the reported cases of male urethritis which are not gonorrhea.

THE CONDOM

SEXUALLY TRANSMITTED DISEASE (STD) PREVENTATIVE AND CONTRACEPTIVE FOR MALE AND FEMALE

Since semen and female genital secretions are...

...on to block passage of the relatively small viruses such as those which cause AIDS infection, herpes, and hepatitis.

Commonly referred to as "latex" or "rubber" condom and sometimes called "prophylactic..."

...break. Those who experience breakage may wear two condoms at the same time.

AIDS (HIV) infection is spreading. (See chapter on AIDS). To prevent possible transmission of this deadly virus, a...

...wide availability of condoms, the female shares the responsibility of using this easy method of disease prevention and contraception. Anyone, regardless of age, can obtain condoms from pharmacies or other outlets...

...penicillin along with other antibiotics, the cure for syphilis required over a year of weekly injections which many failed to complete; extreme personal discomfort accompanied the usually long, always annoying, course...

...physically debilitating infections.

Only those who observed or experienced firsthand the hardship resulting from STD infection and ...was perfected.

The U.S. Government was extremely concerned by the high rate of STD infection and excessive time lost by men on sick leave in the Armed Forces, and as...

...he stated: "The prophylaxis, if properly used, is so surely a protection, that any venereal disease arising must be severely punished."

The U.S. Army Medical Dept. expressed the opinion that this prophylaxis, when correctly administered, was 99.6% effective against chancroid, syphilis, and gonorrhœa.

The U.S. Navy supplied "pro..."

...especially welcome if a man who has been exposed through sex contact wants to avoid infection because he does not have access to adequate treatment, or since he wants to avoid...

...against the infectious agents of certain STDs including gonorrhea, herpes 1 & 2, trichomoniasis, Chlamydia trachomatis infection, HIV infection (caused by human immunodeficiency virus) leading to AIDS (acquired immune deficiency syndrome) or ARC (AIDS...)

...1 part to 3 parts water), may furnish some prophylactic value against oral-pharyngeal STD infection.

Further scientific studies on germicidal preparations are needed.
THIS BOOKLET IS OFFERED AS A PUBLIC...

...APPLICABILITY OR EFFICACY OF ANY INFORMATION, SUGGESTION, OR PROCEDURE CONTAINED HEREIN.

POINTS ON SEXUALLY TRANSMITTED DISEASE (STD) PREVENTION

The American Foundation For The Prevention Of Venereal Disease, Inc., realizes that abstinence may be considered, but presents preventive measures, recognizing that needs vary...

...every effective STD PREVENTION program is epidemiology which, through case finding, locates the source of disease and breaks the chain of infection by treatment of contacts.

Successful STD control requires the patient's complete cooperation in identifying...

...the occasion of one sex contact. Having had an STD does not provide immunity; re-infection is possible on exposure to that disease. AIDS (HIV) infection, however, is ...by unclothed persons, some of whom may be infected.

The birth control pill and the intra-uterine device (IUD) serve only as contraceptives and do not prevent STDs.

The use of...

...or break in the skin and invades the bloodstream. Unsterilized acupuncture, tattoo or (especially among intravenous drug abusers) hypodermic needles contaminated by blood during previous use on an infected person may...

...take 2-12 weeks or more after being exposed to and acquiring syphilis for the disease to show up in the blood and to be accurately reflected by a positive blood...

...symptoms.

Having had syphilis does not provide immunity; reinfection is possible on exposure to the disease.

At any stage, the visible symptoms may go away without treatment, but the infection will progress, sometimes causing irreversible damage. Due to the seriousness of untreated syphilis, the patient...

...Unless treated, this lesion may remain, before disappearing, 1-8 weeks at the site of infection on the genital or anal parts, or on that part of the body at which...

...sometimes follows a firm, painless bubo (swelling) in the nearby lymph gland. If untreated, the disease progresses to the -
Secondary Stage - in a period varying from several weeks to 6 months ...

...after symptoms of secondary syphilis have disappeared.

Late Latent Stage - indicates ongoing untreated asymptomatic syphilitic infection.

Note: Certain classifications indicate an early latent stage of less than 4 years, a late...

...as 20-40 years or may attack the body with the following possible consequences: Heart Disease, Blindness, Nerve and Brain Damage, Paralysis, Insanity, Death. The use of the condom, germicidal preparations ...

...tests.

Having had gonorrhea does not provide immunity; reinfection is possible on exposure to the disease.

Direct contact of the gonorrhea germ with the eyes can produce blindness. Newborn infants receive silver nitrate eye drops as prophylaxis against possible gonococcal infection. The following parts of the body are also highly vulnerable to infection:

The Penis: Pain or burning may be present on urination, accompanied by a white or yellow discharge from the urethra (urinary opening). The infection may also be asymptomatic (without symptoms).

The Female Genitals: There may or may not be inflammation, pain, or tenderness in lower abdomen, or genital discharge. Usually the infection progresses without noticeable symptoms.

The Rectum: There may be irritation, itching, pain on bowel movement, pus in the stool. Or, the infection may go unnoticed.

The Throat: Gonorrhea germs do not seem to survive as long in...

...no symptoms. It would appear relatively rare that gonorrhea is transmitted from the throat.

Gonococcal infection is systemic when it enters the bloodstream becoming disseminated gonococcal infection with such possible results as skin lesions, arthritis, endocarditis, meningitis. Penicillinase-producing *Noisseria gonorrhoeae* (PPNG)...

...treatment, or as directed.

Some possible consequences of untreated gonorrhea are: Infertility, Blindness, Arthritis, Heart Disease, Meningitis, Prostatitis, Epididymitis, Pelvic Inflammatory Disease (PID).

The use of the condom, germicidal preparations, and...

...GONOCOCCAL URETHRITIS (PGU) -

NGU and NSU are terms sometimes used interchangeably. NGU refers to urethritis (infection of the urinary canal) not caused by the gonococcus; NSU refers to urethritis the cause...

...as half of the cases of male urethritis were NGU or NSU.

PGU is urethral infection remaining present after gonococcal urethritis has been cured, in which instance PGU is caused by...

...contact causing vaginitis in the female, requiring simultaneous treatment of both partners to avoid re-infection.

VAGINITIS -

Inflammation of the vulvo-vaginal area. Can be caused by micro-organisms present in...

...with or without symptoms. Therefore simultaneous treatment of both partners is necessary to avoid re-infection. Two prevalent types of vaginitis are:

CANDIDIASIS (candidosis, monilia, moniliasis, thrush, yeast) -

A fungus, Candida albicans, may cause infection with thick, white, curdy, vaginal discharge, discomfort with intense itching and swelling.

May be transmitted...

...trich) -

A protozoan, Trichomonas vaginalis (incubation period 4-20 days, average 7 days), may cause infection with foamy, yellowish, vaginal discharge, unpleasant odor, itching, and discomfort. May be transmitted by sex...

...female from toilet seats or damp washcloths previously used by an infected female.

PELVIC INFLAMMATORY DISEASE (PID) -

PID is an extremely serious female condition involving infection of possibly the uterus, fallopian tubes, ovaries, and abdominal cavity (peritonitis), caused by the spread of an untreated vaginal or cervical infection due to gonococcal or non-gonococcal organisms. PID is often the result of untreated gonorrhœa or Chlamydia trachomatis infection. The attending physician may indicate other causes.

Symptoms may include lower abdominal pain or cramps...

...germicidal action against the agents of such STDs as those producing gonorrhœa and chlamydia trachomatis infection, two significant causes of PID. See chapter on The Condom and Germicidal Preparations for Male...

...cells, damaging the immune system and diminishing the body's ability to defend itself against infection and disease. Frequently occurring are a form of cancer known as Kaposi's sarcoma (KS) ...as Pneumocystis carinii pneumonia (PCP), tuberculosis, cryptosporidiosis, cytomegalovirus (CMV), Epstein-Barr virus, candidiasis (a fungal infection).

The infectious agent of AIDS is a retrovirus called HIV (human immunodeficiency virus), originally designated...

...now noted in the U.S. as early as 1969, has been described as a disease of tropical origin which has now reached temperate zones where its spread within specific high...

...diseases (STDs). Note: AIDS is spreading among sexually active promiscuous heterosexual males and females. (2) Intravenous drug abusers who shared contaminated hypodermic needles. Current statistics indicate that the number of new...

...bisexual males who have changed their sexual behavior to reduce the possibility of acquiring HIV infection; (3) Those, including hemophiliacs, who, before universal screening of donors in 1985, received transfusion of...

...of HIV; (6) Sex partners of the above; (7) Infants born to mothers with HIV infection or AIDS/ARC. Note: There are those who belong to more than one of these high-risk groups.

The incubation period of this complicated, fatal disease is variable and may be as long as 10 years or more according to currently available information.

It is reported that HIV infection may develop as early as 2 to 6 weeks after exposure, at which time conversion...

...not, recur or lead immediately or later to the following symptoms also associated with HIV infection and AIDS/ARC: persistent night sweats, fatigue, diarrhea, dry cough, shortness of breath, sore throat...

...had sex contact since 1978 without a condom with a partner likely to have HIV infection, should be blood tested in order to determine seropositive (HIV+) or seronegative (HIV-) status. Testing...

...seropositive indicates the presence of antibodies to the AIDS virus, reflecting previous exposure to and infection with the virus; an HIV- result indicates that the individual has not been infected, or...

...blood and be accurately reflected by an HIV+ test. Therefore, even in the presence of infection, a blood test taken too soon after exposure may result HIV-, and be misleading. Those at risk for AIDS virus infection should have periodic blood testing.

The ELISA (enzyme-linked immunosorbent assay) test is given first...

...may then be given for confirmation.

The PCR (polymerase chain reaction) test does not reflect antibody status but determines actual presence or absence of the AIDS virus.

Persons with AIDS/ARC...in the genital-anal area by such STDs as chancroid, syphilis, or herpes encourage HIV infection by allowing direct entry of the AIDS virus to the bloodstream.

Male to male, male...

...sex partner is HIV+, is in danger of giving birth to an infant with AIDS infection or AIDS/ARC.

Blood, semen, and female genital secretions including the blood of menstrual flow...

...tears where it would appear not to be present in sufficient quantity/strength to transmit infection. However, it must be remembered that any body fluid or discharge would be rendered more infectious if HIV injected blood had been secreted into it within the body.

The latex (rubber) condom is an important risk-reduction factor in the prevention of AIDS infection and other STDs, acting as a physical barrier for the parts or areas involved during...

...on to block passage of the relatively small viruses such as those which cause AIDS infection, herpes, and hepatitis.

while not necessary within a monogamous relationship where both sex partners are...

...no exposure to, and no taking into one's body, another individual's bodily fluids.

Disease prevention requires that all individuals, regardless of HIV+ or HIV- status, avoid exposing any cut...

...FSWs) and personal service workers (PSWs) such as barbers, massage therapists, etc., regardless of HIV infection status, but without other infectious diseases, may perform their duties without risk to the public...

...or body fluids which might transmit the AIDS virus.

For further information on AIDS virus infection consult local health department and/or Morbidity and Mortality Weekly Report (MMWR) on following subjects 5. (3) Guidelines for counseling and antibody

testing. Aug. 14, 1987; 36/31: 509-15. (4) Recommendations for prevention of transmission in...

...health care settings. June 24, 1988; 37/24:377-88. Prepared by the Centers for Disease Control of the US Dept. of Health and Human Services; distributed by Massachusetts Medical Society...

...vital to the control of communicable diseases and to individual and collective health.

CHLAMYDIA TRACHOMATIS INFECTION

Chlamydia trachomatis, a bacterium (incubation period 5-21 days), now producing increasingly widespread infection, is transmitted by intimate bodily or sex contact with an infected mucous membrane or its...

...urethritis (NGU), proctitis, or post-gonococcal urethritis (PGU), and in the female, proctitis, or cervical infection which may lead to the serious complication of pelvic inflammatory disease (PID). (See chapter on PID).

All commercially available vaginal spermicidal contraceptive foams, creams, suppositories, and trachomatis infection. Infected sex partners must be treated simultaneously to prevent reinfection.

GASTRO-INTESTINAL DISEASES -

AMEBIASIS, caused...

...before and after sex contact.

VIRAL HEPATITIS -

A serious and complex communicable, sometimes sexually transmitted, disease that attacks the liver. Symptoms may be mild or severe including nausea, fatigue, fever, abdominal...

...should wash genitals and rectal area before and after sex contact.

Immune globulin (IG) by injection before or immediately after exposure to HAV may offer protection against, or lessen the severity of, the infection.

Of great concern to community health are the outbreaks of hepatitis A (HA) caused by...

...virus in their intestinal and urinary tracts, contaminating the food they serve and spreading the disease as they work. Restaurant owners and kitchen supervisors have the obligation to teach their cooks...

...traditionally known as "serum" hepatitis. Usually associated with transmission through infected blood transfusion, or among intravenous drug abusers by way of contaminated hypodermic needles.

Since semen is a primary vehicle of transmission of HBV, many cases of this disease resulting from sex contact with an infected male could be prevented by use of the...

...vaccine if not immune. Hepatitis B immune globulin (HBIG) possibly along with HB vaccine by injection after exposure to HBV, may protect against, or lessen the severity of, the infection.

If a pregnant woman is found on testing to be an HBV carrier, the newborn...

...Delta hepatitis virus is activated only in the presence of HBV, causing an extremely dangerous infection which is also preventable by way of the HB vaccine.

HEPATITIS NON-A, NON-B (HNANB) is an additional form of this disease.

HERPES SIMPLEX (HS) (herpes) -

Infection with herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2), herpes...the blisters may last for three weeks, or much longer if they become infected. Genital infection may produce

lymph gland enlargement in the groin. These symptoms are ordinarily less severe on...

...blisters which usually break, releasing fluid containing the infectious virus and facilitating transmission of the disease.

Transmission is also possible when the virus may be shed in such body fluids as...

...of those with HSV-2 do not have visible symptoms but may nonetheless transmit the disease, sometimes unintentionally.

Both types 1 and 2 may be transferred to other parts of the body; for example, persons with genital herpes may transmit the infection to their eyes unless they wash their hands after touching their genitals.

It is traditionally...

...chancre) -

Caused by a bacterium, Haemophilus ducreyi (incubation period 3-10 days; if site of infection is a fissure or abrasion, as short as 24 hours) which attacks skin or mucous...

...or sex contact with skin or mucous membrane of an infected person. This systemic infectious disease of lymph channels and lymph nodes may begin with a small, painless papule (bump) or...many STDs is simple and consists of antibiotics that can be given orally or by injection. Instructions regarding medication should be carefully followed. AIDS (HIV) infection, however, is more complex and being permanent, requires continuing medical supervision and consultation.

People must...

...of syphilis may be suppressed and the accuracy of the blood test affected while the disease progresses.

Both syphilis and gonorrhoea are frequently acquired during a single sex contact. The antibiotic...

...there is no noticeable secretion, he may still be infected and capable of transmitting the disease.

For males and females under treatment for certain STDs, a follow up visit to the...

...taking antibiotics for certain STDs, until completely cured, no sex contact which may spread the disease; no alcohol during treatment, and especially during treatment for urinary tract infections, no alcohol which...

...healing.

It must be remembered that certain drugs such as tetracycline act as a skin photosensitizer, increasing susceptibility to sunburn.

Certain STDs may be passed back and forth (pingpong'ed) from one sex partner to another; steady partners must be treated simultaneously to avoid re-infection.

Self-treatment or home remedies should not be attempted. Only a physician can properly diagnose...

Special Features:

Descriptors:

...AIDS (Disease)--...

...Pelvic inflammatory disease--

Geographic Codes:

ozone3.txt

11/3/K/98 (Item 1 from file: 159) Links
Cancerlit
(c) format only 2002 Dialog. All rights reserved.

02507485 PMID: 98701382

PHOTODYNAMIC THERAPY WITH A PHOTOIMMUNOCONJUGATE IN COMBINATION WITH CISPLATINUM ADMINISTRATION FOR THE TREATMENT OF ADVANCED EPITHELIAL OVARIAN CANCER (Meeting abstract).

Hasan; Duska; Miller; Hamblin

Wellman Laboratories and Vincent Gynecology, Massachusetts General Hospital, Boston, MA.

Proc Annu Meet Am Soc Clin Oncol

1998 ,

17 ,

Document Type: MEETING ABSTRACTS

Languages: ENGLISH

Main Citation Owner: NOTNLM

Record type: Completed

PHOTODYNAMIC THERAPY WITH A PHOTOIMMUNOCONJUGATE IN COMBINATION WITH CISPLATINUM ADMINISTRATION FOR THE TREATMENT OF ADVANCED EPITHELIAL OVARIAN CANCER (Meeting abstract).

...in vitro and in cells obtained from human solid tumor and ascites ex vivo. The photosensitizer chlorin e₆ was conjugated to the F(ab')₂ fragment of the murine monoclonal antibody OC125 directed against the CA125 antigen. Solid tumor and ascites samples were obtained from patients.... offers promise for initial treatment of ovarian cancer and for treatment of recurrent cisplatin resistant disease. (C) American Society of Clinical Oncology 1998. {

d s	Items	Description
S1	83	S E1-E2
S2	1	S S1 AND (ANTIBOD? AND SENSITIZER)
S3	1633	S E1-E13
S4	3	S S3 AND (ANTIBODY AND SENSITIZER)
S5	2172	S ((ANTIBODY OR IMMUNOGLOBULIN OR FAB OR FV OR SFVZ) AND (SENSITIZER OR PHOTOSENSITIZER))
S6	2182	S ((ANTIBODY OR IMMUNOGLOBULIN OR FAB OR FV OR SFV) AND (SENSITIZER OR PHOTOSENSITIZER))
S7	0	S S6 AND (ADMINIS\$ OR INJECT\$ OR INOCUL\$ OR INTRA\$)
S8	863	S S6 AND (ADMINIS? OR INJECT? OR INOCUL? OR INTRA?)
S9	281	S S8 AND (INFECTION OR DISEASE OR DISORDER)
S10	174	RD (unique items)
S11	98	S S10 AND PHOTOSENSITIZER

?